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Abstract 
 
Immunological suppression and regulation may be involved in tumour progression in 
many cancers. An integrated study has been carried out with regard to the protein 
expression of immune surface markers, soluble cytokines as well as the functional 
analysis of immune cells and their relationship to ovarian cancer and its prognosis. 
Peripheral blood, ascites, and tumour tissues were collected from patients with 
untreated ovarian cancers and benign ovarian tumours. Peripheral Blood Mononuclear 
Cells (PBMCs) from healthy women were used as a control. The immune cells that had 
been isolated for phenotypic analysis were analysed for immune surface and activation 
marker expressions using flow cytometry. Ovarian cancer tissues were used for 
immunohistochemistry (IHC) and for tissue RNA extraction to screen immune-related 
genes by quantitative real time PCR (qRT-PCR). Functional and enzymatic assays were 
performed to further characterise the regulatory and inhibitory molecules in the 
patients‟ PBMCs and ascites. It was found that the expression of regulatory T cells and 
T cell associated programmed death-1 molecule (PD-1) was significantly upregulated 
in cancer patients on the T cells. The programmed death ligand-1 (PD-L1) expression 
on monocytes from the patients‟ PBMCs and ascites was observed to have significantly 
increased in patients with ovarian cancer compared to women with benign diseases. 
From the functional results, it was hypothesised that PD-L1 may be involved in T cell 
dysfunction in ovarian cancer. The PBMCs, ascites, and tissues from ovarian cancer 
patients were also used to study the expression and potential role of immunomodulatory 
enzymes such as indoleamine 2,3-dioxygenase (IDO) and arginase in ovarian cancer. 
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1.0 Chapter 1: Introduction 
1.1 Ovarian cancer  
 
Epithelial ovarian cancer (EOC) is one of the leading causes of death among 
gynaecological malignancies (1). According to the International Federation of 
Gynaecology and Obstetrics (FIGO), ovarian cancer is commonly diagnosed in the 
advanced stages (2). About two-thirds of the patients present at the advanced stages 
initially due to the fact that there is a lack of reliable screening tools and also the 
absence of particular symptoms in the early stages of the disease (3). 
The survival of patients with ovarian cancer will depend on the effectiveness of surgery 
and the stage of the disease at presentation (4), (5). Surgical cytoreduction and 
platinum/paclitaxel-based combination chemotherapy are the first-line agents, 
contributing to a 70 – 80% response rate (3). Chemotherapy is routinely used in more 
advanced cases. The response depends on the dose administered, and the use of 
anthracyclines can also be beneficial (6), (7), (8). Despite that, recurrence and death 
from the disease will occur in 60  70% of patients (9). This occurrence may be due to 
emerging chemoresistant clones and the colonisation of the peritoneum, resulting in 
poor accessibility by chemotherapeutic agents (10), (11), (12). There is interest in 
developing alternative therapies, including immunotherapy, to reduce the high 
recurrence rate of ovarian cancer and to improve long-term survival (13). EOC has a 
limited prognostic value, which until now includes histologic subtypes, tumour grades 
and the volume of residual disease after cytoreductive surgery (14), (15). The most 
common symptom of patients during the initial presentation is abdominal swelling or 
26 
 
bloating, which is commonly associated with the presence of ascites and intra-
abdominal tumour spread. About one-third of the patients present with ascites at the 
time of diagnosis, and a much greater number develop ascites during the course of the 
disease (16). Therefore, patients with ascites are commonly referred to gynaecologists 
for evaluation (3). 
Ascites is defined as the presence of abnormal levels of fluid in the peritoneal cavity, 
which is believed to closely mimic the tumour microenvironment in ovarian cancer (3). 
Therefore, this offers a unique opportunity to easily obtain viable cancer cells and 
tumour associated lymphocytes (TALs) directly from the site of the disease by 
paracentesis (17). There is evidence, mainly from in vitro and in vivo experimental 
studies, that TALs may be important for the immune response of the host against the 
tumour (13), (18). In ovarian cancer, interesting results were obtained, where the 
proportion of T regulatory cells (Tregs) in TALs and in the peripheral blood 
mononuclear cells (PBMCs) of the patients was found to be higher than in non-cancer 
patients (18). More recently, the clinical relevance of immune responses in ascites was 
studied and significant differences between PBMCs and TALs were again proven in the 
Tregs population and in the CD3
+ 
CD56
+
 population as a new predictive factor of 
platinum resistance (17). Despite these recent findings, the prognostic significance of 
TALs isolated from ascites or tumour infiltrating lymphocytes (TILs) isolated from 
fresh tumour samples has not been systematically studied up to now (17). However, the 
prognostic significance of TILs and of specific lymphocyte populations has been 
recently recognised in various neoplasms (18), (19). This identification of human 
cancers has been done by defining the specific lymphocyte populations of CD8
+
 and 
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CD4
+
 T cells (20), (21). For example, the function of Tregs, which are involved in 
establishing immunologic tolerance in cancer immunosuppression, has been reported to 
be the inhibition of CD8
+
 and CD4
+
 T cells (22). In EOC, studies performed in 
paraffin-embedded tissue showed that the presence of TILs was an independent 
favourable prognostic factor, while subsequent studies showed that the regulatory CD4
+
 
CD25
+
 cells were associated with the suppression of tumour specific T cell immunity 
and a worse outcome, while increased cytotoxic CD8
+
 lymphocytes were associated 
with an improved prognosis (18), (19), (23). 
 
1.1.1 Standard treatment in ovarian cancer 
 
The survival of patients with ovarian cancer will depend on the effectiveness of surgery 
and the stage of the disease at presentation (4), (5). According to FIGO, approximately 
15% of EOC is diagnosed at a late stage of the disease (stage III and IV). Overall, the 
median survival for patients at a late stage of the disease is approximately 15 to 23 
months, with an estimated 5 year survival of 20% (24), (25), (26), (27). Cytoreductive 
surgery is a foundation of the initial treatment for patients with advanced ovarian 
cancer (28). The recommended standard surgery in primary ovarian cancer includes 
radical tumour debulking (29). Radical surgical procedures, including radical pelvic 
clearance, intestinal resection, splenectomy, diaphragmatic resection, and hepatic 
resection, have been described as treatments for advanced ovarian cancer (30), (31), 
(32), (33), (34), (35). The standard therapy consists of primary cytoreductive surgery 
followed by platinum-paclitaxel chemotherapy (36). Several studies have demonstrated 
a survival benefit for patients undergoing “optimal” versus “suboptimal” tumour 
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debulking prior to the initiation of chemotherapy (37). The definition of “optimal” 
cytoreduction has been the subject of debate for decades (38). Disease nodules left in 
situ that measure less than 1 cm are now generally accepted as optimally debulked, and 
if there is any disease nodule larger than 1 cm, then this is known as suboptimal 
debulking. The bulk of the disease that is left in place at the end of surgery is correlated 
with the prognosis. 
 
1.1.2 Typical prognostic markers and survival predictors in ovarian cancer 
 
Several factors are recognised as prognostic of clinical outcomes in patients with EOC. 
EOC has a limited prognostic value, which until now includes histologic subtypes, 
tumour grades and the volume of residual disease after cytoreductive surgery (14), (39). 
According to FIGO, the stage and residual volume of a tumour after primary surgical 
cytoreduction are the most consistently reported prognostic factors (38), (40), (41). 
Residual disease, and a high histologic stage and grade are regarded as predictors of 
survival (42), (43), (44), (45). However, the analysis may be confounded because these 
factors frequently result in suboptimal cytoreduction (46). Residual disease has been 
described as one of the most important prognostic factors (37), (47). Most importantly, 
residual disease is the only prognostic factor under the control of the operating surgeon 
(29). The amount of residual disease after primary surgery is generally considered the 
most important modifiable prognostic factor influencing the survival of patients with an 
advanced stage of the disease (48). Previous studies have inconsistently described the 
relationship between tumour histology and prognosis. One study found that tumour 
histology‟s of stages III and IV EOC or high histologic grades were not independent 
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predictors of the clinical outcomes (49). In contrast, a study of stage IV EOC found that 
patients with mucinous and clear cell histologies had a worse overall survival relative to 
those with serous tumours (28). Further, recent microarray experiments have revealed 
that clear cell carcinoma has a genomic expression pattern that differs from serous 
epithelial ovarian cancers (50). Although tumour grade is a significant prognostic 
variable in the early stages of EOC, it does not appear to be a predictor of a poor 
outcome in the advanced stages of the disease (26), (51), (52). This conclusion has not 
changed even when clear cell cancers were designated as grade 3 and included in the 
model (53). Borderline tumours of the ovary show cells with malignant potential but 
are not invasive. They can be disseminated as invasive or non-invasive deposits and can 
reoccur as borderline or invasive tumours. 
 
1.2 Cellular immune response 
 
The immune response can be divided into either humoral (antibody-mediated) 
responses or cell mediated (T cell–mediated) responses (54). Humoral and cellular 
immunity are the two main lines of defence that higher organisms rely on for 
combating foreign antigens and pathogens (55). Cellular immune responses require 
intercellular communication followed by T cell receptor (TCR) coupling to downstream 
pathways in order to initiate or repress soluble cytokines and receptor-ligand pairs on 
the cell surface known as TCR signalling (56). 
The adaptive immune response is initiated by the interaction of T cell antigen receptors 
with major histocompatibility complex molecule-peptide complexes in specialised 
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junctions between a T cell and an antigen presenting cell, referred to as an 
immunological synapse (IS) (57). An immunological synapse is a localised 
environment on the T cell which requires the coordinated activities of several TCR-
associated molecules, including co-receptors CD3 and CD8 or CD4, and other co-
stimulatory receptors (58). The immunological synapse consists of a central cluster of T 
cell receptors surrounded by a ring of adhesion molecules (58). The bulk of the engaged 
TCR is transported to the centre of the contact area and the engaged integrins are forced 
into a surrounding ring (58). This pattern can remain stable for several hours and 
sustained signalling on this time scale is required for full T cell activation (59).  
Although many cell surface receptors can enhance signalling through the TCR, T cells 
also express several co-signalling molecules that direct, modulate and fine tune TCR 
signals (60). The co-signalling molecules engage their ligands in organised patches of 
cell to cell interaction between T cells and antigen presenting cells (APCs) (61). The 
immune system is regulated by a highly complex balance of signals transmitted by the 
co-signalling molecules, which are also known as stimulatory and inhibitory receptors. 
As a consequence, these membrane molecules positively and negatively control the 
priming, growth, differentiation, and functional maturation of a T cell response (56). 
The functional effects on T cell activation classify co-signalling molecules as co-
stimulators or co-inhibitors (56). T cells are activated when they bind antigens 
presented by APCs through their TCR CD3 complex (56). The two-signal model for T 
cell activation proposes that signal one is provided by the TCR/CD3 complex, while 
signal two is generated by the engagement of T cell co-stimulatory receptors (61).       
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1.2.1 Recognition of MHC class I and class II by TCR 
 
 
While antibodies recognise intact antigens, T cells distinguish foreign material from 
self through the presentation of fragments of the antigen by the major 
histocompatibility complex (MHC) cell surface receptors. Only if an MHC molecule 
presents an appropriate antigenic peptide will a cellular immune response be triggered 
(55). In the cellular immune response, antigens are displayed to T cells in a complex 
with class I or class II MHC molecules. Both classes of MHC are heterodimers and are 
composed of three domains, one α-helix/β-sheet (αβ) super domain that forms the 
peptide-binding site and two Ig-like domains (55). In the class I MHC molecules, the 
peptide-binding site (called the α1α2 domain) is constructed from the heavy chain only, 
and an additional light chain subunit, the β2-microglobulin, associates with the α3 of 
the heavy chain (55). In contrast, the class II MHC peptide-binding site is assembled 
from two heavy chains (α1β1) (55). The class II MHCs present peptides that originate 
from the proteolysis of extracellular antigens in endosomal-type compartments, 
whereas class I MHCs present peptides primarily derived from the intracellular 
degradation of proteins in the cytosol (55). 
TCRs that recognise these MHCs are found on two distinct cytotoxic and T helper (Th) 
cell lineages, depending on the class of the MHC to which they are restricted (55). 
TCRs are cell surface heterodimers consisting of either disulphide-linked α- and β- or 
γ- and δ-chains (55). Each TCR chain is composed of variable and constant Ig-like 
domains, followed by a transmembrane domain and a short cytoplasmic tail (55). The 
TCR binding to MHCs is complemented by additional interaction events prior to T cell 
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or killer cell activation (55). For example, the extracellular domains of CD4 and CD8 
co-receptors with other additional signalling modules (CD3εγ and CD3εδ) can interact 
to form the signalling-competent, supramolecular complex of TCR-peptide MHC (62), 
(63). Models of the TCR-peptide MHC complex with co-receptors and signalling 
modules were found to have a major role in immune responses (55). An adaptive 
immune response, for example, eliminates the source of viral replication or 
abnormal/cancerous cells, and is mediated by CD8
+
 cells, also known as cytotoxic T 
lymphocytes (CTLs) (64). The CTL recognises infected or transformed cells that 
display on their surface MHC class I molecules presenting antigenic peptides derived 
from viral proteins or mutated gene sequences and then kills the offending cells (64). 
This process allows the CD8
+
 T cells of the immune system to identify cells that are 
synthesising abnormal genes (viral or mutant) and eliminate them. The pathways 
through which the antigen is presented and stimulates CD8
+
 T cells in the initiation and 
effector phases of the responses can be different (64). The mechanisms through which 
cells present their own internally synthesised antigens on MHC class I molecules are 
referred to as the classical class I pathway (Figure 1.1) (64). 
In some circumstances, antigens from the extracellular environment or exogenous 
antigens can be presented on MHC class I molecules and stimulate CD8
+
 T cell 
immunity, a process termed cross-presentation (64). A great deal has been learned 
about how peptides that bind to MHC class I molecules are generated, but many 
important issues in the cross-presentation pathway remain unresolved (65). However, in 
most cells, the MHC class I molecules faithfully display peptides synthesised within the 
cell (64). Endogenous antigens must be transported into the endoplasmic reticulum 
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(ER) by transporters associated with antigen processing (TAP) in order to bind and be 
presented by the MHC class I molecules (64). However, exogenous antigens are not 
presented on the MHC class I molecules of most cells because they cannot pass through 
the plasma membrane or endosomes to gain access to the cytosolic compartment. In the 
cytosol, proteins are degraded into peptides by proteasomes. Once a suitable peptide 
has been bound, the MHC class I molecules exit the ER, and transit through the Golgi 
apparatus to the cell surface to present their load to CD8
+
 T cells (66). The MHC class 
I/peptide complexes are recognised by the CD8
+
 cytotoxic T cells. The CD8
+
 T cell can 
scan hundreds of cells per hour and be activated by ~ 5 - 10 antigenic complexes 
distributed over the surface. The CD8+ T cells prevent the spread of intracellular 
pathogens through the recognition of pathogen-derived peptides (epitopes) that are 
produced by intracellular proteolysis and are displayed at the surface of the infected cell 
in combination with the MHC class I molecules (67), (68). Also, the CD8
+
 T cells, with 
their combination of sensitivity, specificity, and lethality, may be the best hope for 
immune-based cancer therapy (69). The activated CD8
+
 T cells, once loaded with 
cytolytic machinery, kill infected cells or infiltrate tumour tissues to mediate tumour 
cell destruction (56). 
 
1.2.2 Peptide: MHC complex and TCR interaction 
 
The formation of an immunological synapse is a multistep process that begins with the 
adhesion of the T cell to the APC (58). The initial adhesion is mediated by integrins, 
such as lymphocyte function-associated antigens 1 (LFA-1), which promotes the 
interaction of smaller adhesion molecules such as CD2-CD58 into bringing the actin   
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Figure 1.1 Cytotoxic T cell antigen presentation. The mechanism by which proteins are 
hydrolysed by proteasomes into oligopeptides, which are then transported by TAP and loaded 
onto the MHC class I molecules in the ER. Cross-presentation enables the MHC class I–peptide 
presentation prior to becoming established and arming their immunoevasion strategies.  
 
cytoskeleton to centre stage (58).  The initial adhesion may also be achieved using 
other larger adhesion mechanisms like the Intercellular Adhesion Molecule 1 (ICAM-1) 
on the APC that would work immediately beside the TCR (70). Initial adhesions play 
an essential role in T cell activation (70). T cell activation also includes a series of 
sequential stages of T cell polarisation, IS (initial signalling) formation, and IS 
maturation (sustained signalling) (70). Sustained TCR signalling is required for full T 
cell activation. During migration to the inflammatory sites, T cells are exposed to 
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chemokines (71), (72), (73). This induces polarisation prior to contact with the APC 
(71), (72), (73). Polarisation allows the establishment of a sensory contact with the 
APC, which involves the formation of actin-based protrusions. These protrusions 
generate a force based on actin polymerisation (74). The protrusive force exerted by 
these structures is counter-balanced by the anchoring force of the integrin interactions 
at the centre of the contact area (75). For example, LFA-1 „anchoring‟ leads to initial 
TCR triggering. TCR triggering is crucial to the organisation of the IS, which initiates 
cytoskeletal rearrangements. Therefore, the process of forming the immunological 
synapse involves the entire T cell surface and the actin and myosin cytoskeletal systems 
to translate the short-lived interaction of TCR and MHC-peptide complexes into a 
stable, supramolecular structure of cell-sized proportions. 
The TCR interacts with the peptide: MHC (pMHC) complex by making contact with 
both the MHC molecules and the antigen. The TCR has shown remarkable adaptability 
to enable MHC-restricted recognition due to the fact that certain antigens select a very 
restricted TCR repertoire (76). Unique TCR-pMHC complexes are required for the 
field to build a comprehensive collection of structures that will allow further 
understanding of the interaction (76). It is also important to understand the early steps 
of TCR docking because they define the antigen and TCR selection processes. The 
TCR-pMHC interface is generally extensive, although its shape complementarity is 
generally quite poor, and this is consistent with the low affinity for the interaction (77). 
In addition, the individual contributions of the complementarity determining regions 
(CDR) loop to the interactions with the pMHC and vary to a certain degree between the 
different TCR-pMHC complexes (78). The TCR-pMHC crystal structures show that the 
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CDR1 and CDR2 loops primarily contact the MHC, whereas the highly diverse CDR3 
loops mainly interact with the peptide (76). T cell activation may include the formation 
of an encounter complex of the TCR with the MHC α1- and α2-helices, followed by a 
more intensive sampling of the content of the MHC peptide-binding groove by the TCR 
CDR3 loops (55). Although the MHC surface generally dominates the interaction with 
the TCR, one study has revealed that the TCR focus can be more peptide-centric (76). 
 
 
1.2.3 Intracellular events in T cells following MHC-peptide recognition by the 
TCR 
 
 
The downstream effector pathways in the membrane domains contain the intracellular 
protein tyrosine kinases and a series of adaptor proteins that interpret signals in the 
context of „danger‟ and adopt an appropriate response (78). It is important that cells do 
not become activated in the absence of further danger signals. Activation requires two 
or more signals from the environment that are particularly important for immune cells 
to recognise foreign antigens and pathogens (79). The biochemical events in the 
membrane domains sense the environment and modulate cellular responses to ensure 
activations are appropriate for that environment (79). Membrane domains rich in 
signalling molecules are transported to the centre of the forming synapse. This allows 
sustained TCR signalling (Figure 1.2). 
The first biochemical event that can be detected upon TCR/CD3-ligation is the 
lymphocyte-specific protein-tyrosine kinase (Lck)-mediated phosphorylation of 
tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAMs) 
(80). Protein kinase Lck is critical for initiation of the TCR signalling process through 
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the CD3 (81). Lck is a cytosolic protein that becomes membrane associated as a result 
of fatty acid modifications to its amino terminus, after which it can bind to the cytosolic 
tails of the transmembrane CD4 and CD8 co-receptors and thus initiate TCR signalling 
(82), (83). Other components of the TCR signalling complex, such as CD4 or CD8, are 
also likely to influence T cell signalling (55). Class I and class II MHCs are recognised 
by their respective CD8 and CD4 co-receptors (55). TCR signalling can be either co-
receptor dependent or co-receptor independent. Co-receptor dependent TCR signalling 
is thought to be more efficient than co-receptor independent TCR signalling, requiring 
lower antigen doses for equivalent levels of stimulation (84). The CD4 co-receptor 
interaction is achieved in the MHC class II system (85). While both domains of CD8 
cooperate to bind class I MHCs, only one domain (the N-terminal variable-like region) 
of CD4 makes contact with the class II MHCs, with the second tandem CD4 domain 
being distal to the interface (55). The co-receptor-Lck associations of CD4/Lck or 
CD8/Lck to the TCR/CD3 complex exist to enhance antigen-specific TCR signalling 
(86), (87), (88).  
The cytoplasmic domains of the CD3 and δ polypeptides contain ITAMs (58). The 
ITAMs can appear in tandem thrice in the TCR zeta chain and once in each of the CD3 
subunits (γ, δ, and ε) (58). Different ITAMs of the TCR/CD3 complex can interact with 
different adaptors that transmit antigen receptor signals, indicating that variations in the 
phosphorylation of individual ITAMs during T cell activation will generate a signalling 
diversity (89), (90). One of the main adaptors is the membrane-anchored adaptor 
molecule linker for the activation of T cells (LAT) which contains many ITAMs (91). 
The phosphorylation of ITAMs is determined by the avidity of ligation and the 
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resulting pattern of partial or complete ITAM phosphorylation and the differential 
recruitment of signalling molecules (79). Therefore, the phosphorylation of ITAMs 
leads to cell activation, depending on the intensity of the receptor stimulation and the 
presence or absence of co-stimulatory signals (79). ITAMs and the associated receptors 
mediate activating signals that are opposed by a distinct set of receptors that signal 
through cytoplasmic-domain Immunoreceptor Tyrosine-based Inhibitory Motifs 
(ITIMs) (77). ITIMs recruit phosphatases, including the tyrosine phosphatases; Src 
homology 1-domain containing tyrosine phosphatase (SHP-1) and Src homology 2-
domain containing tyrosine phosphatase (SHP-2) that attenuate ITAM-induced 
signalling by dephosphorylating and thereby inactivating signalling intermediates (77). 
ITAMs can also generate inhibitory signals and attenuate signalling by heterologous 
receptors (92), (93), (94). Although specific ITAM-associated receptors may be 
predominantly inhibitory, several experimental systems show that the same ITAM-
coupled receptors can generate both positive and negative signals (77).  
Next, ITAMs with both tyrosines phosphorylated are required to recruit the non-
receptor tyrosine kinase, zeta-chain-associated protein kinase of 70 kDa (ZAP-70), 
through its paired Src homology 2 (SH2) domains (95). The ZAP-70 kinase was 
originally identified by virtue of its association with the TCR zeta homodimer, an 
association mediated by the binding of the two Src homology (SH2) domains of ZAP-
70 to tyrosine-phosphorylated motifs in the zeta protein (95), (96). The recruitment and 
activation of ZAP-70 then phosphorylates a series of adaptor proteins that lead to the 
recruitment of phospholipase C-γ (PLC-γ) and phosphatidylinositol-3 kinase (PI3-K) to 
the activated TCR complex (97).  The ZAP-70 phosphorylate sites that lead to the 
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recruitment of adaptor proteins; SH2 domain-containing leukocyte phosphoprotein of 
76 kDa (SLP-76), LAT, Gads (Grb2-related adaptor downstream of Shc) and Grb 2 
(growth factor receptor bound protein 2) (97). The SLP-76 recruits the guanine 
nucleotide exchange factor (Vav) and the non-catalytic region of tyrosine kinase (Nck), 
which then recruits the Wiscott-Aldrich syndrome protein (WASP). The activated 
WASP orchestrates the formation of complex actin-based structures which induce 
cytoskeletal rearrangements (98). These rearrangements are important for integrin 
signalling and the formation of the immunological synapse. The immunological 
synapse is triggered by tyrosine phosphorylation by ITAMs and Ca
2+ 
mobilization by 
PLC-γ (58). The predominant effector systems involved in the intracellular 
transmission of TCR signals resemble those defined in other systems, such as calcium-
dependent kinases and phosphatases (77). Also, the guanine triphosphate (GTP)-
binding proteins control common signalling effectors such as serine / threonine kinase 
cascades of the mitogen-activated protein kinase (MAPKs) type. Signalling effectors 
act to regulate the function of transcription factors, such as the nuclear factor of 
activated T cells (NF-AT) (77). NF-AT and the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF- B) promote the transcription of a number of genes, 
most importantly interleukin-2 (IL-2), which is a cytokine which promotes the long 
term proliferation of activated T cells (77).  
1.3 Tumour antigens 
 
Antigens found in tumours are non-immunogenic antigens (99). Adaptive immune 
responses have been found against many tumour antigens in  cancer  patients  (100),  
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Figure 1.2 TCR signalling. Protein tyrosine kinases activated by the ligand binding of 
the TCR initiated TCR signalling by phosphorylating tyrosine residues on a number of 
associated membranes and soluble substrates. The engagement of the TCR by an 
MHC/peptide complex initiates the activation of Lck and ZAP-70, the recruitment of 
adaptor proteins, and the activation of effector pathways. The co-receptors (CD4 or 
CD8) and signalling modules (CD3εγ and CD3εδ) can be assembled to form a complete 
TCR/pMHC complex that influences the TCR signalling event.  
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(101). The most frequently analysed antigens are p53, MUC1, NY-ESO-1, c-myc, 
survivin, p62, cyclin B1, and Her2/neu (102). There are two types of tumour antigens – 
tumour-specific antigens (TSA) and tumour-associated antigens (TAA). TSA are 
specifically expressed in tumours and may even be over-expressed in tumours. As TAA 
are self-antigens, responses to them may be limited due to self-tolerance. The tolerance 
of T cells to tumour-specific antigens results in T-cell anergy, which can be caused by 
host APCs, myeloid cells or regulatory T cells (103). The immune responses in cancer 
patients may be initiated by alterations in the tumour itself that result in the increased 
immunogenicity of self-antigens (103).   
The immune system does not recognise the low levels of TAA in the early phases of 
tumour growth. Several antigens have been identified in tumour cells but none at all, or 
only in very low levels, in normal cells and these might therefore function as TAA 
capable of priming the immune system to recognise tumour cells (104), (105). TAA can 
emerge through different mechanisms, such as the coding of DNA mutations that lead 
to new epitopes in expressed proteins, post-translational modifications with 
immunological relevance, and altered tissue-specific expression patterns that can lead 
to the exposure of antigens in immunoprivileged sites (106), (107), (108). The 
immunosurveillance hypothesis forwarded the idea that the immune system recognises 
malignant cells as foreign agents and eliminates them (109).  
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1.4 How tumours evade immune recognition 
 
 
It is postulated that the immune system recognises and eliminates tumour cells (110). In 
the 1980‟s, the cancer immunosurveillance concept forwarded the idea that the immune 
system may have a protective role against tumour development (111). Developing 
tumours may therefore present with a mechanism to escape immunologic detection and 
elimination (111).  The hypothesis of cancer immunosurveillance rapidly led to many 
studies (111), (112), (113), (114). These experiments were aimed at testing whether 
hosts with impaired immune systems would exhibit increased incidences of induction 
of transient immune responses by tumour and cancer development (110). Because 
tumour cells that evade the immune system are selected, this immunoselection in 
cellular immune responses may prevent the development of cancer (112). Despite many 
studies and the continuing lack of convincing support for the immunosurveillance 
concept, it has opened opportunities for other theories on the possible functions of 
immune cells during the development of cancer (111). As a result, the cancer 
immunosurveillance concept was considered irrelevant to describe the protection of the 
dual host and the tumour sculpting actions accurately (113). Cancer immunoediting was 
used to describe the process involving the selection of tumour cells that have developed 
immune evasion strategies (114). Tumour cells evade the host‟s immune response via a 
variety of active and regulatory mechanisms (115), (116). Some of these mechanisms 
are the downregulation of MHC Class I molecules in the tumour cells, lack of tumour 
co-stimulatory molecules, stimulation of inhibitory receptors on the T cells, tumour 
overproduction of indoleamine 2,3-dioxygenase (IDO) and the induction of increased 
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tumour infiltration by Tregs. Several of these mechanisms might potentially be 
responsible for the failure of the immune system to respond to tumours (117). When the 
immune system ultimately fails to eliminate tumours, tumours may emerge and be 
capable of escaping immune destruction (118). In some circumstances, these tumours 
may perform editing to manipulate certain reactions for their own benefit 
(118). Immunoediting can bring about three outcomes; elimination of the cancer, cancer 
equilibrium and tumour escape (Figure 1.3) (119), (120).  
Elimination consists of the classical concept of cancer immunosurveillance (120). 
Elimination is where premalignant and early stage malignant cells are directly or 
indirectly removed by immune cells (120). In the equilibrium process, the host‟s 
immune system and any tumour cell variant that has survived the elimination process 
enter a dynamic equilibrium (120). Equilibrium is the period of immune-mediated 
latency after incomplete tumour destruction (120). Escape refers to the growth of 
tumour variants that resist immune destruction (119). In the escape, surviving tumours 
from the elimination process begin to expand in an uncontrolled manner (110). Tumour 
escape may also result from the downregulation of key receptor ligands and the 
acquisition of apoptotic resistance due to alterations in the extrinsic or intrinsic death 
signalling pathway (110). Recently, the concept of cancer immunosurveillance was 
integrated in the cancer immunoediting hypothesis. It summarised that a physiologic 
function of the immune system is the recognition and elimination of transformed cell 
clones (121). An integrated cancer immunoediting concept with immunosurveillance 
proves that the immune system not only protects the host against tumour development 
but also poses significant challenges to successful cancer immunotherapy (113).  
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Figure 1.3 The three Es of cancer immunoediting: elimination, equilibrium and escape. 
Elimination corresponds to immunosurveillance, while equilibrium may promote 
oncogenesis/tumour development by immunoselection. Escape is where tumours grow 
in an uncontrolled manner and lead to immunosubversion. The arrows indicate the 
activation and inhibition activity. 
 
1.5 Cellular responses to tumours 
 
The majority of cancer immunotherapy efforts are devoted towards stimulating cellular 
immune responses against the growing tumour (122). The tumour cells have acquired 
the ability to affect the expression of a number of cell surface molecules. The 
expression of these molecules is required for efficient host cellular-tumour interactions 
and tumour cell destruction (117). The overall cellular response is determined by the 
integration of all signals, either stimulatory or inhibitory (123). For example, T cell 
populations in TILs obtained from cancer patients showed a decrease in tyrosine 
kinases, which play a role in the proximal TCR, signalling events that lead to optimal T 
cell activation (124). In some cancer patients, the number of circulating T cells, 
particularly CD8
+
 T cells, are decreased because of tumour-induced mechanisms of 
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apoptosis (125), (126). CD8
+
 T cells are distinguished by their fine specificity for 
antigens, which they recognise using a clonally unique TCR. Target cells are „flagged‟ 
for the attention of CD8
+
 T cells when they present antigen-derived peptide fragments 
on the cell surface, inserted into the grooves of MHC class I molecules (127). CD8
+
 T 
cells represent a crucial component of the adaptive immune system (127). Activated 
CD8
+
 T cells, once loaded with cytolytic machinery, will kill target cells that can 
express the target antigen complex with a small number of MHC Class I molecules 
(66). CD8
+
 T cells have the capacity to promote the apoptotic death of carefully chosen 
target cells, using a combination of granules (perforin or granzyme) - and receptors 
(Fas or tumour necrosis factor-mediated mechanisms) (127).  
In addition to their cytolytic function, a number of other properties render the CD8
+
 T 
cells attractive as mediators of anti-tumour immunity (127). The widespread expression 
of the MHC class I molecules means that CD8
+
 T cells can be deployed against 
malignancies of diverse origins. CD8
+
 T cells continuously recirculate throughout the 
body to seek out antigens, a useful property for the treatment of systemic diseases 
(128). The target recognition is impressively sensitive, as even a single peptide–MHC 
class I complex may trigger cytolysis by high-avidity CD8
+
 T cells (129). CD8
+
 T cells 
also employ non-lytic effector mechanisms, including the production of IFN-γ, a 
cytokine with several direct and indirect anti-tumour properties (130). The induction of 
CD8
+
 cytotoxic T lymphocytes may need the activated CD4
+
 T cells, which also 
mediate in tumour cell destruction and promote inflammation. The CD4
+
 T cells 
cooperate with the CD8
+
 T cells and help the B cells to produce cell destructive anti-
tumour antibodies (117). The induction of CD8
+
 cells with a specific immune reactivity 
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depend on interactions not only with CD4
+
 T cells but also with APCs (127). APCs, 
mainly DCs (dendritic cells), monocytes/macrophages and activated B cells, express or 
upregulate relevant MHC and co-stimulatory molecules under appropriate 
inflammatory conditions (113). These cells are then capable of inducing an immune 
activation by presenting TAA through either exogenous or endogenous pathways to the 
CD4
+
 and CD8
+ 
T cells respectively (113). A growing tumour attracts a response from 
many components of the host such as DCs, CD4
+
 T cells and CD8
+
 T cells (131).  
Tumour antigens and soluble tumour products attract DCs to the tumour site (131). For 
full T cell activation, the DCs must have the capacity to process and present TAA to 
both the CD4
+
 and CD8
+
 T cells and simultaneously supply the relevant co-stimulatory 
signals (113). DCs are mainly responsible for the initiation of an immune 
response. However, within a highly immunoresponsive tumour microenvironment, DCs 
may fail to induce effector functions in the antigen-specific T cells that they interact 
with (113). Therefore, DCs have been shown to play a major role in dictating whether T 
cell priming or tolerance can occur. These DCs take up tumour antigens, mature into 
interleukin-12 (IL-12) producing cells, and in the draining lymph node stimulate T 
helper 1 (Th1)–type CD4+ T cells that produce interferon gamma (IFN-γ) (131). DCs 
help expand the population of CD8
+
 T cells that can destroy tumour cells through 
effector molecules granzyme B and perforin (131). To achieve the optimum expansion 
of CD8
+
 T cells, two additional requirements should be met (127). First, since CD4
+
 
and CD8
+
 T cells are restricted by different MHC families, it is desirable that DCs 
process antigens to enable the presentation of derived epitopes both by MHC class I 
and II (127). Second, appropriate co-stimulatory signals must be provided to 
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complement those delivered by the TCR (Figure 1.4) (127). These accessory signals are 
delivered by several ligands, many of which are upregulated on dendritic cells (127). 
The best characterised of these are the members of the B7 family, which engage the T 
cell-associated CD28. Nevertheless, tumour cells display multiple immunosuppressive 
mechanisms to evade effector T cells and avoid immune or antigen recognition (132), 
(133), (134). These mechanisms include defects in proximal TCR signalling, secretion 
of proapoptotic factors and activation of negative co-stimulation pathways.  
Anti‐tumour immune responses generally exist but are inadequate because tumours 
evade immune recognition. In addition, tumours may avoid presenting their antigens, 
which result in inefficient activation of effector cells. The tumour microenvironment is 
immunosuppressive. Tumours can suppress immunity, both systemically and in the 
microenvironment of the tumour (135). However, there have been clinical scenarios 
where the immune response, if appropriately manipulated, can mediate anti-tumour 
activity (113). The immune system is naturally equipped with complex inhibitory 
circuits to keep T cell responses under control (117. Evidence suggests that tumour 
cells can recruit different types of immunosuppressive effectors within the tumour 
microenvironment and draining lymph nodes (136). The main question concerns how 
many negative pathways must be shut down to affect the immune response to cancer 
(136). Tumours can escape from immune targeting by CD8
+
 T cells in several ways. 
Cancer cells contain a predominance of poorly immunogenic self-antigens because 
cancer cells are closely related to „self‟ (127). Cancer cells have poor antigen 
presenting properties since they provide limited co-stimulation and may downregulate 
the MHC antigen expression (127).   
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Figure 1.4 Immunosuppressive mechanisms that may act in a contact dependent 
manner to counteract effective immune responses. The best characterised of these are 
the members of the B7 family, which engage the T cell-associated CD28. The 
activation of negative co-stimulation in the tumour microenvironment is contributed by 
the PD-1/PD-L1 binding.  
 
49 
 
The tumour microenvironment is frequently rich in cytokines. The tumour 
microenvironment may also compromise DC differentiation by the presence of 
cytokines such as interleukin-6 (IL-6), interleukin-10 (IL-10), the macrophage colony 
stimulating factor (MCSF), the vascular endothelial growth factor (VEGF) and the 
transforming growth factor-β (TGF-β) in the tumour microenvironment (127). Other 
than that, the activation, proliferation and effector function of the T lymphocytes are 
also compromised (127). Cancer cells may acquire resistance to apoptosis, which is the 
key effector mechanism of CD8
+
 T cells and other cells of the immune system (127). It 
has been suggested that the specific recruitment of cell populations, such as Tregs, 
promotes immune tolerance to cancer.   
Central tolerance and peripheral tolerance are responsible for maintaining a balance 
between health and disease (118). Central tolerance is the first line of defence against 
self-destruction. Meanwhile, peripheral tolerance, which is the second line of defence, 
is where mature T cells are deleted in the lymphoid and non-lymphoid organs. Since 
central and peripheral tolerance fail to eliminate all self-reactive immune effector cells, 
other immune regulating mechanisms have evolved in order to prevent an excessive 
immune response (118). Immune regulating mechanisms can function to alert the 
immune system of potential collateral damage and trigger immunosuppressive actions 
(Figure 1.5) (118). Regulatory cells, such as Tregs, produce immunosuppressive 
cytokines and express CTL-associated antigen-4 (CTLA-4) (136). CTLA-4 is one of 
the best studied molecules, and the antibody-mediated blockade of CTLA-4 enhances 
anti-tumour immunity (136). 
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Figure 1.5 Immunosuppressive actions on tumour cell by immune cells. Tumours are 
often infiltrated by a broad range of cells such as regulatory T cells, DCs, T helper cells 
and cytotoxic T cells. Some of these cells produce a number of immunosuppressive 
cytokines such as TGF-β, IL-6, IL-10, IL-13 and IL-23.  
 
 
1.6 Humoral responses to tumour cells 
 
 
An antigen-specific adaptive immune response is comprised of activated cytotoxic 
CD8
+
 T cells, different CD4
+
 T cell subsets, and B cells (137). CD8
+
 T cells have the 
ability to directly destroy antigen-expressing target cells, while CD4
+
 T cells may 
modulate the strength, duration, and efficacy of the immune reaction. Additionally, B 
cells produce antigen-specific antibodies in the humoral immune response.  
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Almost 30 years after their development, monoclonal antibodies (mAbs) are now 
commonly used in the treatment of selected malignancies (127). Therefore, the humoral 
response against tumours is present, but its significance is not very clear (136). 
Researchers have tried to produce mAbs with new effector functions against known 
targets and to identify new targets for therapeutic mAbs (131). The analysis of humoral 
immune responses against tumour antigens could yield diagnostic and prognostic 
markers and might lead to the exploration of new targets for immunotherapy (102). 
MAbs against tumour antigens are frequently found in the serum of cancer patients and 
have been analysed in many studies in the past (102). However, the biological and 
clinical relevance of humoral immune responses against tumour antigens has not been 
systematically evaluated to date. Some mAbs directed against TAA seem to be mere 
markers of exposure to the antigen without functional relevance. These immune 
responses might be used for early detection as a prognostic marker and for post-
treatment surveillance (102).   
 
1.7 Successful anti-tumour immune therapies 
 
Three criteria are required for the immunologic destruction of established tumours. 
Firstly, sufficient numbers of immune cells with a highly avid recognition of tumour 
antigens must be generated in vivo. Secondly, these cells must travel to and infiltrate 
the tumour stroma. Thirdly, the immune cells must be activated at the tumour site to 
manifest appropriate effector mechanisms such as direct lysis or cytokine secretion 
capable of causing tumour destruction (122).  
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Tumour cells can induce immune tumour suppressor mechanisms, which can be 
exploited therapeutically (122). Much has been learned about the potential of the 
immune system to control cancer and the various ways that immunotherapy can boost 
the potential of the immune system for the benefit of the patient (131). Immunotherapy 
knowledge has stimulated the development of many new therapeutic antibodies, cell-
based treatments and vaccines which are starting to be used in clinical practices, either 
alone or in various combinations. Moving preventive efforts from mouse models to 
clinical trials is problematic. Evidence of safety and potential efficacy in humans is 
needed for approval to initiate early-phase trials, yet the results of such trials are needed 
to provide the required evidence. The solution to this impasse may be to obtain 
supportive evidence indirectly (131). The greatest success of clinical immunology has 
been the development of vaccines for infectious diseases (127). This approach is 
unlikely to be effective in cancer. The majority of infectious disease vaccines achieve 
host immunity since they elicit a protective antibody response (127).  
 
1.8 Immune regulatory signals 
 
The activation of T lymphocytes is dependent upon the presentation of processed 
antigenic peptides in association with MHC molecules to lymphocytes that express a T 
cell receptor specific for that binary complex (137), (138). However, optimal 
lymphocyte activation requires a second signal that is delivered by the interaction 
between co-stimulatory and accessory molecules (139), (140). T cell co-regulatory 
receptor-ligand interactions can provide either positive “go” signals to amplify antigen-
specific-T cell activation or “stop” signals” that can inactivate or kill T cells (141). 
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1.8.1 Immunological features of regulatory T cells  
 
A subpopulation of T cells known as suppressor T cells were first described in early 
1971 by Gershon and Kondo as being able to suppress immune responses (142), (143). 
Following a study by Gershon in 1975, suppressor T cells in mice were thought to 
cause suppression by secreting antigen-specific suppressor factors (144). With these 
descriptions of suppressor T cells in the early 1970s, the characterisation of suppressor 
T cells, now known as T regulatory cells (Tregs), has made considerable progress. It is 
now well established that human Tregs can be divided into subpopulations based on 
their expression of cell surface markers.  
Human Tregs were first characterised as CD4
+
 CD25
+
 T cells in 2001 by several groups 
based on the finding in 1995 that mouse Tregs constitutively express CD25 (145), 
(146), (147), (148). CD25 is the interleukin-2 receptor α chain (IL-2R) (149). Besides 
the fact that the CD25 expression can be easily identified and isolated from 
unmanipulated mice and humans, this chain of the IL-2R is also expressed on activated 
T cells (150), (151), (152). Therefore CD25 is not a unique surface marker for T 
regulatory cells. Subsequent studies on T regulatory cells were hindered because of a 
lack of specific molecular markers and difficulties in their isolation and culture (153). 
In 2003, the forkhead helix transcription factor (FOXP3) was described as a master 
control gene for the development and function of T regulatory cells in mice, and 
subsequent studies have confirmed that the FOXP3 is a specific marker for human 
Tregs (154), (155), (156). The FOXP3 is a member of the forkhead family of 
deoxyribonucleic acid (DNA) transcription factors and was cloned a few years ago 
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(157). The FOXP3 was shown to be specifically expressed by CD25
+
 Tregs (157), 
(158), (159) and is highly expressed by Tregs. However, whether the FOXP3 is the 
marker that uniquely distinguishes all populations of Tregs still remains unclear. The 
classic Treg is a thymus derived CD4
+ 
CD25
+ 
FOXP3
+
 T lymphocyte (153). It is as yet 
unclear whether the FOXP3 is induced exclusively at a specific period of development 
in the thymus, or whether it can be upregulated in the periphery (160). However, there 
is now considerable evidence that the FOXP3 is a key control molecule for Tregs 
development and function, and is an excellent marker for the study of Tregs (153), 
(155).  
Both CD25 and the FOXP3 expression could be upregulated in human naive CD4
+
 T 
cells through cell activation but it is unclear whether the FOXP3
+
 T cells can be 
identified as pure T regulatory cells (161). Subsequent studies from other groups 
reported that the FOXP3 could also be upregulated on non-regulatory T cells, CD4
+
 
CD25  T cells (162), (163). It is still unclear whether this upregulation was in Tregs 
that had lost the expression of CD25 (160). Therefore, more studies are needed to 
confirm the function of the CD4
+ 
CD25
+ 
FOXP3
+
  T cells as it is now clear that some 
FOXP3  T cells are suppressive and that not all FOXP3
+
 cells are Tregs (164), (165), 
(166). The existence of this non-regulatory FOXP3 low T cell population in normal 
individuals precludes the use of the FOXP3 expression as a sole marker for human T 
regulatory cells (167). As detection of intracellular FOXP3 makes it difficult to conduct 
a functional assessment of T regulatory cells, cell surface markers are crucial for 
identifying viable T regulatory cells (167).  
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Although the CD4
+ 
CD25
+
 Tregs do not have a unique cell surface phenotype, Tregs 
express cell surface markers that have enabled investigators to selectively purify the 
cells and to demonstrate their function in vivo and in vitro (168). The CD25, CTLA-4, 
glucocorticoid induced tumour necrosis factor alpha receptor (GITR) and the CD95 
(also known as the Fas or tumour necrosis factor receptor superfamily) are the known 
Tregs cell surface and biomarkers, where the human FOXP3 was found to be expressed 
by both activated and non-activated regulatory T cells in the peripheral blood (167). 
Recent studies have also shown that the expression of CD45RA or CD45RO cell 
surface markers is mutually exclusive in FOXP3
+
 T cells (167) (168). These cell 
surface markers are particularly useful when combined with CD25 and/or the FOXP3 
expression (169), (170), (171), (172). Specific phenotypic markers are indicated during 
the CD4
+
 T cell differentiation (167). They are either indicated as cell surface markers 
for T cell lineages or T regulatory cells (167). All T cell lineages originate in the 
thymus and emigrate as naïve T cells (CD45RA
+
 cells) (167).  
The activation of naïve T cells in the periphery induces their differentiation into both 
conventional T cells and T regulatory cell subsets (167). Conventional T cells can 
further differentiate into memory T cells (CD45RO
+
 cells), and T regulatory cells have 
been shown to differentiate into terminal effector Tregs with unique cell surface marker 
expressions (167). Moreover, contributing to the CD45RA
– 
peripheral Treg cell 
compartment are converted Treg-like cells, which are derived from conventional T cells 
(167). These converted Treg-like cells have a cell surface marker expression profile 
similar to that expressed by natural T regulatory cells (nTregs) (167).   
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Figure 1.6 Thymocyte differentiation to memory T cells and regulatory cell subsets. 
Human T regulatory cells can be divided into subpopulations based on their expression 
of cell surface markers such as FOXP3, CD45RA, CD45RO, CTLA-4, CD25 and 
CD95. 
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Thymocyte differentiation progresses from FOXP3
–
 and FOXP3
+
 low progenitors 
either directly to memory T cells or to terminal effector T regulatory cells (Figure 1.6) 
(167). Most FOXP3
+
 thymic Tregs differentiate from FOXP3
– 
thymocytes (173). The 
process of thymic Tregs differentiation as defined by induction of FOXP3 requires: (1) 
increased strength of TCR stimulation by self-peptide-MHC complexes presented by 
thymic epithelial cells (TECs) or DCs, (2) CD28 signalling induced by CD80 and 
CD86 ligands expressed on APCs, and (3) high-affinity IL-2R and other cytokine 
receptor signalling. Treg cell homeostasis is dependent on interleukin-2 (IL-2) 
produced by effector T cells (173). 
The two most relevant classes of Tregs described within the CD4
+
 subset are T 
regulatory type 1 (Tr1) cells and CD4
+
CD25
+
 Tregs (174), (175), (176). These two 
Treg subsets differ in a number of important biological features, including their specific 
cytokine secretion profile, cellular markers, ability to differentiate in response to 
antigen-specific stimuli, and dependency on cytokines versus cell to cell contact 
mechanisms for mediating suppressive activity (177). However, Tregs are commonly 
known for their phenotypically identical populations of CD4
+ 
CD25
+
 Tregs, which have 
now been described as nTregs and induced Tregs (iTregs) (178). Tregs exist in the 
normal host as nTregs, but can also be induced in the presence of suppressive cytokines 
(150). nTregs represent a small fraction (5 to 10%) of the overall CD4
+
 and have been 
characterised in humans (179). nTregs can either be identified as CD4
+
CD25
+
 or 
CD4
+
CD25
−
 T cells (179). nTregs arise in the thymus under homeostatic conditions 
(179). nTregs develop during the normal process of T cell maturation in the thymus and 
execute their regulatory function during the normal surveillance of self-antigens (178).  
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Figure 1.7 Induced suppressor T cell existing in the normal host. iTregs are generated 
by cultures in the presence of suppressive cytokines (such as IL-10 and IFN-α), by the 
administration of antigens in a tolerogenic form or by exposing effector T cells to 
antigens under anergising conditions such as immature dendritic cells (iDC),  IL-10 and 
IFN-α.  
 
nTregs suppress immune responses in a contact dependent manner and function in 
general homeostasis to block the actions of autoimmune T cells in non-inflammatory 
settings (167). The thymus is not the only place where Tregs are generated. Induced 
CD4
+ 
CD25
+
 Tregs or iTregs arise during inflammatory processes such as infections 
and cancers (178). iTregs suppress immunity through heterogeneous mechanisms that 
include direct contact or the production of soluble factors (178). Other types of iTregs 
might be generated by cultures in the presence of suppressive cytokines, such as 
interleukin-10 (IL-10) and interferon alpha (IFN-α), by the administration of antigens in 
a tolerogenic form or by exposing effector T cells to antigens under anergising 
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conditions (Figure 1.7) (180). The iTregs enhance the nature of suppression in an 
inflammatory milieu. Most importantly, iTregs can develop from CD4
+
CD25
–
 nTregs 
(180). 
 
1.8.2 Regulatory T cells suppressive mechanisms 
 
In 1995, Sakaguchi and colleagues focused on Tregs and demonstrated that the 
suppressive function of Tregs largely resided in a population of CD4
+
 T cells 
expressing high levels of CD25 (181). Following studies by other groups later, they 
confirmed that only the CD4
+ 
CD25
+
 subset of Tregs can be functionally suppressive 
(178), (182). Tregs can mediate their suppressive function via multiple mechanisms 
(Figure 1.8) (183). Tregs suppress auto-reactive T cells without killing them, and this 
may be mediated via a cell contact dependent mechanism or through the actions of 
cytokines (Figure 1.8) (178), (182), (183). Suppression is triggered only when the 
CD25
+
 T cells are activated through their TCR. However, these cell contact dependent 
mechanisms are incompletely understood (164), (165), (178), (182), (184), (185), (186), 
(187).  
Human Tregs must be activated through their TCR to be functionally suppressive (188), 
(189), (190), (191). Human Tregs undergo activation-induced modulation of specific 
cell surface molecules and can mediate suppression (167). FOXP3
+
 Tregs, most of 
which are CD4
+
 T cells that express CD25, can suppress the activation, proliferation 
and effector functions (167). This involves cytokine production by a wide range of 
immune cells, including CD4
+
 and CD8
+
 T cells, natural killers (NK), NKT cells, B 
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cells and APCs, in vitro and in vivo (192). In the periphery, FOXP3
+
 Tregs mediate 
immune suppression through a cell contact dependent mechanism involving 
suppression of IL-2 and IFN-  secretion by these immune cells (193). The unique 
ability of FOXP3
+
 Tregs to control immune responses makes FOXP3
+
 Tregs important 
for the prevention of autoimmune diseases, for immunopathology and allergies as well 
as for the maintenance of allograft tolerance and foetal–maternal tolerance during 
pregnancy (194). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Two classes of regulatory T cells which involve mechanisms of contact-
dependent and cytokine-mediated suppression. Arrows indicate stimulation and 
suppression activity; while cytokine secretions were also present.  
Contact dependent suppression         Cytokine-mediated suppression 
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Only 1 to 2% of cells with the highest CD25 expressions have been shown to be 
functionally suppressive and can be considered as Tregs (146), (195). Similarly, the 
existence of specific cell surface molecules which may be involved in direct T cell to T 
cell interactions also remain to be established (196), (197), (198). IL-2 signalling is 
thought to be crucial for the development of Tregs. If Tregs fail to produce IL-2, they 
will present a specific defect in their ability to proliferate after TCR mediated activation 
(181), (199). A murine study found that there are reduced numbers of CD4
+
 Tregs in 
IL-2-deficient mice. This was also followed by other studies which revealed that IL-2 is 
essential for the peripheral maintenance of Tregs but not for their generation and 
development in the thymus (200), (201), (202), (203). Another experiment, which was 
conducted to study IL-2 deficiencies, discovered that neutralisation with specific 
antibodies will substantially, although not completely, reduce the number of FOXP3 
Tregs (204), (205). This means that CD25, which is the IL-2R α-chain, is not only a 
highly specific marker for nTregs but is also functionally essential for the survival of 
Tregs (206), (207), (208).. 
FOXP3
+
 T cells are heterogeneous and include regulatory and non-regulatory T cell 
subsets (167). It is important and necessary to quantitatively and qualitatively assess 
each subpopulation of FOXP3
+
 T cells, rather than to assume that the whole FOXP3
+
 T 
cell population is comprised of CD25 high T regulatory cells (167). The FOXP3 is 
clearly responsible for the suppressive function of Tregs that controls the expression of 
several characteristic genes, such as the CD25, GITR and CTLA-4, which are also 
highly expressed in conventional T cells upon TCR stimulation (164), (187). The 
CD25, GITR, CD95 and CTLA4 are all known to be upregulated by activated 
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conventional CD4
+
 T cells (167). The CD25 is expressed by activated effector T cells 
and Tregs, whereas the CTLA-4 is a negative promoter factor necessary for CD4
+ 
CD25
+
 Tregs to exert inhibitory functions via the CD80 or CD86 (209). 
The CTLA-4 is a negative immunomodulator that is expressed on activated T cells and 
delivers an inhibitory signal during immune responses (210). The CTLA-4 is also 
constitutively expressed by CD4
+
 CD25
+
 Tregs and is upregulated after TCR 
stimulation (173), (211), (212). The CTLA-4 expressed by T regulatory cells can 
modulate CD80 and CD86 expressions by DCs and thereby inhibit the activation of 
effector T cells (167). The engagement of the CTLA-4 on CD4
+
 CD25
+
 T cells by its 
CD80 or CD86 ligands is required for the induction of suppressor activity in these T 
cells (213). It downregulates or prevents the upregulation of CD80 and CD86, the 
major co-stimulatory molecules on APCs (213). A recent study in mice has shown that 
CTLA4 is crucial for the suppressive function of FOXP3
+ 
Tregs both in vitro and in 
vivo (214). Also, the engagement of the CTLA-4 on CD4
+ 
CD25
+
 T cells by anti-
CTLA-4 antibodies can lead to the inhibition of the signals that are required for the 
induction of suppressor activity (215).  
GITR is a co-stimulatory molecule expressed at different levels in resting CD4
+ 
and 
CD8
+
 T cells and it is upregulated by T cell activation (216). The molecule is also 
constitutively expressed on CD4
+ 
CD25
+
 Tregs at high levels (216). GITR may 
contribute to the tuning of CD4
+ 
CD25
+
 regulatory T cells in immunoregulation 
because active signalling through GITR to CD4
+ 
CD25
+
 regulatory T cells attenuates 
their suppressive activity (216), (217). Nevertheless, studies to incorporate a blockade 
of GITR on Tregs failed to abrogate completely their suppression (218). This is due to 
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the fact that GITR is not only expressed on the surface of Treg cells but also on CD4
+ 
CD25
−
 T cells and APCs in varying degrees (219). Therefore, the activation of GITR 
signalling with agonistic anti-GITR mAb or GITR ligands can inhibit the suppressive 
activity of CD4
+ 
CD25
+
 Tregs (220), (221), (222). The expressions of CD25, CTLA-4 
and GITR are not faithful indicators of regulatory T cells because conventional CD4
+ 
CD25
−
 T cells tend to express those phenotypic markers once activated by TCR 
stimulation (223). Therefore, expressions of CD25, CTLA-4 and GITR are not 
sufficient to distinguish regulatory T cells from activated responder T cells (197). In 
addition to these markers, Tregs also secrete immunosuppressive cytokines such as 
TGF-β and IL-10 (224). The secretion of TGF-β and IL-10 is also a common feature of 
Tregs, and the activity of these two cytokines is involved in their ability to control 
some, but not all, immune responses in vivo (225). 
TGF- , a 25 kDa homodimeric polypeptide, was initially thought to be produced by 
CD25
+
 T cells and to be the main mechanism by which CD25
+ 
T cells mediate 
suppression (150). Now, TGF-β is also known to be produced by many different cell 
types, including tumour cells (226). Tumour cells may stimulate immature myeloid 
dendritic cells to secrete TGF-β (227). Numerous studies have revealed that TGF-β 
could convert peripheral CD4
+ 
CD25
−
 T cells into CD4
+ 
CD25
+
 regulatory T cells 
(162), (228). TGF-β can act on CD4+ CD25− naïve T cells to induce FOXP3 and 
generate iTregs that suppress immune responses (162), (229). TGF-β also plays an 
important role in the maintenance of the FOXP3 expression, suppressive function and 
homeostasis in peripheral CD4
+ 
CD25
+
 Treg cells (196), (230), (231). Tumour cells not 
only secrete TGF-β but also IL-10, thus promoting the generation of Tregs from CD4+ 
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CD25
− 
naïve T cells in the tumour microenvironment (227), (232). IL-10 was originally 
described as a cytokine produced by Th2 cells (233). Now, it has become clear that IL-
10 is also produced by numerous cell types such as macrophages, B cells and dendritic 
cells (233), (234). IL-10 is required for the induction of antigen specific Tr1 cells in 
vitro and in vivo (235). The Tregs function in vivo is IL-10 and / or TGF-β-dependent in 
several systems, where suppression can be abrogated by antibodies against IL-10 and / 
or TGF-β (236).  
Tregs can condition DCs through a mechanism dependent on interactions between 
CTLA-4 and CD80 and CD86 to express IDO, which is a potent regulatory molecule 
that induces the catabolism of tryptophan into proapoptotic metabolites that result in the 
suppression of the activation of effector T cells (213). IDO induction was found to 
depend on a high expression of CTLA-4 on the Treg cells (213). However, there is no 
clear evidence of the involvement of IDO in T regulatory cell functions in vivo or in 
vitro (213).  
 
1.8.3 Regulatory T cells in tumour environment 
 
nTregs possess the following features relevant to their roles in tumour immunity (141). 
First, nTregs are capable of suppressing a wide variety of immune responses against 
self and non-self antigens, including tumour antigens (237), (238). Second, nTregs are 
highly IL-2-dependent for their survival. This means that CD25, which is the IL-2 
receptor α chain, is not only a highly specific marker for nTregs but also functionally 
essential for Treg survival. Third, nTregs are hypoproliferative in vitro on TCR 
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stimulation and suppress the proliferation and cytokine secretion of responder T cells 
(239), (240). The tumour itself and the cells in the tumour microenvironment may 
induce the differentiation of nTregs and/or iTregs through various mechanisms (149), 
(197). Differentiated nTregs and/or iTregs can inhibit tumour specific CD8
+
 and CD4
+
 
T cell effector functions through incompletely understood mechanisms, including cell 
to cell contact and the production of soluble factors (150), (181), (199), (241), (242), 
(243).  
iTregs can be induced in vivo and in vitro (149), (165), (244). These iTregs, also known 
as FOXP3
+
 Tregs, can also suppress anti-tumour immune responses and favour tumour 
progression (245). iTregs may be induced from the conversion of CD4
+ 
CD25
− 
FOXP3
− 
T naïve T cells to CD4
+ 
CD25
+ 
FOXP3
+
 Treg cells in the suppressive cytokine milieu 
of tumour sites (245). CD4
+ 
CD25
+ 
FOXP3
+
 Treg cells mediate their suppression by 
cell contact and the secretion of immunosuppressive cytokines such as IL-10 and TGF-
β (224). There is growing evidence that CD4+ CD25+ FOXP3+ Treg cells impede the 
development of effective tumour immunity in cancer bearing hosts (167). Once nTregs 
are activated by a specific antigen, they suppress responder T cells in an antigen-
nonspecific and bystander manner in vitro (239), (240). This implies that tumour 
infiltrating Tregs activated by either tumour derived self-Ag or TAA can similarly 
suppress specific anti-tumour immune responses (141).  Tumour cells not only provide 
antigenic stimulation for T cell activation but also interact with tumour infiltrating 
immune cells to secrete essential cytokine and chemokines for T cell differentiation. 
For example, the C-C motif chemokine 22 (CCL22) produced by tumours and tumour 
infiltrating macrophages, recruit C-C chemokine receptor type 4 (CCR4) expressing 
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Tregs responsible for Treg migration (141). Tregs accumulated via CCR4-CCL22 
recognise tumour associated immunogenic self-antigens and proliferate (Figure 1.9) 
(141).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Tregs suppress anti-tumour immune responses. The mechanism of Tregs 
recruitment to tumours proposed that tumour cells and tumour-infiltrating macrophages 
produce the chemokine CCL22, which attracts and recruits CD4
+
CD25
+
Tregs 
expressing CCR4. The arrows indicate the stimulation and suppression activity; while 
cytokine secretions were also present.  
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Immune cells secrete crucial cytokines for T cell differentiation and Treg cell 
expansion. Therefore, Treg expansion can also be further enhanced by DCs induced by 
TGF-β derived from tumours (226). Tregs derived from this mechanism can also 
suppress anti-tumour effector cells (141). Although most studies focus on tumour sites, 
Treg expansion also occurs in the draining lymph nodes (141). Some Tregs produced 
directly by the thymus might have cross-reactivity with antigens expressed by cancer 
cells, leading to accumulation of such Tregs at tumour sites (246). It has been 
documented that a large number of CD4
+ 
CD25
+ 
FOXP3
+
 Tregs are present in tumours 
and draining lymph nodes in patients with cancer (167). However, the origin of Tregs at 
tumour sites is not clear. CD4
+ 
CD25
+
 phenotype Tregs have been shown to have a 
suppressive effect in many cancers (244), (247), (248). Many groups reported elevated 
percentages of Tregs with CD4
+ 
CD25
+
 phenotype in the total T cell population isolated 
from peripheral blood or tumour tissues in a variety of cancers (247), (249), (250), 
(251), (252), (253),  (254). A large number of CD4
+ 
CD25
+
 Tregs are present in 
tumours and draining lymph nodes in tumour bearing rodents and also patients with 
cancers in the head and neck, lung, liver, gastrointestinal tract, pancreas, breast or ovary 
(255), (256), (257), (258), (259), (260), (261), (262), (263), (264). There have been a 
number of immunohistochemical studies using FOXP3 as a more specific marker of 
Tregs in tissues (153). These studies showed that increased numbers of FOXP3
+
 Tregs 
have been demonstrated in ovarian, lung, breast, pancreatic, hepatocellular, anal, head 
and neck carcinomas and lymphomas (265), (266), (267), (268), (269), (270), (271). 
The high percentage of Tregs in the tumour microenvironment might be due to the 
conversion of Tregs from CD4
+ 
CD25
− 
naïve T cells in the periphery because of antigen 
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or TCR stimulation (272). The stimulation of T cells using a low antigen dose in the 
absence of co-stimulatory molecules favours the conversion of CD4
+ 
CD25
− 
naïve T 
cells into CD4
+ 
CD25
+
 Tregs (273), (274). Another in vitro assay study using CD4
+ 
CD25
+
 T cells from the PBMCs of healthy women showed that they presented a low 
proliferative response to anti-CD3 and anti-CD28 stimulation (272). Many other reports 
revealed that CD4
+ 
CD25
+
 Tregs played a significant role in the maintenance of 
immunotolerance and the suppression of anti-tumour immune responses (275), (276), 
(277), (278), (279), (280), (281), (282). By using in vitro function assays, most human 
cancers of the CD4
+
CD25
+
 phenotype were found to possess a potent ability to 
suppress immune responses (272). Furthermore, human Tregs can expand in vitro and 
maintain their unique cell surface marker profile and suppressive functions (283).  
It has also been shown in numerous mouse models that the depletion of Tregs enhances 
anti-tumour immune responses, leading to the suppression of tumours (284). It has been 
demonstrated through in vivo studies that the depletion of Tregs in murine models 
improves endogenous immune mediated tumour rejection and tumour antigen specific 
immunity (276), (285). In humans, recent studies have shown that after the depletion of 
Tregs, tumour antigen-specific CD4
+
 T cells can expand in patients with cancer and in 
healthy individuals following the in vitro antigenic stimulation of peripheral CD4
+
 T 
cells isolated from the individual (286). Based on these findings, efforts have been 
made to find cell surface molecules that are predominantly expressed by T regulatory 
cells, or that can specifically modulate the functions of Tregs (167). In addition, the use 
of monoclonal antibodies specific for such molecules have revealed that monoclonal 
antibodies specific for CD25 (a depleting antibody), CTLA4 (a blocking antibody), 
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GITR (an agonistic antibody) and OX40 (an agonistic antibody) can enhance tumour 
immunity in mice (131). 
Another important observation which provides strong evidence that Tregs have an 
impact on protective immunity against a wide variety of human tumours is that the 
accumulation of Tregs in tumour-associated tissue predicts a poor prognosis (287). In 
particular, decreased ratios of CD8
+
 T cells to CD4
+ 
CD25
+ 
FOXP3
+
 Treg cells in 
tumours correlate with a poor prognosis (23). mportantly, the number of CD4
+ 
CD25
+ 
FOXP3
+
 Treg cells present in tumours and the decreased ratios of CD8
+
 T cells 
to CD4
+ 
CD25
+ 
FOXP3
+
 Treg cells in tumours correlate with a poor prognosis in 
patients with breast cancer, gastric cancer and ovarian cancer (288), (289), (290), (291), 
(292), (293). The straightforward quantification of FOXP3
+
 Tregs and CTLs in solid 
tumours using immunohistochemical techniques can be performed on formalin-fixed 
paraffin-embedded tissues (23). Determining the ratio of these two cell populations 
may help to predict which patients are at highest risk of recurrence (23). Therefore, 
later it will facilitate patient selection for more aggressive treatment and to identify 
patients with tumours who may benefit from future immunotherapies targeting this 
suppressor cell type (23).  Despite all the in vitro and in vivo studies conducted, the 
most important question is why and how Treg cells are recruited and accumulated in 
the tumour microenvironment and whether their antigen specificity is crucial in this 
process. Therefore, the success of peptide-based immunotherapy against cancer and 
other diseases probably will depend upon our understanding of the nature of antigens 
that preferentially activate Tregs or Th cells, thus providing a new opportunity to 
modulate the balance between Tregs and effector T cells.  
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1.9 Immune inhibitory signals 
 
It has been shown that highly orchestrated T cell co-regulatory receptor-ligand 
interactions act to direct, modulate, and fine tune T cell receptor signalling to either 
promote or suppress T cell activation. Depending on the timing and location, co-
stimulatory molecules can control T cell priming, growth, differentiation, and 
functional maturation (294). Co-stimulatory molecules are important to the initiation 
and termination of immune responses and modulate signalling through the TCR (295). 
The CTLA-4 and PD-1 ligand 1 (PD-L1) represent negative co-regulators (also referred 
to as „„co-inhibitors‟‟) that can downregulate T cell functions and truncate T cell 
survival, presumably to prevent self-antigen recognition and thus, the genesis and 
evolution of autoimmune diseases (294), (296). 
 
1.9.1 B7 family 
 
Members of the B7/CD28 superfamily play a critical role in providing signals that co-
stimulate or co-inhibit T cell activation (297), (298), (299). The B7/CD28 superfamily 
has expanded in recent years to include programmed death-1 (PD-1) and its ligands, 
PD-L1 and PD-1 ligand 2 (PD-L2) (300), (301), (302). The best-characterised T cell 
co-stimulatory pathway involves the B7-1 (CD80) and B7-2 (CD86) ligands that share 
two receptors, CD28 and CTLA-4 (CD152) (303). The CD28–B7 pathways promote T 
cell activation, whereas the cytotoxic CTLA-4–B7 and programmed death-
1 programmed death-ligand (PD-1–PD-L) pathways lead to the downregulation of T 
cell activity (304), (305), (306), (307), (308). The structural similarity of PD-1 to 
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CTLA-4 and CD28 led to the hypothesis that the ligand for PD-1 (CD279) might be a 
member of the B7 family. PD-1–PD-L belongs to the CD28–B7 signalling family, 
based on the homology shown in Figure 1.10 (309). The five members of the B7 
family; B7-1 (CD80), B7-2 (CD86), inducible co-stimulator ligands (ICOS-L), B7-H1 
(PD-L1) and B7-DC (PD-L2), share 21–27% amino acid identity and a structural 
organisation (310). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 PD-1 / PD-L1 as part of the CD28-B7 family. PD-1 PD-L belongs to the 
CD28-B7 family based on their homology, interactions and functions. The arrows 
indicate the interactions between the ligands, and the receptors. (+)  and ( ) indicate the 
co-stimulatory and co-inhibitory signalling.  
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T cells express the co-stimulator CD28 and the inducible co-stimulator (ICOS) as well 
as the co-inhibitors CTLA-4 and PD-1 (311). Both CD28 and ICOS enhance TCR/ 
CD3-induced proliferation and cytokine production (311). The co-inhibitors CTLA-4 
and PD-1 are expressed on activated T cells, inhibiting TCR/CD3-induced proliferation 
and cytokine production (297), (298). 
 
1.9.1.1 PD-1 
 
PD-1 is a negative co-stimulatory molecule that plays an important role in the balance 
and regulation of adaptive immune responses (312). PD-1 is a co-stimulatory molecule 
that provides an inhibitory signal in T-cell activation (313). PD-1 shares a 21–33% 
amino acid sequence homology with CTLA-4 / CD28 / ICOS and delivers an inhibitory 
co-signal by the engagement of PD-L1 or PD-L2 (310), (314), (315), (316). 
The PD-1 receptor is a 55 kDa type I transmembrane protein of the immunoglobulin 
(Ig) superfamily, with an extracellular region having one V-like domain (317), (318). 
PD-1 contains two tyrosine molecules within its cytoplasmic tail (319). The most 
membrane-proximal tyrosine is located in an immunoreceptor tyrosine-based inhibitory 
motif (ITIM), and the distal tyrosine is located in an immunoreceptor tyrosine-based 
switch motif (ITSM) (320). Signalling through PD-1 results in the recruitment of SHP-
1 and SHP-2 (297). The engagement of PD-1 with its ligand PD-L1 or PD-L2 delivers a 
negative signal by the recruitment of SHP-2 to the phosphorylated tyrosine residue in 
the cytoplasmic region (310), (314), (315), (316), (321), (322). This event can only 
occur once SHP-2 associates with PD-1 upon TCR ligation (323). In T cells, SHP-1 
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binds directly to ITSM in the cytoplasmic tail of the PD-1 receptor even in the absence 
of PD-1 ligation (323), (324). Studies of the phosphatases SHP-1 and SHP-2 indicate 
that they are capable of modulating T cell activity (323), (325), (326). SHP-1 can also 
bind to PI3-K and inhibit phosphatidylinositol production and protein kinase B or Akt 
phosphorylation in T cells (327). While SHP-1 has primarily negative signalling 
functions in T cells, the activation of SHP-2 exhibits both positive and negative 
signalling consequences (325). Using a Jurkat T cell model, Latchman et al., showed 
that SHP-2 was recruited to the PD-1 cytoplasmic tail upon receptor engagement with 
PD-L1 (328). 
The intracellular signalling pathways by which receptors activate or inhibit T cell 
proliferation, cytokine production, and integrin-mediated adhesions are still being 
defined (329). An analysis of the activation by CD3 and CD28 indicates a critical role 
for the PI3-K/Akt pathway in T cell activation (329), (330), (331). The TCR/CD3 
and/or CD28 ligation have been shown to increase PI3-K activity, which in turn 
activates Akt (329), (330), (331). The PD-1 and CTLA-4 each inhibit the PI3-K/Akt 
signalling pathway by distinct mechanisms (Figure 1.11) (332). The Akt and PI3-K are 
targets of the CTLA-4 and PD-1 engagement, and it is quite possible that other 
signalling pathways are also differentially regulated by CTLA-4 and PD-1 (332). The 
Akt plays an important role in the regulation of cellular metabolism in human primary 
T lymphocytes (332). Downstream signalling events such as the activation of PI3-K, 
PLC-γ, extracellular-signal-regulated kinase (ERK), and the elevation of intracellular 
Ca
2+
 are consequently inhibited (329), (330), (331), (332). Moreover, detailed studies 
of the biochemical nature of PD-1 signalling in T cells are lacking (333). To date, all 
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reports that specifically target PD-1 using PD-1 Ab have shown that PD-1 acts as a 
negative regulator of T cell activation (334), (335). Despite the shared ability to block T 
cell activation, the cytoplasmic domain of PD-1 shows significant differences from 
CTLA-4 by encoding both an ITIM and an ITSM. Between the two, ITSM appears to 
be the most important for mediating PD-1 suppression of lymphocyte activation (336).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Model of CTLA-4 and PD-1 mediated T lymphocyte inhibition. Signalling by 
CTLA-4 preserves PI3-K activity, allowing the expression of certain genes such as Bcl-xL, 
but inhibiting Akt directly. In contrast, PD-1 antagonises PI3-K activity directly by 
effecting the inhibition of the T lymphocyte function. The arrows indicate the activation 
and inhibition activity. 
 
PD-1 is expressed on activated T lymphocytes but also on B cells, suggesting 
involvement in a broader spectrum of immune regulations than CTLA-4 (337). PD-1 is 
unique among members of the B7/CD28 family of co-stimulatory receptors because it 
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has been directly implicated in thymocyte maturation (338). PD-1 is expressed on 
immature CD4
–
 CD8
–
 double-negative thymocytes during TCR -rearrangements 
(338). PD-1 was also found to be expressed on activated myeloid lineage cells such as 
macrophages and on mature T and B cells following activation (309), (339).  
Two ligands for PD-1, PD-L1 and PD-L2, have been identified and those are cell 
surface glycoproteins belonging to the B7 family (310), (314), (315), (316). PD-L1 and 
PD-L2 both bind and signal through PD-1 (339). Both the PD-1 ligands are also 
expressed in the thymus (338). Although these two molecules share 38% of the identity 
of amino acids, their expression has been suggested to be differentially regulated (340), 
(341). PD-L1 is broadly expressed in the thymic cortex, while the PD-L2 expression is 
restricted to the medullary stromal cells (342), (343). In general, the PD-1 receptor acts 
to downregulate immune responses and its loss leads to a breakdown of peripheral 
tolerance. PD-1 has also been shown to inhibit the proliferation and cytokine 
production of both CD4
+
 and CD8
+ 
T cells (310), (314), (344). PD-1 has been shown to 
be involved in the negative regulation of some immune responses and to play an 
important role in the regulation of peripheral tolerance because its deficiency causes 
autoimmune conditions (309), (317), (318), (345), (346). The functional significance of 
the PD-1-inhibitory signal is demonstrated by the phenotype of PD-1-deficient        
(PD-1-/-) mice (338). C57BL/6 PD-1-/- deficient mice display features of lupus and 
BALB/c PD-1-/- deficient mice develop a dilated cardiomyopathy (347), (348). These 
PD-1-/- deficient mice observations confirm the roles for PD-1 in inhibiting T and B 
cell activation and in regulating peripheral tolerance (338). 
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1.9.1.2 PD-L1 and PD-L2 
 
Two binding ligands for PD-1 have been identified; PD-L1 and PD-L2, and both 
belong to the B7 family (349). PD-L1 is a cell surface glycoprotein within the B7 
family of T-cell co-regulatory molecules (350). The PD-1 ligands, PD-L1 and PD-L2, 
are 38% identical and are members of the B7 family (350), (351). PD-L1 was first 
discovered by Dong et al. in 1999, and later in 2001 Latchman et al. presented the 
initial identification and characterisation of another B7 homolog, PD-L2, which is the 
second ligand for PD-1 (310), (315), (352), (353). Dong et al. have cloned and 
characterised PD-L1 and also indicated that PD-L1 is not a counter-receptor for CTLA-
4 and neither is it a ligand for the ICOS molecule (315). The human PD-L1 gene is 
located in the chromosome 9p24.2 (352). PD-L1 gene encodes a putative type I 
transmembrane protein of 290 amino acids and contains IgV- and IgC-like regions in its 
extracellular portion (352). The secondary structures of these molecules are very 
similar since PD-L1 shares only about 20% amino acid identity with CD80 and CD86 
in its extracellular domain (315).  
The CD80 and CD86 molecules differ in their expression on APCs. CD86 is 
constitutively expressed in low amounts and rapidly upregulated, whereas CD80 is 
inducibly expressed later than CD86 (354), (355). CD80 and CD86 are not only 
expressed on APCs, but also on T cells (355). However, some other reports have 
identified the co-stimulatory functions of these ligands, which are possibly mediated 
via an additional functional receptor for CD80 and CD86 on T cells, with PD-L1 as the 
binding partner (355). The interaction of PD-1 with PD-L1 or PD-L2 has been said to 
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negatively regulate cytokine production and the proliferation of T cells (356), (357), 
(358), (359). Other studies have also suggested that PD-L1 could provide a positive 
signal through an unknown receptor other than PD-1 (315), (360). PD-L1 has also been 
found to co-stimulate T cell growth and cytokine secretion without binding to CD28, 
CTLA-4 and ICOS (354). 
PD-L1 and PD-L2 are more broadly expressed than the other B7 superfamily members 
(360). The PD-1 / PD-L interaction can negatively regulate the autoreactive CD8
+
 T 
and B cells in at least two different environments, namely lymphoid and non-lymphoid 
tissues (309). PD-L1 may facilitate naive T cell activation in lymphoid tissues and 
within areas of acute inflammation (309). In peripheral tissues, which include solid 
tumours, PD-L1 may primarily function to inhibit activated or memory T cell 
phenotypes to downregulate immune responses (361). The PD-L1 expression has been 
detected in non-lymphoid organs such as the heart, placenta and lungs in both human 
and mouse tissues (310). On the other hand, PD-L2 is constitutively expressed in the 
lymphoid organs, including the spleen, thymus, and liver (316). In contrast to the CD80 
and CD86 systems, the ligands to PD-1 are expressed not only inductively on the 
lymphoid system but also constitutively on the parenchymal cells (362). The 
parenchymal tissue cells might induce the inactivation of naive T and B cells owing to 
the absence of the signal 2 co-stimulation and therefore, play a role in the maintenance 
of peripheral tolerance (362). Recent studies have indicated that PD-L1 is expressed in 
DCs and in various tumour cells, and may play an important role in inducing the 
apoptosis of T cells and tumour immune escape (363). PD-L1 and PD-L2 are expressed 
on various tumours including in the ovaries, oesophagus, kidneys and brains (364), 
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(365), (366). Studies indicate that the PD-L1 protein expression is post-transcriptionally 
regulated perhaps in response to pro-inflammatory cytokines such as IFN-γ, which have 
been shown to upregulate the PD-L1 expression (367), (368). The PD-L1 protein has 
been detected in most human cancers but not in normal tissues (315), (354), (364). At 
the mRNA level, the PD-L1 and PD-L2 expressions are upregulated in a variety of 
tumour cell lines (310). When treated with IFN-
express PD-L1. These findings give motion to the investigation of whether the PD-L 
expression on tumours attenuates the anti-tumour responses. Although the PD-L2 
expression has been noted in several murine tumour cell lines, little is known about the 
human PD-L2 expression in tumour tissue (310), (364). 
PD-L1 and PD-L2 are also expressed on APCs (360). The PD-L1 mRNA is expressed 
in nearly all human tissues, but the PD-L1 protein expression is largely restricted to a 
fraction of the macrophage lineage cells and subsets of the activated T lymphocytes 
(353), (368). Dong et al. found that the PD-L1 protein expression in normal immune 
cells is limited to macrophages, a result consistent with their earlier report that freshly 
isolated monocytes express PD-L1 (315). The PD-L1 mRNA is expressed 
constitutively in the heart, lungs, kidneys, liver and spleen, and is upregulated by IFN-γ 
in endothelial cells, keratinocytes, DCs and several tumour cell lines (351), (352). 
Meanwhile, the PD-L2 mRNA is constitutively expressed in the liver and at lower 
levels in the lungs and spleen (368). The PD-L2 mRNA was not detected in 
unstimulated human monocytes but was up-regulated by IFN-γ stimulation (310). A 
similar expression profile of the PD-L1 protein was demonstrated using a mAb (309). 
Dong et al. used a mAb specific for PD-L1 to determine immunohistochemically 
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whether the sites of the PD-L1 protein expression correlated to the sites of the mRNA 
expression (368). They did not detect any immunoreactivity in any of the normal solid 
tissues examined, including the breasts, colon, pancreas, kidneys, uterus, skeletal 
muscles and lungs (368). However, according to Dong et al., an immunohistochemical 
analysis showed PD-L1 immunoreactivity in a majority of freshly isolated human 
carcinomas (368). They found PD-L1 immunoreactivity in the plasma membrane, 
cytoplasm or both. In most cases, the PD-L1 expression was focussed with no 
expression in the adjacent normal tissues (369). Various studies have also reported that 
PD-L1 can both positively and negatively co-regulate immune responses depending on 
the location and context of the PD-L1 expression (361), (368), (370).  
It is well known that the tumour microenvironment can protect tumour cells from 
immune destruction (371), (372). Activated T cells interacting with tumour-associated 
PD-L1 appears to lead to programmed cell death. This suggests a mechanism by which 
tumours may escape immune destruction (364). PD-L1 has been shown within recent 
years to be directly involved in the protection of tumour cells from destruction by 
activated T lymphocytes (373). Soluble factors, such as TGF-β and IL-10, in the cancer 
microenvironment have been shown to induce the synthesis of various proteins, which 
include PD-L1 protein (374). Tumour associated PD-L1 has been shown to inhibit anti-
tumoural T cell–mediated immunity by interacting with T cell PD-1 (or a not-yet-
identified non-PD-1 receptor), resulting in tumour specific T cell apoptosis or 
impairments in cytokine production and cytotoxicity of activated anti-tumoural T cells 
(368), (375), (376), (377). In subsequent studies, both PD-L1 and PD-L2 have been 
shown to induce T cell apoptosis via PD-1 on T cells and inhibit T cell growth and 
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cytokine secretion (314), (316). Because PD-L1 and PD-L2 can inhibit effector T cell 
proliferation and cytokine production, the PD-1/PD-L pathway may be an attractive 
therapeutic target (310). The PD-1/PD-L pathway also inhibits proliferation by 
reducing the production of IL-2 and restricts the number of T cells that gain entry into 
the cell cycle as well as their subsequent division rate (344). Despite the fact that PD-
L1 ligation to naïve or early primed T cells co-stimulates the proliferation and 
production of IFN-γ and IL-10, the binding of PD-L1 to PD-1 on activated T cells 
promotes apoptotic cell death  or cell cycle inhibition (314), (364). The role of IFN-γ 
was reported in many studies, where it was shown that IFN-γ induces PD-L1 and PD-
L2 mRNA expressions (310), (314), (378). The findings by Brown et al. in 2003 
specifically indicate that the culture of monocytes on tissue culture plastic in a medium 
alone induced a PD-L1 expression while a PD-L2 expression was not present (342). 
They also found that the addition of IFN-γ induced somewhat higher levels of PD-L1 
expression at 24 hours as compared with culture on plastic, and the expression was 
sustained for 72 hours (342). In addition, IFN-γ induced a low level of PD-L2 
expression (342). PD-L1 is not expressed by unstimulated monocytes, but is rapidly 
upregulated upon IFN-γ treatment (360). The treatment of monocytes with another pro-
inflammatory cytokine, tumour necrosis factor-  (TNF- ), leads to a low level 
induction of PD-L1 similar to that found with a medium alone (360). 
Later, Curiel et al., suggested that myeloid dendritic cell functions through upregulation 
of PD-L1 by tumour environmental factors contribute to the impaired immune 
responses in tumours and tumour progressions (379). In tumour immunity, tumour-
associated PD-L1 has been proposed to induce apoptosis of tumour reactive T cells 
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(364). In an in vitro study, PD-L1 expressed by tumour cells has been shown to 
enhance apoptosis of activated tumour specific T cells (364). Similarly, PD-L1 
expressed on activated T cells has been demonstrated to impair both T cell function and 
survival (380) (381). Consistent with these observations, the in vivo monoclonal 
antibody blockade of PD-L1 has been shown to potentiate anti-tumoural responses in 
several murine cancer models (368), (376), (382). The blockade of tumour-associated 
PD-L1 has been shown to promote in vivo tumour regression in several murine cancer 
models (383). On the other hand, the in vivo mAb-mediated blockade of PD-L1 has 
been shown to potentiate anti-tumoural T cell responses against immunogenic murine 
cancers that express PD-L1 either endogenously or after gene transduction (368), (376), 
(382). Thus, preclinical studies support the idea that a PD-L1 blockade can be 
immunotherapeutically exploited to facilitate anti-tumour immunity in murine cancer 
models (383), (384).  
It has been suggested that the suppression of dendritic cell functions through the 
upregulation of PD-L1 expression is responsible for the inhibition of proper immune 
responses in cancer patients (349). Therefore, it is hypothesised that PD-L1 may 
facilitate human cancer progression by impairing anti-tumoural immunity of the host 
(349). The blocking of such negative immune regulatory signals on tumour cells has 
given rise to the hope that their manipulation may lead to enhanced tumour specific 
CD8
+
 T cell immunity in vivo (385). For example, the enhanced therapeutic efficacy of 
adoptive transfer strategies in animal models was conducted by a blockade of 
tumour associated PD-L1 by antibodies (386). By definition, a PD-L1 blockade may 
trigger T cell–mediated responses in a more tumour specific fashion, thereby limiting 
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autoimmune side effects (349). Specifically, additional studies are needed to identify 
the regulation of PD-L1 expression in tumour cells. Although a second stimulatory 
receptor for PD-Ls has been postulated, it has yet to be identified (387), (388), (389). It 
is important to note that because of the complexity of the PD-L1 pathway and the 
potential existence of additional receptors other than PD-1, it is currently not known 
whether the effect of enhanced tumour immunity by anti-PD-L1 is entirely attributable 
to a blockade of the interaction between PD-L1 and PD-1 (390). The tumour-associated 
PD-L1 has been shown to inhibit anti-tumoural T cell immunity by interacting with T 
cell PD-1 or a putative non-PD-1 receptor to induce tumour-specific T cell apoptosis or 
by impairing cytokine production and the cytotoxicity of activated T cells (391), (392), 
(393). The functional differences that are associated with PD-L1 binding to counter 
receptors will require the identification and physiological assessment of these 
molecules (394).  
Anti-programmed death-ligand (PD-L) mAbs may have therapeutic potential in a 
clinical setting (378). A study which showed that the PD-L1 blockade enhanced the 
therapeutic efficacy of adoptive T cell immunotherapy for squamous cell carcinoma 
further supports the application of anti-PD-L1 mAbs (394). Anti-PD-L1–specific mAbs 
that can potentiate and improve therapeutic immunity have already been investigated in 
some malignancies (395), (396). On the other hand, Tseng et al. reported that PD-L2 
mAbs strongly co-stimulate T cell proliferation and enhance the secretion of IFN-γ 
(316). PD-L1 has consistently been reported as an immunoinhibitory molecule in the 
context of tumour immunity (397), (398). However, evidence that tumour-associated 
PD-L1 or any other T cell co-stimulatory molecule facilitates solid tumour progression 
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in a clinical setting is lacking. Recently, a strong correlation between PD-Ls expression 
on tumour cells and a negative prognosis has been demonstrated for human cancer 
patients, including those with ovarian cancer (399), (400). PD-L1 is the only co-
stimulatory molecule reported to significantly correlate with survival in a human 
malignancy (401).  
 
1.10 Immunomodulatory enzyme 
 
Tumour-induced T cell anergy can severely impair the potential therapeutic benefit of 
immunotherapy, but the mechanisms leading to tumour-induced T cell anergy remains 
incompletely understood (402). These mechanisms are usually triggered by the 
interaction of T cells with tumour cells or myeloid cells. Among the possible 
mechanisms are T cell apoptosis, regulatory T cells, and inhibition of the immune 
response by limiting amino acid availability (403), (404), (405). The depletion of the 
amino acids, tryptophan and L-arginine, is a process that limits the availability of amino 
acids, which has now been described by either the production of hydrogen peroxide 
(H2O2) or IDO by iDCs (404), (405).  
1.11 Arginase 
 
 
Arginine was first discovered over 100 years ago and is known as a basic amino acid 
that is naturally ingested in our diet (406). L-arginine is an essential amino acid for 
birds and young mammals, and it is a conditionally essential amino acid for adult 
mammals. L-arginine is important and must be supplied in the diet during certain 
physiological or pathological conditions (such as pregnancy, sepsis, cancer and trauma) 
involving changes in the L-arginine metabolic status (407), (408), (409). L-arginine is 
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the substrate for four enzymes, several of which exist as multiple isoforms: nitric oxide 
synthases (NOS1, NOS2, and NOS3), arginases (arginase 1 and arginase 2), arginine-
glycine amidinotransferase (AGAT), and arginine decarboxylase (ADC). The enzymes 
AGAT and ADC convert L-arginine into creatine and agmatine. L-arginine can be 
metabolised by inducible NOS into nitric oxide (NO) and citrulline. Alternatively, 
arginase can convert L-arginine into urea and ornithine, with the latter being the 
substrate for the synthesis of polyamines needed to sustain cell proliferation (Figure 
1.12) (406). Many investigators studied the importance of arginine on specific cellular 
and molecular functions in the T lymphocyte (193), (407), (408), (409), (410). Arginine 
availability is essential for normal T cell proliferation and function (408), (409), (411), 
(412). T lymphocytes depend on arginine for multiple key biological processes, 
including proliferation, the expression of the TCR complex and the CD3 zeta chain 
(CD3-ς chain) peptide, and the development of memory (411), (410). 
 
 
 
 
 
 
 
 
 
Figure 1.12 L-Arginine metabolism. L-arginine can be metabolised by inducible NOS 
into NO and citrulline, while arginase can convert L-arginine into urea and ornithine. 
Polyamines which are synthesised as end products are crucial for sustaining 
proliferation.  
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Subsets of myeloid cells, known as myeloid suppressor cells, regulate T cells by 
manipulating the metabolism of L-arginine through the enzymes, NOS and arginase, 
which are regulated by T helper 1 (Th1) and T helper 2 (Th2) cytokines, respectively 
(412). The arginase-producing myeloid suppressor cells are highly efficient at 
suppressing activated T cells (412). In a healthy adult, normal levels of L-arginine in 
plasma range between 50 and 150 µM. Reports have shown that the rapid depletion of 
plasma levels of L-arginine was accompanied by a markedly decreased T cell function 
in patients undergoing liver transplantation, in trauma patients and also in murine 
models of trauma (410), (413), (414). Experiments using T cells activated in an L-
arginine depleted environment showed decreased expression of the CD3-ς chain. On 
the other hand, experiments using primary T cells (murine or human) did not show any 
effects of L-arginine deprivation on resting T cells (406). These experiments suggested 
a potential role for L-arginine depletion as a mechanism for the induction of T cell 
dysfunction (406). 
In myeloid cells, arginine is mainly metabolised either by inducible nitric oxide 
synthesis (iNOS) or by arginase 1, enzymes that are stimulated by Th1 or Th2 
cytokines, respectively (415). Myeloid cells expressing arginase 1 efficiently deplete 
arginine from the surrounding environment (407), (408). Under resting conditions, little 
arginine is used by myeloid cells due to a lack of expression of high affinity cell 
membrane transporters. In addition, in the absence of immune stimulation, myeloid 
cells do not express the major arginine metabolising enzymes, iNOS and arginase 1 
(404). Neither iNOS nor arginase 1 is induced in T lymphocytes, which is a marked 
difference between these cells and myeloid cells (415). Myeloid cells expressing 
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arginase 1 are described in a growing number of disease processes, particularly in 
cancer, autoimmune diseases, and in graft versus host diseases (411), (412), (410), 
(416), (417), (418), (419), (420). In humans, arginase 1-expressing myeloid cells have 
been reported in cancer and appear to be granulocytic in origin (420).  
Previous reports have suggested that increased arginase in cancer patients comes from 
tumour cells metabolising L-arginine to polyamines (421), (422). The role of these cells 
in patients is unknown. Murine models have suggested that the arginase comes from 
macrophages infiltrating tumours or immature myeloid cells in the spleen (423), (424), 
(425). Macrophages expressing arginase I also increase the production of polyamines, 
which increase tumour proliferation. The increase in arginase 1 expression may not 
only facilitate tumour growth by producing more polyamines, but may also facilitate 
tumour escape by blocking the immune response (416). In addition, studies have shown 
that arginase 1 is preferentially expressed in myeloid cells infiltrating tumours, which 
inhibit T cell function as a possible mechanism of tumour evasion (423). There have 
been variations of myeloid cells infiltrating tumours in cell morphology and maturation 
markers found between different tumour models and between murine and human 
tumours (423). It has been shown in mice (Rodriguez et al.) and in patients with renal 
cell carcinoma (Zea et al.,) and prostate carcinoma (Bronte et al.); arginase comes from 
myeloid cells infiltrating tumours circulating in peripheral blood and infiltrating the 
tumours respectively (412), (420), (423). The mechanisms that induce arginase I in 
myeloid cells infiltrating tumours are still not clear (416). 
Recently, a panel of leading investigators in the field agreed to use the common term 
myeloid derived suppressor cells (MDSCs) to name these arginase 1-producing cells 
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(426). It should be noted that the suppressive functions of myeloid cells were first 
described in the late 1970s and early 1980s. At that time, these cells were mainly 
known as natural suppressor (NS) cells; these were defined as cells that were devoid of 
lymphocyte lineage markers and that suppressed the lymphocyte response to 
immunogens and mitogens in an MHC-independent manner (427), (428). MDSCs have 
been described in disease processes such as trauma (in mice and humans), certain 
infections, and prominently in cancer (407), (410), (418), (419). The major difference 
between the diseases processes (surgical wound versus malignant tumour) would be 
that the surgical wound would heal, ending the role of arginase-producing MDSCs 
(406). In contrast, the malignant tumour would not stop growing and destroying tissue, 
which would trigger instead a chronic inflammatory process mediated by MDSCs that 
would ultimately lead to the depletion of L-arginine from the microenvironment and the 
development of T cell anergy (406). 
Several reports have described the presence of suppressor myeloid cells with high 
arginase activity in mice with lung cancer and colon cancer rapidly depleting arginine, 
blocking T cell proliferation, cytokine production, and the CD3-ς chain expression 
(408), (411), (423), (429), (430), (431). They did not produce H2O2, NO, or IDO. 
MDSCs found in the spleen of mice with colon cancer blocked the T cell function 
through NO and arginase production requiring cell-cell contact (429), (424). The 
blocking of arginase eliminated the suppressor function in vitro and induced an anti-
tumour effect in vivo (420). In humans, the MDSCs release arginase I into the 
circulation (432). MDSCs expressing arginase I deplete L-arginine from the 
microenvironment and profoundly inhibit T cell functions (408), (423). The inhibition 
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of arginase I restores the T cell function in vitro and induces an anti-tumour response in 
vivo (423). In vivo, trauma patients or patients with cancer exhibit T cell abnormalities, 
including decreased proliferation and loss of the zeta chain characteristic of arginine 
deficiency (409). Data published by Rodriguez et al. and others show that infiltrating 
MDSCs are the primary producers of arginase I and are potent inhibitors of TCR 
expression and antigen-specific T cell responses in vivo (416), (423), (424), (433). 
Although MDSCs have been well studied in murine models, their role in human 
diseases has only recently been understood (433). Low levels of L-arginine can also 
affect tumour growth in vitro by inducing the arrest of tumour cell proliferation (434), 
(435). However, the mechanisms by which low levels of L-arginine affect tumour 
growth in vivo are unknown (416).  
In cancer, the infiltration of tumours by MDSCs and the circulation of MDSCs are 
important mechanisms for tumour evasion and for impairing the therapeutic potential of 
cancer immunotherapies (416). In contrast to murine MDSCs, the human MDSCs 
phenotype varies significantly, ranging from iDCs to activated granulocytes expressing 
CD11b
+
, CD14 , CD15
+
, CD34
+
, CD33
+
  and CD13
+
, depending on the disease being 
studied (436),  (420). It is likely that human MDSCs represent a subpopulation of 
myeloid cells induced by tumour-derived factors as suggested by Gabrilovich (437). 
The mechanisms for the accumulation of human MDSCs in peripheral blood are still 
unclear (432). Zea and colleagues were the first to show the existence of suppressor 
myeloid cells producing arginase in human cancer patients (436). They found that 
human MDSCs in the circulating blood of renal cell carcinoma (RCC) patients present 
with the morphology and cell markers of polymorphonuclear cells, which could 
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represent an immature stage of myeloid differentiation such as promonocytes, 
myelocytes, metamyelocytes, and even iDCs (436). Interestingly, the arginase-
producing cells in RCC are polymorph mononuclear (PMN) cells and not macrophages 
or iDCs as suggested in murine tumour models (436). Their MDSCs phenotype fits that 
of suppressor PMN cells described earlier by Schmielau and Finn in pancreatic cancer 
patients, where these cells produced H2O2, but were not tested for arginase (438).  
Munder et al., reported that granulocytes can produce arginase I as a potent anti-fungal 
mechanism (439). MDSCs are also present in the granulocytes from the circulating 
blood of healthy individuals. Recently, human MDSCs in RCC patients were found to 
represent a subset of activated granulocytes expressing high levels of CD66b, CD11b, 
and VEGF receptor 1 (VEGFR-1) (432). MDSCs from RCC patients express markers 
of mature activated PMN granulocytes, including high levels of CD66b and low levels 
of CD62L and CD16 (432). A retrospective study of patients with metastatic RCC 
demonstrated a six to ten-fold increase in arginase activity in the PBMCs as compared 
to normal controls (436). The separation of the different subpopulations in the PBMCs 
of these patients demonstrated that the cells containing all the arginase activity were 
activated granulocytes, which separated with the PBMCs when centrifuged using Ficoll 
Histopaque. These patients also had a significantly diminished expression of the CD3 
zeta chain. This phenotype fits that of the activated PMN granulocyte previously 
described by Elghetany (440). An increased arginase activity has been described in 
patients with different types of tumours and can be produced by certain tumours or 
MDSCs (421), (422), (423).  
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1.12 Overall aims  
 
Experiments were conducted to understand immune tolerance in ovarian cancer using 
tumour cells and immune cells obtained from patients‟ tumour tissues, peripheral blood 
and ascites. The aim was to perform an integrated study of the protein expression of 
immune markers, immune related gene expression arrays, as well as a functional 
analysis of immune cells and explore their relationship to diagnosis and prognosis.  
The main aims were: 
 To define immune responses in the ascites, blood and tumour tissue in women 
with ovarian cancer and the phenotype of the immune cells, particularly in respect 
to the regulatory cells.  
 To correlate the immunological observations to the diagnosis and prognosis of 
ovarian cancer. 
 To identify the mechanisms of immune inhibition in ovarian cancer. 
 
In particular the aim was to characterise the following with respect to immune 
suppression: 
1. The distribution of regulatory molecules in ovarian cancer (including PD-L1 and 
cytokines that drive its upregulation). 
2. The role of arginase as an immunomodulatory enzyme in ovarian cancer. 
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2.0 Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Patient and human subjects 
 
A total of 116 patients aged 25 to 85 years, who had been operated on for EOC in 
Hammersmith Hospital between 2007 and 2009, were studied. Out of the 116 patients, 
68 patients were diagnosed with benign and borderline ovarian tumours. These patients 
were undergoing surgery for suspected ovarian masses where peripheral blood and 
ascites (if present) were gathered from each patient at the beginning of the operation. 
All the patients gave their written and informed consent. In parallel, samples from 
healthy women (n = 8), ranging in age from 25 to 40 years, were collected as controls. 
All the patients had undergone an initial staging and debulking surgery, including 
optimal and suboptimal debulking. Clinical information was available on all the 
patients. 
 
2.1.2 Human cell lines 
 
All cell lines were the kind donation of Professor Hani Gabra, Ovarian Cancer Action, 
Imperial College London, United Kingdom. The cell lines were cultured as described 
by the respective manufacturers. Table 2.1 shows the cell lines that were used in this 
work. 
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Cell line Cell line origin Histology type Medium 
OVCAR-3 Ovary Serous RPMI 
OVCAR-5 Ovary Serous RPMI 
CaOV-3 Ovary Serous RPMI 
SKOV-3 Ovary Serous RPMI 
TOV-21G Ovary Clear cell RPMI 
KOC-7C Ovary Clear cell RPMI 
OVISE Ovary Clear cell RPMI 
TOV-112D Ovary Endometrioid RPMI 
HEP-G2 Liver Human liver DMEM 
HUH-7 Liver Human liver melanoma DMEM 
 
Table 2.1 Cell lines used in this study, their histological background and medium used 
for expansion (RPMI; Roswell Park Memorial Institute medium and DMEM; 
Dulbecco‟s modiﬁed Eagle's medium). 
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2.2 Methods 
2.2.1 Human cells and ovarian tumour tissues collection 
 
Peripheral blood and ascites were collected in an aseptic fashion into sterile heparinised 
containers during the patients‟ routine work up for primary treatment or at the time of 
surgery. Plasma and supernatants from the peripheral blood and ascites were stored for 
future analysis. All the histological and cytological samples were sent to the laboratory 
for evaluation just after the operation for routine diagnosis. Ovarian tumour tissues 
were collected and were divided into two parts: one for histopathological examination, 
while the other was frozen in liquid nitrogen immediately after removal and stored at  
80°C for ribonucleic acid (RNA) extraction.  
 
2.2.2 Cell isolation 
 
Following centrifugation at 1800 rpm for 10 minutes at room temperature, the ascitic 
fluid supernatant was removed and the ascitic cells or peripheral blood were separated 
over a Ficoll Histopaque (Sigma Chemical Co., St. Louis, MO) density gradient for 30 
minutes at 2500 rpm at room temperature. The dense layer, which was enriched with 
mononuclear cells, PBMCs and TALs, was collected and washed several times. 
 
2.2.3 Flow cytometry 
 
Immunophenotyping of the cells isolated from the peripheral blood and ascites was 
performed using flow cytometry. The cells that had been isolated from the blood and 
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ascites were stained with fluorescein isothiocyanate (FITC), phycoerythrin (PE) and 
allophycocyanin (APC) conjugated monoclonal antibodies specific for both surface and 
intracellular cell markers. The PBMCs and TALs were stained with a combination of 
markers (Table 2.2 and 2.3). In brief, 4 x 10
5
 cells were stained and incubated in the 
dark at 4ºC for 20 minutes. The labelled cells were washed with phosphate buffer saline 
(PBS) containing 2% foetal calf serum. For the flow cytometric analysis of the 
expression of FOXP3 and CTLA-4, the cells were fixed with the fixation buffer that 
was supplied in the intracellular staining kit (eBioScience, UK) for at least one hour or 
overnight before washing with a permeabilization buffer. The permeabilization buffer 
was used for antibody staining and washes. 
Firstly, the cell population representing lymphocytes was gated and this was followed 
by the gating of the monocytes/macrophages in the forward and side scatters. In the 
CD3
+
 gated cells, the cells that had been stained with the CD3-FITC antibody were 
observed first, followed by the APC and PE staining of the other T cell markers (Figure 
2.1). A similar step was performed on the CD14
+
 gated cells, with the cells that had 
been stained with the CD14-FITC antibody being observed first followed by the APC 
and PE staining of the other monocyte markers (Figure 2.2). CD3 is the lymphocyte 
marker used for the detection of T and B cells. The CD3 cells appear to co-express CD4 
and CD8. In the CD14 gated cells, the CD14 cells were found to be co-expressing 
CD11c and HLA-DR. Both CD3
+
 and CD14
+
 cells were used for immunophenotyping 
cell sub-populations. 
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Figure 2.1 A representation of triple staining of lymphocytes obtained from patients‟ circulating 
blood and ascites. Different markers are labelled with different fluorochromes. The marker CD3 is 
labelled with FITC, CD4 is labelled with APC and CD25 is labelled with PE. [A]i. and [A]ii. 
represent the gating of the lymphocytes in the forward and side scatters, [B]i. and [B]ii. indicate that 
the CD3 cells appear to co-express CD4 labelled with APC; and [C]i. and [C]ii. indicate the 
percentages of cells expressing both markers CD4 (APC) and CD25 (PE), respectively. 
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Figure 2.2 A representation of triple staining of monocytes obtained from patients‟ circulating 
blood and ascites. Different markers are labelled with different fluorochromes. The marker CD14 is 
labelled with FITC, C11c is labelled with APC and HLA-DR is labelled with PE. [A]i. and [A]ii. 
represent the gating of the lymphocytes in the forward and side scatters, [B]i. and [B]ii. indicate that 
the CD14 cells appear to co-express CD11c labelled with APC and; [C]i. and [C]ii. indicate the 
percentages of cells expressing both markers CD11c (APC) and HLA-DR (PE), respectively. 
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Table 2.2 Combinations used for immunophenotyping of patients‟ PBMCs and ascites. 
There were altogether 20 combinations routinely used for immunophenotyping 
patients‟ PBMCs and ascites, with healthy women‟s PBMCs as controls. 
 
 
 
 
 
 
1. CD3 FITC / CD4 APC / CD25 PE 
2. CD3 FITC / CD28 APC / CTLA-4 PE  
3. CD3 FITC / CD4 APC / FOXP3 PE 
4. CD3 FITC / CD8 APC / FOXP3 PE 
5. CD3 APC / NK 1.1 PE / FOXP3 FITC 
6. CD3 APC / CD62L PE / CD3 zeta FITC 
7. CD3 APC / CD69 FITC / PD-1 PE 
8. CD3 FITC / CD4 APC / PD-1 PE 
9. CD3 FITC / CD8 APC / PD-1 PE 
10. CD3 FITC / CD19 APC / PD-1 PE 
11. CD14 FITC / CD86 PE / CD 11c APC 
12. CD14 FITC / HLA-DR PE / CD 11c APC 
13. CD14 FITC / PD-L1 APC / HLA-DR PE 
14. HLA-DR PE / PD-L1 FITC / CD 11c APC 
15. CD11c APC / CD14 FITC / CD16 PE 
16. CD11b APC / CD14 FITC / CD16 PE 
17. CD11c APC / CD33 FITC / CD16 PE 
18. CD11b APC / CD33 FITC / CD16 PE  
19. CD11b APC / CD33 FITC  / CD14 PE 
20. CD11c APC / CD33 FITC  / CD14 PE 
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Antibody Source and Location Isotype Clone 
CD3  Becton Dickinson, Franklin Lakes, NJ IgG1 UCHT1 
CD3 zeta AbCam, Cambridge, United Kingdom IgG2a G3 
CD4  Becton Dickinson, Franklin Lakes, NJ IgG1 RPA-T4 
CD8  Becton Dickinson, Franklin Lakes, NJ IgG1 RPA-T8 
CD25 Becton Dickinson, Franklin Lakes, NJ IgG1 M-A251 
CD28 Becton Dickinson, Franklin Lakes, NJ IgG1 CD28.2 
CD14 Serotec, Oxford, United Kingdom. IgG1 MEM-18 
CD80 AbCam, Cambridge, United Kingdom IgG1 2D10 
CD86 AbCam, Cambridge, United Kingdom IgG1 B-T7 
NK 1.1 AbCam, Cambridge, United Kingdom IgG1 PK136 
FOXP3 eBioscience, San Diego IgG1 PCH101 
CTLA-4 (CD152) AbCam, Cambridge, United Kingdom IgG1 BN13 
CD69 Becton Dickinson, Franklin Lakes, NJ IgG1 UC/4 
PD-1 (CD279) R&D sytems, Minneapolis IgG1 ICA01 
PD-L1 (CD274) Becton Dickinson, Franklin Lakes, NJ IgG1 MIH1 
HLA-DR AbCam, Cambridge, United Kingdom IgG1 UCHL1 
CD11b Becton Dickinson, Franklin Lakes, NJ IgG1 Mac-1,CR3 
CD11c Becton Dickinson, Franklin Lakes, NJ IgG1 S-HCL-3 
CD16 Becton Dickinson, Franklin Lakes, NJ IgG1 3G8 
CD33 Becton Dickinson, Franklin Lakes, NJ IgG1 HIM3-4 
CD62L Becton Dickinson, Franklin Lakes, NJ IgG1 DREG-56 
 
Table 2.3 Sources and isotypes / clones of fluorochrome labelled human antibodies 
used in this study. 
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2.2.4 Quantitative real-time PCR 
Two types of samples, which were the tissue biopsies and cell lines, were used for the 
quantitative real-time PCR (qRT-PCR). Tissue biopsies of 100 to 200 mg were snapped 
frozen in liquid nitrogen. The total RNA was isolated according to the manufacturer‟s 
instructions (Qiagen, Germany). The first step of RNA isolation from the tissue 
biopsies was by done by weighing the frozen tissue in its original cryo tube. Next, 5-10 
volumes of RNAlater (Sartorius, Germany) were left overnight at 4
o
C to allow 
penetration. The frozen tissues were homogenised using a Mikro-Dismembrator-U 
(Sartorius, Germany). The powder was immediately transferred into 1ml of ice-cold Tri 
Reagent and was allowed to stand for 5 minutes at room temperature. As for the RNA 
isolation from the cell lines, a straightforward cell collection of 1 x 106 total cells were 
pelleted by centrifugation before the addition of 1ml of ice-cold Tri Reagent.  
For every 1ml of Tri Reagent added, 0.2 ml of chloroform was added next and these 
were shaken vigorously. The mixture was centrifuged for 15 minutes at 4 C at 10,000 
rpm and the aqueous supernatant was collected and transferred in to a new tube. Next 
0.5 ml of isopropanol was added and was centrifuged for 10 minutes at 4 C at 10,000 
rpm. The pellet was washed with 1 ml of 75% ethanol using centrifugation at 9,500 rpm 
for 5 minutes at 4 C. The RNA was used for purification using Qiagen column and was 
quantified using a NanoDrop. The RNA quantification will determine the volume of 
messenger ribonucleic acid (mRNA) being sued for the complementary DNA (cDNA) 
synthesis. cDNA from archived fresh frozen tissue and some recruited patients‟ 
specimens during this study were used in this work. Five micrograms of mRNA was 
used to synthesise cDNA using the First Strand cDNA Synthesis Kit (Roche Diagnostic 
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, UK). Experiments with qRT-PCR were performed with the use of the ABI Prism 7900 
Analyser and SYBR Green I PCR kits (Applied Biosystems). Complementary DNA 
was normalised against housekeeping hypoxanthine phosphoribosyltransferase (HPRT). 
The amplification primers are listed in Table 2.4. Positive controls of the pcDNA, 
hIDO and pcDNA 3.1 human arginase 1 vectors were used in appropriate experiments 
and negative controls were included in each analysis run. The experiments were 
performed in duplicate and the average of the relative mRNA expression was used for 
analysis. 
  
2.2.5 Tissue sections from tissue microarray blocks  
 
A total of 60 cases were identified as suitable for tissue microarray (TMA) as shown in 
Table 2.5. These included 28 serous ovarian cancer cases and 11 other histological 
types which were compared to 13 benign and 8 borderline cases. 300 tissue cores were 
prepared from the 60 ovarian cancer cases. In addition, 30 cores from a normal ovary 
were also cut. For this study, 16 blocks were prepared (labelled A to K) and 50 to 100 
tissue cores were arrayed in each block. The pathologist from the pathology department 
used a manual tissue microarrayer (Beeher Instruments Inc. Sun Prairie). This tissue 
microarrayer allows investigators to array up to 1000 tissue samples in a single paraffin 
block. The advantages of using this tissue array technology are that it increases the 
capacity, all the tissue sections are treated uniformly, there is negligible damage to the 
original tissue blocks and the tissue specimens are precisely positioned for comparison 
of the morphology of the serial sections after immunostaining. For each patient‟s 
sample, at least three sections were examined blindly by two investigators trained in the 
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pathology of ovarian cancer. The investigators analysed them for each of the immune 
markers.  
 
2.2.6 Immunohistostaining 
 
 
Immunohistochemical staining was performed on formalin-fixed and paraffin-
embedded archival tissues. The formalin-fixed paraffin-embedded sections from the 
ovarian tumours were evaluated for the presence of infiltrating lymphocytes and APCs 
expressing markers of interest. The paraffin block tissue sections were processed in a 
microwave (10 min at 850 W in pH 6.0 citric buffer) for antigen retrieval. Most 
formalin-fixed tissues require an antigen retrieval step before the immunohistochemical 
staining can proceed. This is due to the formation of methylene bridges during fixation, 
which cross link proteins and therefore mask antigenic sites. The method of antigen 
retrieval used in this study was the heat-mediated method. Heat-induced epitope 
retrieval was performed using a microwave. The antigen retrieval method was 
performed as stated on the antibody datasheet and the optimal method for each antigen 
was found experimentally. Subsequently, the microtome sections measuring 5 µm thick 
were treated for the immunohistochemical demonstration of markers of interest, using 
the avidin / labelled biotin complex (ABC) immunohistochemical staining method 
(Appendix 1). The markers of interest, mAbs (Table 2.6), were incubated on the slides 
for 30 min and the presence of these markers was visualised with the EnVision AP kit 
(Dako, UK) according to the manufacturer‟s instructions. The marker of interest 
positivity was graded according to the presence of <10% (+), 10–50% (++) and >50% 
(+++) of positive cells. 
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Antibody Sequence (5‟ to 3‟) 
HPRT Forward GCA GAC TTT GCT TTC CTT GGT C 
HPRT Reverse CTG GCT TAT ATC CAA CAC TTC GTG 
PD-L1 Forward TAT GGT GGT GCC GAC TAC AA 
PD-L1 Reverse TGC TTG TCC AGA TGA CTT CG 
PD-L2 Forward GTA CAT AAT AGA GCA TGG CAG CA 
PD-L2 Reverse CCA CCT TTT GCA AAC TGG CTG T 
IDO Forward GGT CAT GGA GAT GTC CGT TAA 
IDO Reverse ACC ATT AGA GAG ACC AGG AAG AA 
Arginase 1 Forward GCG CCA AGT CCA GAA CCA TAG 
Arginase 1 Reverse TAG GGC CTT CTT CCA CCC CT 
Arginase 2 Forward GGC TGA GGT GGT TAG CAG AG 
Arginase 2 Reverse CTG GCT GTC CAT GGA GAT TT 
 
Table 2.4 Forward and reverse primer sequences used in this study 
 
Category Number of cases Number of cores 
Serous 28 84 
Clear cell 5 15 
Endometriod 6 18 
Borderline 11 33 
Benign 13 39 
 
Table 2.5 Samples included in TMA study according to histological type 
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Primary 
antibodies 
Clonality Suppliers Diluti
on 
Secondary 
antibodies 
Suppliers Dilution 
CD3 Rabbit 
Polyclonal 
Dako, USA 1/100 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
CD4 Mouse 
Monoclonal 
Novocastra, 
UK 
1/400 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
CD8 Mouse 
Monoclonal 
Novocastra, 
UK 
1/400 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
FOXP3 Mouse 
Monoclonal 
eBioscience, 
UK 
1/200 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
CD68 
KPM 
Mouse 
Monoclonal 
Novocastra,
UK 
1/400 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
CD68 
PGM 
Mouse 
Monoclonal 
Novocastra, 
UK 
1/400 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
CD11c Mouse 
monoclonal 
Novocastra, 
UK 
1/400 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
PD-L1 Rabbit 
Polyclonal 
Dako, USA 1/100 Biotinylated 
Mouse Ig in 
Goat 
Vectorlabs,
UK 
1/200 
 
Table 2.6 Sources and dilutions of antibodies used in this study for immunohistochemistry 
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2.2.7 Luminex cytokine array 
 
Luminex technology or multiplex array has been recently developed from the 
traditional enzyme-linked immunosorbent assay (ELISA) for the purpose of measuring 
multiple cytokines in the same sample at the same time. This multiplex array is 
available in several different formats based on the utilisation of flow cytometry, 
chemiluminescence, or electrochemiluminescence technology. It is also known as a 
bead-based multiplex assay which represents probably the most commonly used format 
at the present time. Compared with the traditional ELISA, multiplex arrays have a 
number of advantages including: a) high throughput multiplex analysis; b) less sample 
volume needed; c) efficiency in terms of time and cost; d) ability to evaluate the levels 
of one given inflammatory molecule in the context of multiple others; e) ability to 
perform repeated measures of the same cytokine panels in the same subjects under the 
same experimental assay condition; f) ability to reliably detect different proteins across 
a broad dynamic range of concentrations.Luminex technology was used to detect 
cytokines in ascitic supernatant samples. The samples were diluted (ascites; 1:8) and 50 
μl of each were plated in duplicate onto a 96-well plate, along with serially diluted 
standard cocktails of each cytokine (R&D systems, Minneapolis) (Table 2.7).  
The plate was then washed a final three times with wash buffer and then read using a 
Luminex 200 machine (Biorad, California). Multiple proteins could be simultaneously 
detected in the same sample. One laser was microparticle specific and determined 
which cytokine was being detected; a second laser was used to determine the magnitude 
of the labelled signal, which was directly proportional to the amount of cytokine bound. 
The unit of cytokine concentration was in pg/mL. 
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Table 2.7 Luminex human cytokines analyte and standard values in pg/mL 
Analyte Sensitivity (pg/mL) Standard Value (pg/mL) 
IL-1β 0.57 1920 
IL-2 2.23 2320 
IL-4 4.46 2200 
IL-6 1.11 2400 
IL-8 1.97 2500 
IL-10 0.30 2320 
IL-12 14.9 34,000 
IL-13 15.6 28,000 
IL-17 1.10 2100 
TNF-α 1.50 2900 
IFN-γ 1.25 1900 
GMCSF 1.98 1800 
TGF-β 1 24.6 24,300 
VEGF 1.84 2400 
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2.2.8 Statistical analysis 
 
Differences between two groups, such as cell surface expression, were determined by 
using a Student‟s t test and corrected with a Welch‟s correction method. Box-and-
whisker plots and scattergrams were used to display expressions or to compare 
expressions between groups. The mean value for each group was determined and 
included in all the plots and scattergrams. A Chi-square test for independence was used 
to evaluate the associations among the biomarkers (low versus high expression), as well 
as between the biomarkers and other clinical characteristics. Kaplan-Meier survival 
curves based on disease-free survival and overall survival were calculated and 
compared using the log-rank test. The Cox proportional hazards model was used to 
identify the independent prognostic factors as well as to estimate their effects on 
disease-free survival and overall survival.  
The hierarchical clustering (HCL) analysis, which has been established since 1998 by 
Eisen et al., was used to run algorithms which display a dialog that allows different 
linkages and options to cluster genes, samples or both. Once the computations are 
complete, commands can be included to view the hierarchical tree. Examples of the 
commands used are the „tree selection‟, „order optimisation‟ and „distance metric 
selection‟. Each command has different functions. A tree selection command is used to 
indicate whether to cluster genes, samples, or both; an order optimisation command is 
used to indicate whether the ordering of the leaves will be optimised for genes, samples 
or both; and a distance metric selection command is used to indicate the distance metric 
that will be used in calculating the tree. The default distance metric is „Euclidean‟. The 
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display is similar to the main display, but similar genes and experiments are connected 
by a series of „branches.‟ The algorithm also produces a “reference” which displays the 
number of terminal nodes in the tree given a particular inter-node distance threshold.  
There are three types of „linkage methods‟ available in HCL. A linkage method is a 
parameter used to indicate the convention used for determining cluster-to-cluster 
distances when constructing the hierarchical tree. The three types are the „single 
linkage‟, „average linkage‟ and „complete linkage‟. The single linkage is the distances 
which are measured between each member of one cluster and each member of the other 
cluster. The minimum distance is considered as the cluster-to-cluster distance. The 
average linkage is the average distance of each member of one cluster to each member 
of the other cluster that is used as a measure of the cluster-to-cluster distance. The 
complete linkage is the distances which are measured between each member of one 
cluster with each member of the other cluster. The maximum of these distances is 
considered the cluster-to-cluster distance. The average distance of each member of one 
cluster to each member of the other cluster is used as a measure of the cluster-to-cluster 
distance.  
Two hierarchical clusters were developed using 30 variables: the 25 immune 
biomarkers, stage and grade, histological type, debulking status, disease-free survival 
and mortality. The first factor selected by the algorithm defined 3 groups that had the 
most similar cell surface marker expressions. This process was then repeated in each 
specimen type. The survival rates computed from the survival and their 95% confidence 
intervals were presented for the 25 immune biomarkers only instead of for the groups 
defined by hierarchical clustering. All the statistical tests were two-tailed with a 
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significance level set at 5%. Descriptive statistical analyses were performed with the 
SPSS software and were validated with the R programme software by a 
bioinformatician. 
 
2.2.9 Tritiated thymidine (3H) incorporation proliferation assays 
 
 
3
H labelled thymidine was used to measure the proliferation of T cells in mixed 
lymphocyte reactions (MLR) or proliferation assays. T cells were plated into 96 well 
plates at a concentration of 2 x 10
6
 cells/ml and stimulated with either anti-CD3 / CD28 
beads or a stimulator cell (cell type depending on what experiment was being carried 
out) and incubated for the length of time required for the specific experiment. Blocking 
antibodies were also added at this point, if required. On the day of the analysis of 
proliferation, 
3H thymidine was added to each well at a concentration of 1 μCi/well and 
the cells were incubated for a further eighteen hours before harvesting or freezing. The 
cells were harvested (Harvester 96 MACH III M, TOM TEC; Receptor Technologies, 
Adderbury, UK) onto a filter mat and counted using a Wallac Trilux 1450 Microbeta 
liquid scintillation counter (Perkin Elmer, UK). 
 
2.2.10 Isolation of CD14 populations 
 
Cells were obtained from peripheral blood, ascites and fresh ovarian tumour tissues. 
PBMCs and TALs were washed and suspended in PBS at a concentration of 
10
8
cells/ml. Next, the cells were labelled with anti-CD14 MicroBeads (Miltenyi 
Biotech, Surrey, UK) and finally separated on a Super MACS equipped with MS 
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columns according to the manufacturer‟s instructions. The cell populations were > 98% 
pure as confirmed by flow cytometry (Canto I, Becton Dickinson). The cells were 
eluted in 1ml of RPMI media (Sigma, UK) by adding the media to the column and then 
flushing the column with the plunger provided. The CD14
+
 positive cells were then 
used in monocyte experiments. 
 
2.2.11 Staining and histological analysis PD-L1 cells 
 
PD-L1 cells were quantified by systematically screening the entire tumour area of at 
least three sections obtained from different areas of the tumour using the supersensitive 
polymer detection or Biogenex method (Appendix 2). Then, the PD-L1 expression of 
individual cases was checked by their extent of tumour cells and TILs. The stromal 
tissue was considered to be negative due to non-specific cytoplasmatic staining and the 
expression in epithelial cells was both membranous and cytoplasmic but not nuclear. 
All the counting was performed independently by two investigators without knowledge 
of clinical information. The expression was checked in tumour cells and TILs, and the 
percentage of cells expressing PD-L1 was quantified in 5% to 10% increments by a 
pathologist. 
Three cores were evaluated from each tumour. Each core was scored individually and 
then the mean of the three readings was calculated. An assessment of the staining was 
based on a semi-quantitative approach. A modified histochemical score (H-score) was 
used. To date, H-scoring and similar semi-quantitative systems are the only 
mechanisms used for TMA analysis. The H-score includes an assessment of both the 
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intensity of staining and the percentage of stained cells. A score index of 0, 1, 2 and 3 
corresponding to negative, weak, moderate and strong staining intensity was used. The 
percentages of positive cells at all the staining intensities were estimated subjectively. 
A composite score of 0-300 was the product of both the intensity and the percentage. A 
final score on a scale of 0 to 3 was obtained: 0: no expression; 1: weak expression 
(composite score < 100); 2: moderate expression (composite score 101-200) and 3: 
strong expression (composite score 201-300). For statistical purposes, the 
immunoexpression patterns were divided into two groups: reduced phenotype with a 
staining score of 0 or 1, and preserved phenotype with a staining score of 2 or 3. The 
pathologic parameters studied were FIGO staging, histological subtype, tumour 
differentiation and peritoneal dissemination. 
 
2.2.12 Assay for arginase activity 
 
Arginase activities in PBMCs and ascites cells were measured with the use of a 
colorimetric assay. PBMCs and ascites cells at a concentration of 1 x 10
6
 cells were 
counted and used in the assay. Experimental samples and urea standards were prepared 
by adding 25 µl of PBS and lysis buffer (0.1% Triton X-100, 25mM Tris-HCL and 
10mM MnCl2) to the cells followed by 7 minutes of incubation at 56 ºC in a thermal 
cycler with serially diluted urea standard from 3.5 - 120µg mixed with 400µl of acid 
mix and 20µl of ISPF (Sigma, UK) for the establishment of a standard curve.  
The cells were then lysed and the lysates were incubated with 50µl of 0.5M L-arginine 
(pH 9.7) for 60 minutes at 37 ºC. Then 400µl of acid mix containing H2SO4 (96%) / 
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H3PO4 (85%) / H2O of V:V 1:3:7 ratio was added to each lysate sample to stop the 
enzymatic activity. In the final step, 20µl of 6% 2C-Methyl-D-erythritol 2,4-
cyclodiphosphate synthase (ISPF) (Sigma, UK) was added to the lysate sample and 
incubated for 45 minutes at 100 ºC and then 30 minutes at 4 ºC, and the collected fluid 
was measured at 550 nm in a microplate reader. Water was used instead of cells as a 
blank. A human liver carcinoma (HEPG2) cell line expressing little arginase activity 
was used as a negative control and a human hepatocyte (HUH-7) cell line expressing 
high arginase activity was utilised as a positive control. The results were expressed in 
units calculated as milliunits of arginase / million cells (Appendix 3), where one unit of 
arginase activity was defined as the amount of enzyme that is required to catalyse the 
formation of 1µg of urea per minute. 
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3.0 Chapter 3: Distributions of regulatory molecules in ovarian cancer 
 
 
3.1 Chapter 3: Introduction  
 
 
 
There is a network of cell surface molecules and cytokines involved in humoral and 
cellular immune responses (441). Cellular immune responses have an important role in 
stimulating a response against tumour growth (442). Recently, researchers have 
emphasised the importance of active suppressor mechanisms arising from the tumour 
and from the immune system itself that can inhibit anti-tumour immune reactions in 
vivo (157), (181), (443). A wide array of regulatory mechanisms of the immune system 
is exploited by tumours to avoid or suppress immune responses (444), (445). These 
include a network of soluble factors such as cytokines and specialised T cell subsets 
that repress cellular immunity known as Tregs. 
The past 10 years have witnessed an increased interest in the field of active 
mechanisms of immune regulation, and much of this renewed interest has been centred 
on Tregs (446), (447). Tregs keep the immune system in check, limiting the potential 
for auto reactivity and autoimmune diseases (448). Most of the early studies of human 
cancer defined Tregs using a platform of CD4 and CD25 co-expressions. Some studies 
have characterised Tregs as being unnecessary for the activation of cells that express 
CD69, lacking in CD62L, exhibiting a blastoid phenotype or expressing Ki67 and 
corroborating the CD4
+ 
CD25
+
 Treg phenotype and CTLA-4 (18), (250), (449), (450), 
(451). However, the core features of Tregs now include the expression of FOXP3, the 
constitutive expression of CTLA4 and GITR, an inability to proliferate in response to 
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TCR-driven signals in vitro, a dependence on IL-2 for expansion, and the ability to 
suppress the proliferation of other T cells in vitro and in vivo (202), (446), (452), (453), 
(454). Despite their differences, the most physiologically relevant Treg population is 
CD4
+
 CD25
+ 
Tregs, which are naturally present in the immune system as 10% of CD4
+
 
T cells and which specifically express the transcription factor FOXP3 (449).  
Numerous studies in recent years have found increased frequencies of CD4
+ 
CD25
+
 T 
cells, with some or all of the features of Tregs in the peripheral blood of patients with a 
wide array of cancers, including head and neck cancer, lung and ovarian cancer, 
gastrointestinal cancers, pancreatic and breast cancers and skin cancer (250), (254), 
(450), (455), (456), (457), (458). In addition, in several studies the tumour associated 
Tregs that were identified via phenotypic criteria were further isolated and shown to be 
highly suppressive in in vitro functional assays (459). The two most frequent 
observations collectively provide strong evidence that Tregs do improve immunity 
against a wide variety of human tumours. Firstly, the frequency of Tregs is increased in 
the peripheral blood of cancer patients and enriched in frequency among TILs or within 
tumour draining lymph nodes. Secondly, an accumulation of Tregs in tumour-
associated tissue predicts poor prognosis or survival (459). How and why CD4
+
 CD25
+
 
FOXP3
+
 Tregs increase in cancer patients may be due firstly, to the possibility that 
proliferating and dying tumour cells provide a large amount of self-antigens; secondly, 
the inflammatory milieu in tumours might also recruit Tregs; thirdly, the fact that it has 
been proposed that tumour cells and tumour infiltrating macrophages produce CCL22; 
and finally, the fact that it is  likely the FOXP3
+ 
Tregs are induced from non-Tregs 
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because of high concentrations of TGF-β secreted by tumour cells and DCs present in 
tumours (18), (197), (460), (461), (462), (463).  
There are clearly soluble factors present in the tumour microenvironment of cancer 
patients that encourage Tregs recruitment and differentiation. Therefore, it would be 
useful to characterise these soluble factors and see if it would be possible to predict 
who is likely to have immunosuppression leading to tumour escape. In general, most 
studies have failed to identify a soluble suppressor cytokine (278), (279), (280), (281), 
(282), (464), (465). Therefore, besides characterising the Tregs population in ovarian 
cancer patients in the circulating blood, ascites and tumour tissues, a comprehensive 
study is included to characterise the cytokines present in the ovarian cancer peritoneal 
tumour microenvironment that is the ascites supernatant. Previous studies have been 
conducted to understand immune tolerance in ovarian cancer using tumour cells and 
immune cells obtained from patients‟ tumour tissues, peripheral blood and ascites. Cells 
isolated from tumour tissues, peripheral blood and ascites are termed TILs, PBMCs and 
TALs, respectively. 
In this project, results are included from the flow cytometric analysis of lymphocytic 
and monocytic populations in blood, ascites or tumour tissue derived lymphocytes. The 
results from this approach could contribute to findings of prognostic significance of 
immunological markers which have not been systematically studied up to now. 
Therefore, this study, which consists of data produced using the bioinformatics 
approach with further validation using qRT-PCR and IHC simultaneously, is the first to 
be conducted in ovarian cancer research. 
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3.1.1        Chapter 3: Aims and hypotheses 
 
In this chapter, both the clinical data and experimental data are analysed. The 
association between selected cell surface marker protein expression and other 
phenotypic markers such as FOXP3 were looked at with patients‟ histological 
diagnosis, surgical debulking status, disease free survival and prognosis. 
 
The hypotheses is that immune responses (as characterized by studying phenotypic 
markers and cytokines) with either regulatory or inhibitory function may be associated 
with clinical diagnois of ovarian cnacer and prognosis from cancer.  There is evidence 
in the literature to suggest immune regulation in patients with ovarian cancer and these 
hypotheses is likely to be significant and may be used to aid diagnosis and predict 
prognosis in these patients. 
 
The aims in this chapter are: 
 To identify the specific immune signatures associated with clinical parameters 
such as patients‟ histological diagnosis, surgical debulking status, diagnosis, 
disease free survival and prognosis. We have used a panel of markers identified 
from the literature to do this.  
 To characterise the distribution of Tregs in peripheral blood, ascites and tumour 
tissue of pateints with ovarian tumours. 
 To identify the patterns of cytokine expression associated with clinical diagnosis 
in patients‟ ascitic supernatant from patients with both benign and malignant 
ovarian disease. 
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3.2 Chapter 3: Results 
3.2.1 Ovarian cancer patients’ clinical data analysis 
 
From June 2007 to November 2009, samples of the peripheral blood, ascites and 
tumour tissues from 116 patients were obtained and processed for experiments. Among 
these, 64 patients were diagnosed with serous histological type cancer, 10 patients were 
diagnosed with clear cell histological type cancer, 6 patients were diagnosed with 
endometrial histological type cancer, 27 patients were diagnosed with benign 
histological type cancer and 8 patients were diagnosed with borderline histological type 
cancer.  
In the cohort for this study, in keeping with the reported literature, the most common 
EOC was the serous histological type, followed by the clear cell, endometrioid and 
mucinous types. The clinicopathological characteristics of the cases recruited for this 
study are shown in Table 3.1. The ascites were obtained for initial diagnosis in 57 
cases. Out of the 57 cases, only 10 cases were from patients diagnosed with benign and 
borderline ovarian disease. Normal ovarian tissue was processed and included as a 
negative control for some experiments such as qRT-PCR and IHC. Meanwhile, tumour 
tissue samples from ovarian cancer patients were obtained during surgery in 60 cases.  
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Table 3.1 Clinical details of patients whose samples were used in this study 
Clinical data Total n Percentage 
Age Mean age: 54 years old  
FIGO stage   
IA  6 (116)   5.0% 
IB -  
IC  6 (116)   5.0% 
IIC 16 (116) 14.0% 
IIIA 17 (116) 15.0% 
IIIB 12 (116) 10.0% 
IIIC 45 (116) 39.0% 
IV 14 (116) 12.0% 
Grade   
1  8 (116)   7.0% 
2 32 (116) 28.75% 
3 76 (116) 64.25% 
Histology   
Serous 64 (116)   55.0% 
Clear Cell 10 (116)    9.0% 
Mucinous   1 (116)    0.25% 
Endometrioid   6 (116)    5.0% 
Benign and borderline 35  (116)  30.75% 
Surgical debulking status   
Optimal 89 (116) 76.75% 
Suboptimal 27 (116) 13.25% 
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3.2.2 Relationship between immune markers with clinical parameters: 
unsupervised analysis 
 
Data was entered from 25 immunological markers and 5 clinical parameters for 116 
ovarian cancer patients in a bioinformatics input for PBMCs and ascites. Two protein 
array outputs were produced in a heat map format using the PBMCs and ascites data 
with bioinformatics software (Figure 3.1 and 3.2). This hierarchical clustering check 
box was selected to perform hierarchical clustering on the elements in each cluster 
created. The algorithm constructs a binary tree known as a dendrogram, in which the 
terminal nodes are the resulting clusters. Once the computations are complete, the 
nodes are selected to view the hierarchical tree, where similar percentages of protein 
expressions are connected by a series of „branches‟. The dendrogram displays the 
generated tree with the expression image of each resulting cluster‟s group (Figure 3.1 
and 3.2). Clusters can be coloured as high (red/dark red) and low (green/dark green) 
expression. 
By using an unsupervised clustering approach, 3 different patient groups or clusters, 
designated as cluster 1, cluster 2 and cluster 3, were obtained after analysing the 25 
biomarkers protein expression data for the PBMCs and another 3 different patient 
groups or clusters designated as cluster 1, cluster 2 and cluster 3 for ascites. A further 
analysis showed that cluster 2 PBMCs consist more of benign patients (13/19), 
borderline patients (3/4), all of the clear cell histological subtype patients (4/4) and 
healthy individuals (8/8) (Table 3.2). Similarly, cluster 2 from the ascites consists of 
more benign patients (6/8), all of the borderline patients (4/4) and most of the clear cell 
histological subtype patients (3/5) (Table 3.3).  
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Figure 3.1 Heat map of unsupervised clustering using ovarian cancer patients‟ and healthy 
individual‟s PBMC samples. Output from unsupervised clustering using 25 markers and 4 
clinical parameters; green/dark green indicates low protein expression while red/dark red 
indicates high protein expression. 
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Figure 3.2 Heat map of unsupervised clustering using ovarian cancer patients‟ ascites samples. 
Output from unsupervised clustering using 25 markers and the 5 clinical parameters; green/dark 
green indicates low protein expression while red/dark red indicates high protein expression. 
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As mentioned previously, clinical parameters consisting of histological type, stage, 
residual disease, survival and disease recurrence were included in the analysis. Two 
clinical parameters showed a significant difference between the respective groups with 
a P value of less than 0.0006 for histology and a P value of less than 0.04 for residual 
disease (debulking status) for both patient sample types (Table 3.2 and 3.3).  
The histology, which consisted of benign and borderline, subtypes of cancer serous, 
endometrioid and clear cells, showed an obvious significant difference when compared 
between the groups. The serous histology subtype was found to be the main histology 
subtype present overall when compared across the clusters, except for clusters 2 and 3 
for both patient sample types. Both the PBMCs and ascites for clusters 2 and 3 
consisted of more benign, borderline and clear cell histological types. Clusters 2 and 3, 
which had mostly benign and borderline cases, had a higher percentage of optimally 
debulked patients. These cases were generally easily completely debulked. Overall, 
there seemed to be mostly completely debulked cancers also in these two groups. The 
effect of various markers in predicting the surgical outcome in malignant cases only 
have been looked at and will be discussed later in this section.  
From the unsupervised clustering analysis using the patients‟ PBMCs samples it was 
found that there were no differences between the three patient groups in terms of the 
overall survival and disease free survival with P values of 0.339 and 0.326, respectively 
(Table 3.2). Similar findings were obtained from the unsupervised clustering analysis 
using the patients‟ ascites samples with a P value of 0.887 for overall survival and a P 
value of 0.223 for disease free survival (Table 3.3).  
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Table 3.2 Clinical parameters for the cluster analysis obtained using patients‟ and healthy 
individual‟s PBMCs. Out of the 4 clinical parameters, only 2 were significantly correlated with 
P values of 0.0001 and 0.054 respectively for histology and residual disease. No significant 
correlation was found between the cluster groups for survival and disease recurrence. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 Clinical parameters for cluster analysis obtained using patients‟ ascites. Out of the 5 
clinical parameters, only 2 were significantly correlated with P values of 0.0006 and 0.067 
respectively for histology and residual disease. No significant correlation was found between 
cluster groups for overall survival and disease recurrence.  
Clinical parameters Cluster1 (n=30 ) Cluster 2 (n=20) Cluster 3 (n = 11) P value 
 
 
Histology 
Serous 10 6 3 0.0001 
Endometrioid 1 1 2 
Clear cell 0 4 0 
Benign 0 6 13 
Borderline 0 1 3 
 
Residual 
disease 
Optimal 8 16 17 0.054 
Suboptimal 2 4 1 
 
Survival Alive 9 19 19 0.339 
Dead 2 1 1 
 
Disease  
Recurrence 
Recurrence 2 1 1 0.326 
No recurrence 7 19 9 
 
 
Clinical parameters Cluster1 (n=15) Cluster 2 (n=17) Cluster 3 (n=24) P value 
 
 
Histology 
Serous 13 4 19  
 
0.0006 
Endometrioid 1 0 2 
Clear cell 0 3 2 
Benign 1 6 1 
Borderline 0 4 0 
 
 
Stage 
Stage II 0 1 1  
0.442 Stage III 13 5 17 
Stage IV 1 1 5 
 
Residual  
disease 
Optimal 7 15 14 0.067 
Suboptimal 7 2 6 
 
Survival Alive 11 13 19 0.887 
Dead 3 4 4 
 
Disease 
Recurrence 
Recurrence 6 2 10 0.223 
No recurrence 6 6 6 
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By using the Kaplan Meir survival analysis, a P value of 0.3704 was obtained when 
comparing the proportional disease-free survival between clusters in the PBMCs (panel 
A, Figure 3.3), while a P value of 0.8749 was obtained when comparing the 
proportional disease-free survival between clusters in the ascites (panel A, Figure 3.4). 
These similar observations of no difference in disease-free survival between clusters 
may be attributed to the fact that the number of events present for each cluster was still 
low possibly because of the relatively short follow-up period for these patients. The 
median for disease-free survival was 13.4 months. 
An overall survival function analysis was also performed to look at the proportion of 
live patients at respective times after surgery (P = 0.1107 for PBMCs; panel B, Figure 
3.3 and P = 0.9727 for ascites; panel B, Figure 3.4). Again the lack of significant 
difference could be because the analysis was limited by the small number of patients 
and events (the median for overall survival was 18.4 months). In general, the relative 
survival rates for ovarian cancer are between 5 to 10 years after their initial 
diagnosis/treatment.  
 
 
 
124 
 
 
 
Figure 3.3 Kaplan-Meier survival curves of disease free survival and overall survival in 
PBMCs for each cluster from unsupervised analysis. The three clusters were tested for survival 
analysis of disease-free (panel A) and overall survival (panel B) with cluster 1 (marked in red), 
cluster 2 (marked in blue) and cluster 3 (marked in green). Neither one of the survival analyses 
showed a significant correlation between the clusters and survival since time of surgery (P ≥ 
0.05). 
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Figure 3.4 Kaplan-Meier survival curves of disease-free survival and overall survival in ascites 
for each cluster from unsupervised analysis. The three clusters were tested for survival analysis 
of disease-free (panel A) and overall survival (panel B) with cluster 1 (marked in red), cluster 2 
(marked in blue) and cluster 3 (marked in green). Neither one of the survival analyses showed a 
significant correlation between the clusters and survival since the time of surgery (P ≥ 0.05). 
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3.2.2.1 Ovarian tumours histological subtypes and immune marker correlation 
 
The unsupervised clustering or heat map for the PBMCs and ascites data showed a 
correlation between the histology with clusters with P = 0.0001 for the PBMCs and P = 
0.0006 for the ascites (Table 3.2 and 3.3). A mean comparison was also performed 
using one way ANOVA analysis on all the markers.  
The markers and „marker groups‟ which showed significant P values for both non-
malignant and malignant histology types were identified. They were the T cell 
activation marker of CD69 with P = 0.021 for the PBMCs and P = 0.018 for the ascites 
(panels A and B, Figure 3.5) and the monocyte marker group of PD-L1 related markers 
of PD-L1
+
, CD14
+ 
PD-L1
+
 subset and CD11c
+
 PD-L1
+
 subset with P < 0.0001 for both 
sample types (Figure 3.6, Figure 3.7 and Figure 3.8). The benign and borderline ovarian 
cases in both the PBMCs and ascites had a lower percentage of CD69 and PD-L1 
related marker expression when compared to the respective marker expression in clear 
cell, endometrioid and serous ovarian cancers. 
Therefore, it appears that these two marker groups of CD69 and PD-L1 related markers 
have significant differences between groups of ovarian cancer cases. Benign and 
borderline cases were the two groups with the diagnosis of no malignant cells present, 
while clear cell, endometrioid and serous cases were the groups of malignant 
histological types. Certain markers appeared to be expressed in higher levels in certain 
histological types compared to others, though more cases are needed to validate the 
observations.   
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Figure 3.5 CD69 marker expression according to non-malignant and malignant histology types. 
The ovarian tumour histological diagnosis compared were the benign, borderline, clear cell, 
endometrioid and serous. Both patients‟ PBMCs (panel A) and ascites (panel B) showed 
significant correlation with tumour histological subtypes. 
P = 0.021 
[B] 
[A] 
P = 0.018 
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Figure 3.6 PD-L1 marker expression according to non-malignant and malignant histology 
types. The ovarian tumour histological diagnoses compared were the benign, borderline, clear 
cell, and endometrioid serous. Both patients‟ PBMCs (panel A) and ascites (panel B) showed a 
strong correlation with the tumour histological subtypes.   
P < 0.0001 
 
P < 0.0001 
 
[A] 
[B] 
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Figure 3.7 CD14
+
 PD-L1
+
 marker expression according to non-malignant and malignant 
histology types. The ovarian tumour histological diagnoses compared were the benign, 
borderline, clear cell, endometrioid and serous. Both patients‟ PBMCs (panel A) and ascites 
(panel B) showed a strong correlation with the tumour histological subtypes. 
P < 0.0001 
 
P < 0.0001 
 
[A] 
[B] 
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Figure 3.8 CD11c
+
 PD-L1
+
 marker expression according to non-malignant and malignant 
histology types. The ovarian tumour histological diagnoses compared were the benign, 
borderline, clear cell, endometrioid and serous. Both patients‟ PBMCs (panel A) and ascites 
(panel B) showed a strong correlation with the tumour histological subtypes.   
P < 0.0001 
 
P < 0.0001 
 
[A] 
[B] 
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3.2.2.2 Surgical debulking status and the immune profile 
 
An analysis was carried out to assess the relationship between the debulking status and 
the expression of the immune markers under study. A non-significant P value (P ≤ 
0.067) was obtained for the correlation between the patient clusters and the debulking 
status using both the PBMCs and ascites. These analyses included all the patients‟ 
clusters and debulking status. By using a student‟s t test with Welch‟s correction, all the 
markers were further analysed individually using data only from patients who had been 
diagnosed with cancer. Benign / borderline cases were excluded as initially, by 
definition, these were the cases where all the tumours were completely removed and 
were not malignant. Therefore, they were not included in predicting the value of a 
marker in the debulking status for cancer surgery. Data was first presented on the 
malignant cases for PBMCs and ascites, which were detected to have significant 
differences for debulking status (optimal versus suboptimal) in some lymphocyte 
markers of CD4
+
 and CD8
+
 (Figure 3.9) and monocyte markers of PD-L1 related 
markers (Figure 3.10). Among these markers, the PD-L1 monocyte markers in the 
PBMCs showed the most significant correlation with the debulking status with a P 
value of less than 0.006 (panel A, B and C; Figure 3.10).  
The results of the same lymphocyte and PD-L1 monocyte markers using all cases are 
presented here as well (Figure 3.11 and 3.12). The contrasting results obtained using 
the malignant cases only compared to all the other cases may likely have been due to 
the fact that the PD-L1 is highly expressed in cancer cases and the differences 
presented may be purely due to diagnosis. No lymphocyte marker except CD4 may 
have predictive value in determining the debulking status.  
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Figure 3.9 CD4
+
 and CD8
+
 expressions according to debulking status in malignant cases. CD4
+
 
expression was significantly different in the PBMCs between the optimally and sub-optimally 
debulked patients with a P value of 0.051 (panel A), but not in the ascites (panel C). No 
significant correlation between CD8
+
 expression with debulking status was found in either the 
PBMCs (panel B) or the ascites sample type (panel D). 
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Figure 3.10 Correlation of debulking status with PD-L1 monocyte markers in PBMCs and ascites for malignant cases only. Significant 
differences between optimal and suboptimal surgical debulking for ovarian cancer patients were obtained using PBMCs (panel A, B and 
C) with a P value of less than 0.006 for all PD-L1 markers, but not for ascites (panel D, E and F). 
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Figure 3.11 CD4
+
 and CD8
+
 expressions according to debulking status in all cases. CD4
+
 
expression was only significantly different in PBMCs with a P value of 0.038 (panel A) and 
ascites with a P value of 0.0383 (panel C). The CD8 expression was not significantly different 
for the PBMCs (panel B) or the ascites (panel D).  
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Figure 3.12 Correlation of debulking status with PD-L1 monocytes markers in PBMCs and ascites for all cases. Significant differences 
between the optimal and suboptimal surgical approaches for ovarian cancer patients were obtained by both using PBMCs (panel A, B 
and C) and ascites (panel D, E and F) with P values of less than 0.004 for all PD-L1 markers. 
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3.2.2.3 Diagnostic value of immune markers 
 
Following the results obtained after a series of statistical analyses on immune marker 
expressions in different samples, the diagnostic values of those markers that showed a 
high correlation with the histology and debulking status were investigated. The immune 
markers that showed a high correlation to the histology and debulking status for both 
the PBMCs and ascites were the CD69
+
 lymphocyte markers and the PD-L1 related 
monocyte markers.  
In order to investigate the potential of these markers and other markers as a diagnostic 
tool for ovarian cancer, a comparison of non-cancer and ovarian cancer cases for each 
marker was performed according to the sample type (Figure 3.13, 3.14, 3.15, 3.16, 3.17 
and 3.18). A considerable difference in the total lymphocyte CD4
+
 FOXP3
+
, CD69
+
, 
PD-1
+
 and CD4
+
 PD-1
+ expressions in the patients‟ PBMCs and ascites was obtained 
(Figure 3.13, 3.14, 3.15 and 3.16). The CD69
+
 marker expression in patients‟ ascites or 
the tumour environment was found to be two-fold higher than the expression of this 
marker in the patients‟ circulating blood. 
On the other hand, the PD-L1 monocyte markers expression showed a highly 
significant difference when tested individually with a P value of 0.0001 for both sample 
types (Figure 3.17 and 3.18). Also, it was confirmed that the cell subset which was 
expressing the PD-L1 also expressed the CD14
+
 CD11c
+
,
 
and was therefore likely to be 
a myeloid cell subset.  
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Figure 3.13 Tregs marker expression in patients‟ PBMCs and ascites according to diagnosis. 
CD4
+
 FOXP3
+
 as a marker was found to be correlated with the patients‟ diagnosis. The CD4+ 
FOXP3
+
 expression in the ascites (panel B) was significantly more than the CD4
+
 FOXP3
+
 
expression in the PBMCs (panel A).  
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Figure 3.14 T cell activation marker expression in patients‟ PBMCs and ascites according to 
diagnosis. The CD69 as a marker was found to be highly correlated with the patients‟ 
diagnosis. In both the PBMCs and ascites, the CD69 expression in the ascites (panel B) was 
significantly more than the CD69 expression in the PBMCs (panel A).  
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Figure 3.15 PD-1
+
 marker expression in patients‟ PBMCs and ascites according to diagnosis. 
PD-1
+
 was found to be highly correlated with the patients‟ diagnosis. In both the PBMCs and 
the ascites, the PD-1
+
 expression in the ascites (panel B) was significantly more than the PD-1
+
 
expression in the PBMCs (panel A).  
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Figure 3.16 CD4
+
 PD-1
+
 marker expression in patients‟ PBMCs and ascites according to 
diagnosis. CD4
+
 PD-1
+
 was found to be highly correlated with the patients‟ diagnosis. In both 
the PBMCs and the ascites, the CD4
+
 PD-1
+
 expression in the ascites (panel B) was 
significantly more than the CD4
+
 PD-1
+
 expression in the PBMCs (panel A). 
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Figure 3.17 PD-L1 monocyte markers expression in patients‟ PBMCs according to diagnosis. PD-L1 as a marker (panel A) and sub-
markers (panel B and C) were found to be highly correlated with the patients‟ diagnosis of non-cancer and ovarian cancer.  
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Figure 3.18 PD-L1 monocyte markers expression in patients‟ ascites according to diagnosis. PD-L1 as a marker (panel B) and sub-
markers (panel C and D) were found to be highly correlated with the patients‟ diagnosis of non-cancer and ovarian cancer. 
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3.2.2.4 Prognostic value of immune markers 
 
Survival analyses were performed earlier by the Kaplan Meier survival curves on 
patient groups or clusters which showed no significant difference for disease-free 
survival and overall survival using both sample types. Then, a survival analysis was 
conducted on all immune markers to show the correlation with disease-free and overall 
survival by using the Cox proportional hazards model.  
Immune markers were found that showed a correlation with the overall survival. One 
such immune marker was the CD8
+
 PD-1
+
 in the PBMCs (Table 3.4) and the other was 
the CD3
+
 CD4
+
 FOXP3
+
 in the ascites (Table 3.5). The PD-1 related markers will be 
discussed further in Chapter 4. However, the CD3
+
 CD4
+
 FOXP3 immune marker will 
be discussed in greater detail here as a potential ovarian cancer prognostic marker. 
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Table 3.4 Survival analyses of ovarian cancer patients using a Cox proportional hazards model in PBMCs. All 29 ovarian cancer cases 
where the PBMC samples were obtained underwent a survival analysis using a Cox proportional hazards model for disease-free survival 
and overall survival. Out of the 23 markers tested, 4 markers showed a correlation with overall survival: CD4
+
 PD-1
+
 (P = 0.0279), 
CD8
+
 PD-1
+
 (P = 0.0004), CD14
+
 (P = 0.0419) and HLA-DR
+
 (P = 0.0508). No correlation was obtained for disease-free survival with 
any marker. 
Markers Disease free survival in  PBMCs (n = 29)   Overall survival in  PBMCs (n = 29) 
  HR HR Lower 95 HR Upper 95 P value FDR      HR        HR Lower 95 HR Upper 95 P value FDR 
Total lymphocytes CD3+ 1.0252 0.9631 1.0913 0.4275 0.9680 
 
1.0400 0.9632 1.1230 0.3114 0.5754 
Total lymphocytes CD8+ 1.0963 0.9715 1.2372 0.1235 0.9680 
 
0.9610 0.8397 1.0999 0.5622 0.7563 
Total lymphocytes CD4+ 1.0084 0.9350 1.0875 0.8287 0.9680 
 
1.0400 0.9573 1.1298 0.3452 0.5754 
Total lymphocytes CD28+ 1.0055 0.9203 1.0986 0.9029 0.9680 
 
1.0409 0.9590 1.1299 0.3330 0.5754 
Total lymphocytes CTLA-4+ 0.8534 0.4211 1.7295 0.6592 0.9680 
 
0.9999 0.4748 2.1058 0.9998 0.9998 
Total lymphocytes CD19+ 0.9901 0.7800 1.2568 0.9350 0.9680 
 
1.0774 0.8871 1.3087 0.4471 0.6986 
Total lymphocytes CD69+ 0.9272 0.6595 1.3035 0.6621 0.9680 
 
1.0876 0.8093 1.4616 0.5748 0.7563 
Total lymphocytes PD-1+ 1.0557 0.6414 1.7376 0.8309 0.9680 
 
1.0324 0.5641 1.8895 0.9177 0.9747 
CD3+ CD4+ CD25+ 1.0127 0.6788 1.5109 0.9507 0.9680 
 
0.8458 0.4821 1.4837 0.5562 0.7563 
CD3+ CD4+ FOXP3+ 0.9799 0.3629 2.6459 0.9680 0.9680 
 
1.0476 0.3385 3.2422 0.9357 0.9747 
Total lymphocytes CD4+ PD-1+ 0.9389 0.4589 1.9212 0.8631 0.9680 
 
2.0043 1.0125 3.9678 0.0279 0.3173 
Total lymphocytes CD8+ PD-1+ 0.2593 0.0414 1.6240 0.2613 0.9680 
 
1.9123 1.0937 3.3434 0.0004 0.0098 
Total lymphocytes CD19+ PD-1+ 0.5759 0.0976 3.3983 0.5340 0.9680 
 
1.3218 0.4382 3.9868 0.6162 0.7703 
Total monocytes CD14+ 1.0309 0.9464 1.1230 0.4784 0.9680 
 
1.2071 0.9888 1.4736 0.0419 0.3173 
Total monocytes CD86+ 1.0424 0.9725 1.1173 0.2209 0.9680 
 
1.0955 0.9740 1.2322 0.0929 0.3794 
Total monocytes HLA-DR+ 1.0078 0.9392 1.0815 0.8279 0.9680 
 
1.2323 0.9879 1.5371 0.0508 0.3173 
Total monocytes CD11c+ 0.9926 0.9307 1.0588 0.8222 0.9680 
 
1.0615 0.9512 1.1845 0.2612 0.5442 
Total monocytes PD-L1+ 0.9981 0.9663 1.0309 0.9088 0.9680 
 
1.0745 0.9796 1.1787 0.1036 0.3794 
Total monocytes CD14+ CD11c+ 0.9902 0.9321 1.0520 0.7496 0.9680 
 
1.0578 0.9619 1.1634 0.2268 0.5154 
Total monocytes CD11c+ CD86+ 1.0275 0.9676 1.0913 0.3651 0.9680 
 
1.0507 0.9674 1.1412 0.2154 0.5154 
Total monocytes CD11c+ HLA-DR+ 0.9910 0.9237 1.0631 0.8004 0.9680 
 
1.0870 0.9640 1.2258 0.1505 0.4180 
Total monocytes CD14+ PD-L1+ 0.9975 0.9654 1.0307 0.8819 0.9680 
 
1.0735 0.9767 1.1799 0.1152 0.3794 
Total monocytes CD11c+ PD-L1+ 0.9971 0.9653 1.0300 0.8626 0.9680   1.0685 0.9764 1.1692 0.1214 0.3794 
145 
 
 
Markers Disease free survival in Ascites (n = 44)   Overall survival in Ascites (n = 44) 
  HR HR Lower 95 HR Upper 95 P value FDR   HR HR Lower 95 HR Upper 95 P value FDR 
Total lymphocytes CD3+ 1.0387 0.9908 1.0889 0.1136 0.8326 
 
1.0058 0.9637 1.0498 0.7896 0.8353 
Total lymphocytes CD8+ 0.9966 0.9536 1.0415 0.8781 0.9147 
 
1.0084 0.9570 1.0626 0.7535 0.8353 
Total lymphocytes CD4+ 1.0136 0.9711 1.0580 0.5351 0.8326 
 
1.0085 0.9604 1.0590 0.7341 0.8353 
Total lymphocytes CD28+ 1.0124 0.9712 1.0552 0.5614 0.8326 
 
1.0188 0.9678 1.0725 0.4758 0.6891 
Total lymphocytes CTLA-4+ 0.7914 0.5394 1.1611 0.2350 0.8326 
 
1.0921 0.8669 1.3757 0.4529 0.6891 
Total lymphocytes CD19+ 1.0761 0.9183 1.2611 0.3624 0.8326 
 
1.0979 0.9713 1.2411 0.1345 0.6891 
Total lymphocytes CD69+ 1.0155 0.9476 1.0882 0.6633 0.8326 
 
0.9993 0.9252 1.0793 0.9857 0.9857 
Total lymphocytes PD-1+ 0.9900 0.9155 1.0707 0.8013 0.8710 
 
0.9265 0.7842 1.0946 0.3699 0.6891 
CD3+ CD4+ CD25+ 1.0328 0.8973 1.1887 0.6523 0.8326 
 
0.9088 0.7223 1.1434 0.4090 0.6891 
CD3+ CD4+ FOXP3+ 0.7370 0.4680 1.1607 0.1858 0.8326 
 
0.5739 0.3407 0.9666 0.0412 0.6891 
Total lymphocytes CD4+ PD-1+ 1.0183 0.8843 1.1726 0.8008 0.8710 
 
0.9243 0.7371 1.1591 0.4938 0.6891 
Total lymphocytes CD8+ PD-1+ 0.9297 0.7491 1.1538 0.4825 0.8326 
 
0.6689 0.3637 1.2303 0.2582 0.6891 
Total lymphocytes CD19+ PD-1+ 1.5898 0.3870 6.5300 0.5180 0.8326 
 
1.5176 0.4686 4.9145 0.4848 0.6891 
Total monocytes CD14+ 1.0080 0.9817 1.0350 0.5532 0.8326 
 
0.9888 0.9629 1.0153 0.4003 0.6891 
Total monocytes CD86+ 1.0050 0.9825 1.0280 0.6661 0.8326 
 
0.9907 0.9667 1.0153 0.4532 0.6891 
Total monocytes HLA-DR+ 1.0092 0.9843 1.0348 0.4687 0.8326 
 
0.9912 0.9668 1.0163 0.4871 0.6891 
Total monocytes CD11c+ 0.9991 0.9751 1.0236 0.9402 0.9402 
 
0.9847 0.9602 1.0097 0.2210 0.6891 
Total monocytes PD-L1+ 1.0144 0.9897 1.0396 0.2488 0.8326 
 
0.9884 0.9644 1.0130 0.3468 0.6891 
Total monocytes CD14+ CD11c+ 1.0117 0.9832 1.0411 0.4208 0.8326 
 
0.9915 0.9643 1.0195 0.5467 0.7193 
Total monocytes CD11c+ CD86+ 1.0053 0.9816 1.0295 0.6643 0.8326 
 
0.9914 0.9670 1.0165 0.4962 0.6891 
Total monocytes CD11c+ HLA-DR+ 1.0033 0.9788 1.0285 0.7927 0.8710 
 
0.9892 0.9634 1.0157 0.4187 0.6891 
Total monocytes CD14+ PD-L1+ 1.0179 0.9918 1.0447 0.1717 0.8326 
 
0.9892 0.9649 1.0142 0.3913 0.6891 
Total monocytes CD11c+ PD-L1+ 1.0187 0.9924 1.0456 0.1559 0.8326   0.9894 0.9651 1.0144 0.3985 0.6891 
            
Table 3.5 Survival analyses of ovarian cancer patients using a Cox proportional hazards model in ascites. All 44 ovarian cancer cases 
where ascites samples were obtained underwent a survival analysis using a Cox proportional hazards model for disease-free survival and 
overall survival. Out of the 23 markers tested, only one marker showed a correlation with the overall survival. That marker was the 
CD3
+ 
CD4
+
 FOXP3
+
 (P = 0.0421). No correlation was obtained for disease-free survival with any marker. 
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3.2.3 Regulatory molecules in ovarian cancer 
 
3.2.3.1 Expression of CD4+ CD25+ Tregs phenotype by ovarian cancer immune 
cells 
 
 
 
The T cells from the peripheral blood of ovarian cancer patients as well as the ascites 
were studied for the presence of CD4
+
 CD25
+
, CD4
+
 FOXP3
+
 and CTLA-4
+
 T cell 
subsets in the PBMCs and ascites. The examination of the T cell subsets revealed 
increased proportions of CD4
+
 CD25
+
, CD4
+
 FOXP3
+
 and CTLA-4
+
 T cells in the 
ovarian cancer patients compared to the benign / borderline patients and healthy 
individuals both in PBMCs (Figure 3. 19) and ascites (Figure 3.20). Significant P 
values were obtained for differences between the healthy women and the benign / 
borderline cases when compared to the malignant cases for CD4
+
 CD25
+
 and CD4
+
 
FOXP3
+
 expressions. No significant difference of CTLA-4 expression was present 
between the benign / borderline and malignant cases; however, significant differences 
were presented between the healthy women and the malignant cases using peripheral 
blood samples.  
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3.2.3.2 FOXP3 Tregs expression by ovarian cancer immune cells 
 
It is known that the FOXP3 expression in humans is not restricted to CD4
+
 Treg cells. 
Investigations to compare the expression levels of different subsets of FOXP3
+
 Tregs in 
PBMCs and ascites of ovarian cancer patients have never been conducted before. The 
CD4
+ 
FOXP3
+ 
population in malignant cases was found to be significantly higher 
compared to benign / borderline cases and healthy women in the PBMCs samples, as 
well as to the benign / borderline cases in the ascites samples (Figure 3.19 and 3.20). 
There is evidence in the literature where it is stated that CD8
+
 Tregs and natural killer 
(NK) Tregs exist in relatively very low levels (<1 %) in some cancers. Similar evidence 
of this has also been found in this study. Figures 3.21 and 3.22 show the expression 
patterns of CD4, CD8 and NK1.1 co-expressing FOXP3 in both the PBMCs and ascites 
samples. The levels of CD8
+
 FOXP3
+
 and NK1.1
+
 FOXP3
+
 cells were very low and 
there were no differences between the benign / borderline and malignant cases for the 
expression of these markers in the blood or ascites. Significant P values were obtained 
only between groups for the CD4
+
 FOXP3
+
expression. No significant differences in the 
CD8
+
 FOXP3
+
 and NK1.1
+
 FOXP3
+
expressions were present between the groups. 
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Figure 3.19 Tregs and CTLA-4 population in lymphocytes isolated from peripheral blood samples. Distribution of Tregs (CD4
+
 CD25
+
 
and CD4
+
 FOXP3
+
) and CTLA-4 populations according to groups of healthy women (marked in squares), patients with benign / 
borderline (marked with triangles) and malignant ovarian tumours (marked with dark circles). 
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Figure 3.20 Tregs and CTLA-4 population in lymphocytes isolated from ascites samples. Distribution of Tregs (CD4
+
 CD25
+
 and 
CD4
+
 FOXP3
+
) and CTLA-4 populations according to groups of healthy women (marked with squares), patients with benign / 
borderline (marked with triangles) and malignant ovarian tumours (marked with dark circles). 
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Figure 3.21 Tregs population and subpopulation in lymphocytes isolated from PBMCs samples. Distribution of Tregs population and 
subpopulation according to groups of healthy women (marked with squares), benign / borderline (marked with triangles) and malignant 
(marked with dark circles) using PBMCs samples.  
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Figure 3.22 Tregs population and subpopulation in lymphocytes isolated from ascites samples. Distribution of Tregs population and 
subpopulation according to groups of healthy women (marked with squares), benign / borderline (marked with triangles) and malignant 
(marked with dark circles) using ascites samples. 
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3.2.4 Tregs expression within the ovarian tumour infiltrating lymphocytes 
(TILs)  
 
To determine the expression of CD3, CD4, CD8, CD25 and FOXP3 markers in TILs of 
tumour tissues from ovarian cancer patients, a tissue microarray of sections containing 
60 ovarian tumours of different histological types were stained for immunological 
markers. The sections were surveyed microscopically at x100 magnification followed 
by positive staining cell counts at x20 magnification (Figure 3.23). The ratio of the 
mean T cell counts for each sample type was determined. The results showed 
differences in expression in all the samples taken from those patients with ovarian 
cancer and the controls. The mean CD8
+
 and FOXP3
+
 percentage cell counts was 
obtained, and the CD8
+ 
/ FOXP3
+
 ratio was calculated. The ratio of the CD8
+ 
/ FOXP3
+
 
cells showed a difference in PBMCs, ascites and tissues of patients with ovarian cancer 
compared to peripheral blood samples from non-cancer patients (Table 3.6). 
 
Samples %  FOXP3
+
 cells CD8
+ 
/ FOXP3
+
ratio 
PBMCs (non cancer) n = 26 1 15 
PBMCs (ovarian cancer) n = 33 2 7 
Ascites  (ovarian cancer) n = 57 4 9 
Tumour tissue (ovarian cancer) n = 60  8 5 
 
 
Table 3.6 Comparison of average percentage of FOXP3 cells (as a percentage of lymphocytes) 
ratio of CD8
+
 and FOXP3 and 
+
 cells in various patient samples.  
 
153 
 
The mean percentage of the FOXP3
+
 cells was found to increase from 1% in non-
cancer PBMCs samples to 4% of total lymphocytes in ovarian cancer ascites samples. 
Inversely, the CD8
+ 
/ FOXP3
+
 ratios were found to have been reduced from a non-
cancer environment with ratio of 15 to a ratio of 5 in a tumour environment (tumour 
tissue). 
 
                                
                      
 
Figure 3.23 Immunostaining for lymphocyte and Tregs markers. All sections showed positive 
immunostaining for 4 out of 5 lymphocyte and Tregs markers that is the CD3, CD8, CD25 and 
FOXP3. The fifth marker that was negative was CD4. The above were representative cases for 
the staining for CD3 (panel A), CD8 (panel B), CD25 (panel C) and FOXP3 (panel D) in 
sequential sections. 
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3.2.5 Ascitic supernatant cytokine profiling 
 
3.2.5.1 T cell associated cytokines 
 
As part of the study of immune markers in ovarian cancer, cytokines within the tumour 
environment were studied. This was done by studying the cytokine levels in ascites 
using luminex technology. The T helper cells associated cytokines panel in patients‟ 
ascitic supernatant, which included IL-2, IL-4, IL-12, IL-13, IL-17 and IFN-γ, were 
studied. This panel of T helper cells associated cytokines was chosen due to their 
known role in T cell responses. For example, IL-12 and IFN-γ were chosen as these 
were involved in Th1 responses.  
Two groups of cytokines were found to be present. One group was present in low 
concentrations of less than 2 pg/mL and the second group was present in high cytokine 
concentrations of more than 2000 pg/mL. Cytokines IL-2, IL-4, IL-12, IL-13 and IL-17 
either could not be detected or were present in very low concentrations (Figure 3.24), 
while IL-6 and IL-8 were present in high concentrations although no significant 
differences between the benign / borderline and malignant ascitic supernatant were 
present (Figure 3.25). IFN-γ was present in low concentration with no significant 
difference found in malignant and benign / borderline ascitic supernatants (Figure 
3.26). 
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Figure 3.24 Cytokines with low concentrations of less than 2 pg/mL according to benign / 
borderline (marked with triangles) and malignant (marked with dark circles) patient groups. No 
significant difference was obtained when the groups were compared. 
 
 
Figure 3.25 Cytokines with concentrations of less than 2000 pg/mL according to benign / 
borderline (marked with triangles) and malignant (marked with dark circles) patient groups. No 
significant difference was obtained when the groups were compared. 
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Figure 3.26 IFN-γ concentration in ascitic supernatants from patients with ovarian tumours. 
IFN-γ concentrations were analysed according to benign / borderline (marked with triangles) 
and malignant (marked with dark circles) patient groups. A significant difference was obtained 
when the groups were compared, with a P value of 0.003 (P = 0.003) being obtained. 
 
The cytokine concentration data was obtained for both the pro-inflammatory cytokines 
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It was found that both IL-1 β and TNF-α were present in low concentrations; however 
TNF-α in malignant cases had a slightly higher mean level compared to benign / 
borderline ascitic supernatants (panel A and B, Figure 3.27). A significant increase in 
IL-10 concentration in the malignant ascitic supernatant was present, with an average 
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malignant ascitic supernatants had significantly higher TGF-β than the benign / 
borderline ascitic supernatants (panel B, Figure 3.28). The TGF-β concentration was 
high at > 2000 pg/mL on average. It is likely that these two cytokines are partly 
responsible for the immunosuppressive effect in the tumour microenvironment.  
 
3.2.5.2 Dentritic cell differentiation cytokines 
 
Dendritic cell differentiation cytokines such as the granulocyte macrophage colony 
stimulating factor (GM-CSF) and IL-4 are known to be rare in the human tumour 
environment and this was confirmed in the findings of this study, where the GM-CSF 
cytokine concentrations were mostly not detected at all (panel A, Figure 3.29), while 
IL-4 was included in the group of cytokines present in low concentrations of less than 2 
pg/mL (Figure 3.24). On the other hands, vascular endothelial growth factors (VEGF) 
play a key role in recruiting immature myeloid (iMCs) cells as tumour-associated 
immature dendritic cells (iDCs) and tumour-associated macrophages. In this study, 
VEGF presented with high cytokine concentrations (> 2000 pg/ml) in the ovarian 
cancer ascitic supernatants. However, no significance difference was found between the 
malignant ascitic supernatants and benign / borderline ascitic supernatants (panel B, 
Figure 3.29). 
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Figure 3.27 IL-1 β and TNF-α pro-inflammatory cytokine levels in ovarian cancer ascitic 
supernatants. The IL-1 β (panel A) and TNF-α (panel B) cytokine concentrations were analysed 
according to benign / borderline (marked with triangles) and malignant (marked with dark 
circles) patient groups. A significant difference was only obtained between the groups when 
they were compared for TNF-α (P = 0.05) but not for IL-1 β cytokine concentrations. 
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Figure 3.28 IL-10 and TGF-β immunoregulatory cytokines level in ovarian cancer ascitic 
supernatants. IL-10 (panel A) and TGF-β (panel B) cytokine concentrations were analysed 
according to benign / borderline (marked with triangles) and malignant (marked with dark 
circles) patient groups. A significant difference was obtained between the groups when they 
were compared with P = 0.02 for IL-10 and P < 0.0001 for TGF-β, respectively. 
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Figure 3.29 GM-CSF and VEGF cytokine concentrations distributed according to benign / 
borderline (marked with triangles) and malignant (marked with dark circles) patient groups. 
GM-CSF (panel A) was mostly undetectable in the benign / borderline and malignant ascitic 
supernatants. VEGF (panel B) cytokine concentrations were present with a significant 
difference (P = 0.02) when compared between the groups.   
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3.3 Chapter 3: Discussions 
3.3.1 Association of immunological markers with histology and debulking 
status 
 
 
Analyses were performed to confirm whether there was any association between the 
immune biomarkers with the histology and debulking status of the ovarian cancer 
patients. Patient clusters defined by the unsupervised analysis were used. These patient 
subgroups were obtained by bioinformatics analysis using unsupervised clustering on 
PBMCs and ascites. Three patient clusters exhibiting a panel of immune biomarkers 
were obtained, with cluster 2 being significantly associated with a favourable histology 
(benign and borderline). In addition, cluster 2 also had a smaller number of cases 
present with a serous histological type and had the most clear cell histological type.  
 
A clear cell histology has been generally accepted as an unfavourable histology and 
recent microarray experiments have revealed that clear cell carcinoma has a genomic 
expression pattern that differs from serous epithelial ovarian cancer (3), (4). This 
suggests that the biologic phenotype of clear cells is unique. Although the case numbers 
were too small to confirm this, the study managed to identify the PD-L1 monocyte 
markers as the immune marker groups which have a distinct expression pattern to clear 
cell histology. The study found that Cluster 2, which included mostly benign / 
borderline but also clear cell cancers, exhibited a low expression of PD-L1 markers. 
This suggests that the poor prognosis in clear cell tumours is unlikely to be related to 
the PD-L1 expression. Previous studies of the immunohistology of PD-L1 have shown 
a negative relationship between its expression and prognosis (400).  
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The CD69 lymphocyte markers and PD-L1 monocyte markers showed a significant 
difference with a low expression of the respective markers in non-cancer cases when 
compared to ovarian cancer cases both in PBMCs and ascites sample types. These may 
now be further developed as a diagnostic tool at presentation as it is not always easy to 
diagnose a malignant from a benign complex ovarian mass and this can lead to 
unnecessarily radical treatment. Further studies are being carried out in the group to 
validate these markers further. 
As the long-term survival of patients with ovarian cancer has not been uniformly 
improved, the identification of prognostic factors predictive of poor outcomes remains 
important and may lead to new therapeutic options. One of the prognostic factors that 
has been reported as being the most recognised and consistent predictor of the poor 
outcome of advanced disease is the residual volume of tumour after the primary 
surgical cytoreduction (38), (40), (41). The residual tumour size is believed to be an 
important prognostic factor, especially when all of the macroscopic disease is removed. 
Many investigators have studied the relationship between age, tumour histology and 
grade with prognosis. Tumour histology and grade do not appear to contribute to 
surgical cytoreduction (466), (467). It is believed that the expression of some immune 
markers may provide information regarding the surgical outcome prior to surgery, 
which would be very useful. It was found that the expression of high levels of CD69 on 
lymphocytes and PD-L1 on monocytes in ascites showed a significant association with 
the debulking status. However, unlike the study by Haminashi, in the univariate 
analyses conducted by this study there appeared to be no correlation between the PD-
L1 monocyte markers with the disease-free or overall survival status (400).  
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This study attempted to look at the relationship between tumour biology and the 
immune response. As mentioned previously, 3 patient clusters were obtained using 
unsupervised clustering analyses and markers expressed by the cells in the PBMCs and 
ascites. Patient clusters 2 and 3 had more patients with optimal debulking status when 
compared to patient cluster 1 for both the patient sample types that were analysed. 
 
3.3.2 PD-L1 expression as predictor of debulking and prognosis 
 
Optimal debulking is defined as a procedure with varying sizes of residual disease 
(0.5 2 cm) (468). Meanwhile, the most recent definitions now focus on radical 
procedures of no macroscopic residuals versus any residuals (469), (470), (471), (472). 
In this study, 1 cm was taken as the cut off for residual disease for optimal debulking. 
The patient clinical outcomes and levels of specific cell surface markers on immune 
cells in peripheral blood or that were associated with the tumours were studied. The 
data indicated that specific cell surface markers on immune cells may affect the 
behaviour of ovarian carcinoma. It was found that there was a significant association 
between optimal and suboptimal debulking with expressions of PD-L1 on immune cells 
in ascites, suggesting that a certain type of immune response may be responsible for 
tumour behaviour and clinical outcomes. According to previous studies, optimal 
debulking is an important prognostic factor in ovarian cancer (473). Nevertheless, very 
few of these studies associate immune-related markers with debulking and an improved 
clinical outcome. 
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One study found that an improved clinical outcome is strictly associated with the 
presence of intratumoural T cells in ovarian carcinoma; these findings are similar to 
those for oesophageal and colorectal tumours (474), (475). Following that study, many 
researchers examined which intraepithelial T cell populations best predicted the 
survival or outcome of the patient. One group investigated the impact of surgical 
debulking on the survival of patient groups as defined by the presence of either a high 
or a low frequency of intraepithelial CD8
+
 cells (473). They found that optimal 
debulking did not impact the survival of patients whose tumours had a high frequency 
of intraepithelial CD8
+
 T cells (473). However, for patients with a low frequency of 
intraepithelial CD8
+
 T cells, those who had optimal debulking had a significantly better 
prognosis than those who had suboptimal debulking (473).  
In contrast, the debulking status and prognosis of patients defined by the expression of 
PD-L1 monocyte markers (high or low) were examined. The group of patients with a 
low frequency expression of PD-L1 on monocytes was more likely to have optimal 
debulking. It is possible that PD-L1 on the tumour cells can interact with monocytes 
and increase the number of tumour-associated monocytes expressing PD-L1. A 
previous study has shown a prognostic role for the PD-L1 expression on ovarian 
tumours (400). It is therefore possible that more aggressive tumours that are more likely 
to spread to the upper abdomen express more PD-L1 and are responsible for the 
expression of PD-L1 on monocytes within a tumour environment. A more distributed 
disease or a more aggressive tumour is less likely to be completely excised at surgery. 
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3.3.3 Univariate analyses of disease-free survival and overall survival outcomes 
 
Analyses were performed to predict which immune marker can potentially be a 
prognostic factor with respect to overall survival. Surprisingly, each sample type from 
the patient‟s circulating blood and tumour environment showed unique immune 
markers which have an effect towards overall survival. From the PBMCs data set, the 
patients with higher numbers of cells with any of these immune markers CD4
+
 PD-1
+
, 
CD8
+
 PD-1
+
, CD14
+
 and HLA-DR
+
 profiles experienced decreased survival. 
Meanwhile, the ascites data set showed that patients with immune marker of CD3
+
 
CD4
+
 FOXP3
+
 profile experienced decreased survival. In addition, it was shown that 
there was no association between any immune markers with disease-free survival for 
both sample data sets. 
Although the study did not prospectively evaluate the association of histology and 
residual disease with survival, the new prognostic factors data from both the ovarian 
cancer patients‟ PBMCs and ascites provide provocative evidence to suggest that 
tumour biology and the patient‟s immune response in a unique environment do have an 
effect on the survival of ovarian cancer patients.   
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3.3.4 Tregs role as potential T cell marker predicting prognosis and clinical 
outcome 
 
CD4
+
 CD25
+
 Tregs, a population of CD4
+
 T cells with immunosuppressive properties, 
have been shown to be increased in human ovarian cancer and to be associated with 
reduced survival (18), (181), (193) (476). An elevation of CD4
+ 
CD25
+
 Tregs was 
shown in PBMCs, TALs and TILs from patients with various malignancies, including 
ovarian cancer (251), (254), (452).  
In the present study, a detailed immunoprofiling evaluation of Tregs was performed in 
PBMCs, TALs and TILs in EOC. The results indicate that there was a significant 
correlation between the number of Tregs in TALs and the overall survival in the group 
as a whole. Tregs in TILs alone was not associated with poor prognosis and overall 
survival (23). Tregs in TILs expressing FOXP3 are often in close contact with CD8
+
 T 
cells (18). CD8
+
 TILs are known to be a strong prognostic factor and immunological 
prognostic indicator (340). Intraepithelial CD8
+
 TILs predict not only the overall 
survival but also progression-free survival of patients with ovarian cancer (340). 
This study has shown for the first time that Treg TALs are a significant predictor of 
overall survival in ovarian cancer. It has also been hypothesised that the soluble factors 
found in the tumour microenvironment of ascites may be in part responsible for these 
findings. 
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4.0 Chapter 4: Mechanism of immune inhibition in ovarian cancer 
4.1 Chapter 4: Introduction  
 
T cell activation occurs as a result of a balance between positive and negative signals 
(344). Negative signals through cell surface molecules such as CTLA-4 inhibit T cell 
activation or induce apoptosis. In the absence of proper controls, T cell activation can 
lead to compromised self-tolerance and disease (344). Cancer, for example, is a disease 
that is known to have a lack of balance between the positive and negative signals. The 
researchers in this study have been interested in investigating the negative regulatory 
function in ovarian cancer patients.  
The PD-1 receptor was first described in 1992 as a member of the B7 family of co-
stimulatory molecules (317). The PD-1 is structurally similar to the CTLA-4, which 
binds the CD80 and CD86 and plays a crucial role in the maintenance of T cell 
homeostasis (314). PD-1 is induced on activated T, B and myeloid cells (309), (317), 
(318).  The known ligands for PD-1 include PD-L1 and PD-L2 (477), (478). In vitro 
and in vivo studies show that the engagement of PD-1 by PD-L1 inhibits T cell 
proliferation, survival, or function; whereas the blockade of PD-1 promotes the 
generation of auto-reactive T cells as well as greater auto-antibody production (479), 
(480). However, very few studies have shown or proven that the PD-1 or PD-L 
expression may be correlated with patients‟ malignancy and outcome. Therefore, this 
study attempted to investigate whether the PD-1 / PD-L expression on immune cells in 
the circulating blood and tumour microenvironment of ovarian cancer patients can be 
systematically linked to the patients‟ diagnosis or prognosis. The PD-1 blocking 
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antibody was also used in functional studies to further understand its role and capability 
in reversing or improving immune inhibition in ovarian cancer. PD-L1 and PD-L2 have 
been thought to be involved in the negative regulation of cellular and humoral immune 
responses by engaging the PD-1 receptor on activated T and B cells (322), (314). The 
constitutive expression of PD-L1 is normally restricted to macrophage-lineage cells and 
can further be upregulated following the activation of these cells (315). Therefore, 
experiments were performed to investigate the PD-L1 expression on ovarian cancer 
patients‟ monocytes and dendritic cells which had been isolated from the circulating 
blood and ascites. It was hypothesised that PD-L1 is perhaps induced in response to 
cytokines, such as IFN-γ, which have been shown to upregulate the PD-L1 expression 
and also IL-10, which has not been clearly linked to the PD-L expression until now 
(354). In order to investigate the role of cytokines in the PD-L1 expression, functional 
in vitro studies were conducted using the patients‟ ascitic supernatants and IL-10 
blocking antibody to see whether the suppressive effect present could be reversed in 
total or partially. The PD-L1 expression has been reported in human carcinoma of the 
lungs, ovaries, colon and in melanomas. However, its exact effect on the patients‟ 
prognosis and characteristics has not been determined yet (364). In addition, little is 
known about the actual role of PD-L1 in the clinical outcome of human cancers (313).   
Given the enhancement of T cell responses upon a blockade of PD-Ls and the 
stimulatory effect of a blockade of other inhibitory molecules such as CTLA-4, anti-
PD-L mAbs may be useful therapeutic tools for improving anti-tumour T cell responses 
(378). The PD-L1 blockade using anti-PD-L1 mAbs inhibited tumour growth in vivo 
(373). Although these studies have demonstrated a therapeutic potential for PD-L1 
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either in vitro or in vivo using murine tumour models, the clinical relevance in human 
cancer remains unknown (364), (373). However, the development of antibodies 
targeting the PD-1/PD-L1 pathway is currently being evaluated in clinical trials either 
by blocking PD-1 or PD-L1 (480), (481), (482). PD-1 and PD-L1 antagonist antibodies, 
such as MDX-1106 (anti-PD-1 mAb), BMS-936558 (mAb inhibiting ligation to both 
PD-1 and B7-1), MK-3475 (anti-PD-1 mAb) and MPDL3280A (anti-PD-L1 mAb), are 
currently being evaluated in clinical trials (481), (482), (483), (484).   
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4.1.1        Chapter 4: Aims and hypotheses 
 
 
In this chapter, immune cells isolated from ovarian cancer and non-cancer patients with 
a specific focus on inhibitory markers PD-1, PD-L1 and PD-L2 were characterised. PD-
L1 and PD-L2 expressions on tumour cells were also looked at to determine association 
between their expressions with the histological types of ovarian cancer. The inhibitory 
functions of PD-1 and PD-L1 were tested by in vitro experiments in the context of 
ovarian cancer. 
The hypotheses for this chapter are that there is upregulation of PD-1 and PD-L1 on 
immune cells of patients with ovarian cancer, compared to patients with no cancer and 
that these molecules play an important role in immune suppression that is associated 
with ovarian cancer and hence may be targeted for therapeutic purposes in this cancer. 
 
The aims in this chapter are: 
 To determine the PD-1 cell surface expression in patients‟ lymphocytes isolated 
from patients‟ peripheral blood and ascites and correlate with clinical diagnosis. 
 To determine the PD-L1 and PD-L2 cell surface expression on antigen presenting 
cells and its mRNA expression in ovarian cancer cell line and ovarian tumour 
tissue and correlate with clinical diagnosis and histological type. 
 To identify the cytokines that upregulate PD-L1 cell surface expression on 
patients‟ monocytes and characterise effect of PD-L1 upregulation monocytes on 
T cell proliferation.  
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4.2 Chapter 4: Results 
 
4.2.1 PD-1 expression by immune cells  
 
A PD-1 receptor has been described as being expressed on thymocytes and on mature T 
and B cells by others. Therefore, the characterisation of PD-1 is presented here in the 
clinical samples taken from ovarian cancer patients. The patients‟ blood and ascites 
before treatment were processed. 
The approach of studies initially was to determine the total PD-1 expression using the 
flow cytometry method. The cell surface staining of the CD69 marker and the T cell 
activation marker was also performed. As shown in Figure 4.1, the percentage of PD-1 
expressing on the resting T lymphocytes was detected at a lower level, where there 
were not many activated T cells in comparison to the high percentage of cells 
expressing PD-1 when there are more activated lymphocytes. It was hypothesised that 
the tumour microenvironment provides the conditions for the cells to be activated. This 
was particularly observed in cells obtained from ascites. The T cell subsets and B cells 
expressing PD-1 were then analysed. The cell surface staining was then performed 
using the CD3, CD4, CD8, CD19 and PD-1 markers [Figure 4.2 (a) and 4.3(a)]. In both 
sample types, the total significant number of immune cells expressing PD-1 in ovarian 
cancer patients was increased in malignant cases compared to benign and borderline 
cases, including healthy individuals‟ PBMCs [panel A, Figure 4.2(b) and panel A, 
Figure 4.3(b)]. In addition, it was also noted that in the tumour microenvironment, this 
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increase was even higher in the malignant cases compared to the benign cases. This can 
be seen from the total PD-1 expression and the respective PD-1 expressions on the T 
cell subsets, which were found to have increased in the ascites compared to the 
peripheral blood. When comparing the subsets of T cells, the CD4 cells expressing PD-
1 were significantly increased in the peripheral blood of ovarian cancer patients 
compared to the benign / borderline cases [panel B, Figure 4.2(b)] and this was also the 
case for both the CD4 and CD8 cells expressing PD-1 in the ascites [panel B, Figure 
4.3(b)]. 
 
4.2.2 PD-L1 and PD-L2 expressions on antigen presenting cells 
 
The cell surface staining of PD-L1 and PD-L2 was conducted in a similar way to the 
flow cytometry method that was applied for the PD-1 expression, except that here the 
APCs, instead of the lymphocytes, were being studied [Figure 4.4(a) and 4.5(a)]. 
Freshly isolated mononuclear cells from healthy women and ovarian cancer patients‟ 
blood as well as patients‟ ascites were used, and this time 7 antigen-presenting cell 
markers, namely CD14, CD11c, CD80, CD86, HLA-DR, PD-L1 and PD-L2, were 
tested against a panel of antibodies. Out of the 7 markers tested, 5 markers (CD14, 
CD11c, CD86, HLA-DR and PD-L1) were positively present [panel A, Figure 4.4(b) 
and panel A, 4.5(b)]. PD-L2 was not present in the population of APCs that were tested 
and neither was CD80. The analyses showed that the cell surface expression of PD-L1 
on monocytes (CD14
+
) and DCs (CD11c
+
)  is much higher in malignant cases [panel B, 
Figure 4.4(b) and panel B, Figure 4.5(b)], with P ≤ 0.0001 when compared with that of 
non-cancer patients.  
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Peripheral blood 
 
     
 
                                            
Benign case 
 
 
 
   Malignant case 
 
Ascites 
 
  
                                              
                                                   
Benign case  
 
 
 
Malignant case 
 
Figure 4.1 Histogram from flow cytometry showing PD-1 and CD69 marker expressions on patients‟ PBMCs and ascites lymphocytes from 
individual cases. The PBMCs and ascites showed different percentages of cells expressing PD-1 and CD69 according to diagnosis. 
Compared to the PD-1 and CD69 cell surface expressions observed in the peripheral blood in a benign case (panel A), there was an increase 
in the percentage of cells expressing PD1 and CD69 in the ascites, especially in lymphocytes isolated from a malignant case (panel B). The 
green histograms are unstained cells, the red histograms are the isotype controls and the blue histograms are the test samples. 
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Figure 4.2(a) Flow cytometry plots of PBMCs cell surface expressions on lymphocytes from a healthy woman and representative patients from each patient 
group. The PD-1 cell surface expressions on lymphocytes isolated from PBMCs are shown in panel A, panel B and panel C scatter-grams. Panels [A] iii., [B] iii.  
and [C] iii. are the flow cytometry plots from the representative patients from each patient group with the X-axis showing PD-1 staining and the Y-axis showing 
CD4, CD8 and CD19 staining respectively. 
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Figure 4.2 (b) Cell surface expressions of PD-1 and cells expressing PD-1 in lymphocytes 
isolated from PBMCs. Three different groups of patients were analysed for total PD-1 expression 
(panel A), while further analysis on lymphocyte subsets were conducted for benign / borderline 
and malignant cases only (panel B). 
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Figure 4.3 (a) Flow cytometry plots of ascites cell surface expressions on lymphocytes from representative patients from each patient group. PD-1 
cell surface expressions on lymphocytes isolated from PBMCs are shown in panel A and panel B scatter-grams. Panels [A] iii and [B] iii. were the 
flow cytometry plots from representative patients from each patient group with the X-axis showing PD-1 staining and the Y-axis showing CD4, 
CD8 and CD19 staining respectively. 
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Figure 4.3 (b) Cell surface expressions of PD-1 and cells expressing PD-1 in lymphocytes isolated 
from ascites. Two different groups of patients were analysed for the total PD-1 expression (panel 
A), while further analyses on the lymphocyte subsets were conducted (panel B).   
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Figure 4.4 (a) Flow cytometry plots of PBMCs cell surface expressions on monocytes from a 
healthy woman and representative patients from each patient group with the X-axis showing the 
PD-L1 staining and the Y-axis showing the CD11c staining, which also co-expresses CD14 
(panels [A] iii., [B ]iii. and [C ]iii.). 
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Figure 4.4 (b) Cell surface expressions of APC markers, PD-L1 and cells expressing PD-L1 in 
monocytes isolated from PBMCs. Three different groups of patients were analysed for overall 
myeloid cells and their maturation markers (panel A) and for the total PD-L1 expressions and PD-
L1 expressions in its cell subsets (panel B). The differences between malignant cases of serous and 
other non-clear cells with benign and borderline cases were obtained for all cell subsets (◊). The 
same observations were also present for clear cell cases (*).  
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Figure 4.5 (a) Flow cytometry plots of ascites cell surface expressions on monocytes from 
representative patients from each patient group with the X-axis showing PD-L1 staining and the 
Y-axis showing CD11c staining, which also co-expresses CD14 (panel [A] iii. and [B ]iii.). 
0 10
2
10
3
10
4
10
5
PD-L1 Fitc
0
10
2
10
3
10
4
10
5
C
D
1
1
c
 A
P
C
2.11
62.219.7
16.1
 
                       
 
                      
0 50K 100K 150K 200K 250K
FSC-H
0
50K
100K
150K
200K
250K
S
S
C
-H
12.1
0 50K 100K 150K 200K 250K
FSC-H
0
50K
100K
150K
200K
250K
S
S
C
-H
5.27
0 10
2
10
3
10
4
10
5
Isotype IgG1 Fitc
0
10
2
10
3
10
4
10
5
<
A
P
C
>
0.09 0.12
0.08399.7
0 10
2
10
3
10
4
10
5
Isotype IgG1 Fitc
0
10
2
10
3
10
4
10
5
<
A
P
C
>
2.51
0.510.31
96.7
0 10
2
10
3
10
4
10
5
PD-L1 Fitc
0
10
2
10
3
10
4
10
5
C
D
1
1
c
 A
P
C
95.1 0.15
04.78
Benign case Malignant case 
i. 
ii. 
iii. 
[A] [B] Benign case Malignant case 
Benign case Malignant case 
181 
 
 
 
Figure 4.5 (b) Cell surface expressions of APC markers, PD-L1 and cells expressing PD-L1 in 
monocytes isolated from ascites. Three different groups of patients were analysed for overall 
myeloid cells and their maturation markers (panel A) and for the total PD-L1 expressions and 
PD-L1 expressions in its cell subsets (panel B). The differences between the malignant cases of 
serous and other non-clear cells with benign and borderline cases were obtained for all the cell 
subsets (◊). The same observations were also present for clear cell cases (*). 
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4.2.3 PD-L1 and PD-L2 expressions on tumour cells 
 
The study investigated whether ovarian tumour cells constitutively express PD-L1 or 
can be induced. First, several established human ovarian cancer cell lines of different 
histological types such as serous (n = 4), clear cell (n = 3) and endometrioid (n= 1) 
were included in the experiment. The tumour cells were screened for cell surface 
expression of the PD-L1 with and without the presence of IFN-γ (Figure 4.6). 
Interestingly, the PD-L1 expressions on the serous histological type of ovarian cancer 
cell lines were found to be constitutively expressed unlike the clear cell and 
endometrioid histological types. With the presence of IFN-γ for 48 hours, the PD-L1 
expression for both clear cell and endometrioid tumour cells were induced. 
By using qRT-PCR, a screening for the PD-L1 and PD-L2 mRNA expressions was 
carried out in the cDNA generated from frozen tumour tissue RNA (n = 60). Normal 
ovarian tissues (n = 6) were included as the control. Ovarian cancer tumour tissues of 
different histological types were used; benign (n = 13), borderline (n = 8), serous (n = 
28), endometrioid (n=6) and clear cell (n = 5). The PD-L1 mRNA expression showed a 
differential expression pattern between a normal ovary and the different histological 
types of ovarian cancer (panel A, Figure 4.7) compared to the PD-L2 mRNA 
expression, which showed a low level of mRNA expression in all the samples (panel B, 
Figure 4.7). Interestingly, the PD-L1 mRNA expression showed a low level of 
expression in the normal ovary followed by the PD-L1 mRNA expression in the benign 
and borderline cases. The clear cell cases presented with moderate PD-L1 mRNA 
expression, while the serous and endometrioid ovarian cancer cases presented with a 
high PD-L1 mRNA expression.  
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Figure 4.6 PD-L1 expression in ovarian cancer cell lines. PD-L1 is expressed by some of these 
ovarian cancer cell lines as seen by the histograms obtained using flow cytometry. PD-L1 was 
found to be constitutively expressed in the serous type (panel A). The PD-L1 expression can be 
induced by the addition of IFN-γ in other histological types (panel B). The red histograms are 
the isotype control, while the blue and green histograms are the test samples. 
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Figure 4.7 PD-L1 and PD-L2 mRNA expressions in ovarian cancer tumour tissues. Six types 
of tissues were included in this experiment, consisting of five different histological types of 
ovarian tumour tissue and also the normal ovary as a control. The Y-axis shows the PD-L1 
mRNA expression levels normalised to HPRT mRNA level. A variation in the mRNA 
expression was observed only for PD-L1 (panel A) but not for PD-L2 (panel B). 
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4.2.4 Effects of different cytokines on monocytes extracted from healthy 
individual’s blood 
 
This study has looked at the cell surface expression of PD-L1 on monocytes extracted 
from a healthy individual‟s blood using a medium alone and a medium containing a 
recombinant IFN-γ or IL10. A method by Brown et al. (2003) was adapted whereby the 
incubation period was for 8 hours instead of the recommended 24 hours. 
A FACS analysis using the PD-L1 antibody showed that PD-L1 was not detected on 
freshly isolated monocytes from a healthy individual‟s blood using magnetic bead 
separation of CD14 positive cells (panel A, Figure 4.8). The monocytes were cultured 
and harvested every 2 hours and stained with anti CD14 FITC and anti PD-L1 APC to 
measure the cell surface expression using flow cytometry. Isotype controls were 
included in every FACS analysis. The monocytes cultured in a medium with added 
IFN-γ rapidly upregulated the expression of PD-L1 to 54% of the CD14+ cells at 6 
hours and to 95% of the CD14
+
 cells at 8 hours (panel B, Figure 4.8). Meanwhile, 32% 
and 70% of the CD14
+
 cells expressed PD-L1 at 6 hours and 8 hours respectively in the 
medium added with IL-10 (panel C, Figure 4.8). It was found that culturing CD14
+
 
cells in a medium with added IFN-γ in optimal concentration rapidly upregulates the 
expression of PD-L1 within 8 hours, while culturing CD14
+
 cells in a medium with 
added IL-10 with the same concentration moderately induces the expression of PD-L1. 
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Figure 4.8 Induction of PD-L1 expression on monocytes by IFN-γ and IL-10. The PBMCs 
were cultured in a medium alone, a medium with 100 U/ml IFN-γ or a medium with 100 U/ml 
IL-10. Aliquots of cells were harvested at each time point and stained with anti CD14 FITC, 
anti PD-L1 APC (blue lines) and isotype controls (red lines). The zero hour cells were analysed 
directly from peripheral blood without incubation with cytokines. The histograms represent 
staining with the PD-L1 antibody on cells gated on CD14
+
 positive cells. 
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4.2.5 Inhibitory functions for PD-L1 
The aim of the study was to demonstrate that the PD-1 pathway impacts negatively on 
T cell activation. To show this, an in vitro functional assay was performed by culturing 
monocytes isolated from ovarian cancer ascites with T cells separated from a healthy 
individual‟s peripheral blood. T cell proliferation in co-cultures were compared using 
magnetic beads to separate CD14
+ 
cells isolated from malignant ovarian cancer ascites 
samples and ascites from a borderline case. 
To ensure that the T cells used in this co-culture experiment were activated T cells, the 
T cells were treated with CD3 / CD28 beads and later the culturing of stimulated T cells 
alone was included as the control (Figure 4.9). The stimulated T cells were co-cultured 
with monocytes from the peripheral blood of a healthy individual for further 
comparison (Figure 4.9). The T cell proliferation was measured by thymidine 
incorporation assays on days 3 and 5. Co-culture experiments were run in parallel as 
described above but with the addition of a PD-1 blocking antibody. It was observed that 
the presence of monocytes isolated from malignant ovarian cancer ascites suppressed T 
cell proliferation to a significant level when compared to the monocytes isolated from 
ascites from borderline ovarian disease on day 5 (Figure 4.9). The T cell suppression 
was also able to be reversed partially using the PD-1 blocking antibody (Figure 4.9). 
The stimulated T cells cultured with a healthy individual‟s monocytes from peripheral 
blood did not suppress T cell proliferation (Figure 4.9).  
Five malignant ascitic supernatants and three benign / borderline ascitic supernatants 
were added to T cell cultures in dilutions (with RPMI) ranging from 100% supernatant 
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to 0% supernatant each. The T cell proliferation was measured by a thymidine 
incorporation assay on day 5. It was hypothesised that culturing stimulated T cells with 
a malignant ascitic supernatant would have a suppressive effect on their ability to 
proliferate. In addition, it was predicted that IL-10 may be a factor in T cell 
proliferation in these cases. It was found that malignant ascitic supernatants appear to 
have a more suppressive effect on T cells compared to benign / borderline ascitic 
supernatants. The mid-range dilution of 40% was selected as a representative and the 
proliferation between malignant and benign / borderline cases were statistically 
compared. All the 5 malignant ascitic supernatants resulted in greater inhibition of T 
cell proliferation than the 3 benign / borderline ascitic supernatants (panel A, Figure 
4.10). Therefore, at 40% dilution T cells are suppressed significantly more with 
malignant ascitic supernatants compared to benign / borderline ascitic supernatants (P < 
0.03) (panel A, Figure 4.10).  
Stimulated T cells were cultured in malignant ascitic supernatants (40% dilution), with 
and without the IL-10 blocking antibody. For this experiment, malignant ascitic 
supernatants of known IL-10 concentrations obtained by using Luminex ELISA were 
specifically selected. Two cases with high IL-10 ( >100 pg/ml) and three cases with low 
IL-10 (< 50 pg/ml) were chosen. The suppression of T cell proliferation was observed 
in all the malignant ascitic supernatants (panel A, Figure 4.10). However, those 
supernatants with a high IL-10 showed the most suppression (panel B, Figure 4.10). 
The presence of the IL-10 blocking antibody had a small, though insignificant, effect on 
reversing the suppression. This result suggests that IL-10 may be partially responsible 
for the suppression observed when activated T cells are cultured in an ascitic 
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supernatant. The previous data in this chapter show that monocytes from the ascites of 
patients with malignant ovarian cancer have a higher level of PD-L1 than those 
monocytes from patients with benign / borderline ovarian cancer (Figure 4.5). It was 
hypothesised that this PD-L1 upregulation may be due to cytokines expressed in the 
tumour environment. In order to investigate the effect of an ascitic tumour environment 
on a healthy individual‟s monocytes, magnetic separation was used to extract a healthy 
individual‟s monocytes, which were then cultured in ascitic supernatants from patients 
with benign / borderline or malignant ovarian disease and analysed for PD-L1 expression.  
The healthy individual‟s monocytes were measured by flow cytometry for its PD-L1 
expression at 0 hour before they were cultured in their respective ascitic supernatants 
(Figure 4.11). In this experiment a medium alone, a medium containing recombinant 
IL-10, a medium containing recombinant IFN-γ and 100% ascitic supernatants were 
used in the monocyte cultures. The monocytes were incubated for 2, 6 and 8-hour 
durations. At every time point, the PD-L1 expression was measured immediately by 
flow cytometry after the cells had been harvested from their respective culture 
conditions. It was observed that the PD-L1 upregulation occurred between 6 and 8 
hours when the healthy individual‟s monocytes were cultured in malignant ascitic 
supernatants, in a medium containing recombinant IL-10 and in IFN-γ. When compared 
with a healthy individual‟s monocytes cultured in benign / borderline and malignant 
ascitic supernatants at 6 and 8 hours, a significant PD-L1 upregulation of P  0.004 was 
observed (Figure 4.11). There was no PD-L1 upregulation on the monocytes being 
cultured in the medium alone and also the ones being cultured in benign / borderline 
ascitic supernatants.  
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Figure 4.9 T cell proliferation assay; activated healthy individual‟s T cells co-cultured with 
isolated malignant monocytes, monocytes from borderline ascites and healthy individual‟s 
monocytes cultured with and without PD-1 antibody for 3 days and 5 days. The activated T 
cells alone (no monocytes co-culture) were used as an indicator for T cell activation level. The 
T cell activation level for the co-culture using a healthy individual‟s monocytes with or without 
the PD-1 antibody showed a similar T cell activation level. A significantly lower T cell 
activation level (P < 0.0001) for the co-culture using borderline and malignant monocytes was 
observed when compared to the activated T cells alone with suppression on day 5 only. On day 
3, a significant T cell activation difference was observed when compared between the 
borderline and malignant monocytes co-culture. Nevertheless, the suppressions observed were 
not as striking as those observed on day 5. 
 
             
3 
 
5 
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Figure 4.10 T cell proliferation assay; healthy individual‟s T cells cultured in ascitic 
supernatants, and ascitic supernatants with and without IL-10 blocking antibody. [A] T cell 
proliferation assay; healthy individual‟s T cells cultured in ascitic supernatants. Isolated T cells 
from a healthy individual were cultured for 3 days in benign/borderline, malignant ascitic 
supernatants and a medium only as a control. When the T cell activation levels were compared 
between T cells cultured in malignant ascitic supernatant and T cells cultured in benign and 
borderline supernatants at 40% dilution factor, a significant difference was obtained (P < 0.03). 
[B] T cell proliferation assay; healthy individual‟s T cells cultured in ascitic supernatant with 
and without IL-10 blocking antibody. T cells were cultured in 40% ascitic supernatants with 
and without the IL-10 blocking antibody being added. A small increase in the T cell activation 
level was observed for the T cells cultured in malignant ascitic supernatants with IL-10 
blocking antibody added when compared with the T cell activation level for T cells cultured in 
the same malignant ascitic supernatants but without the IL-10 blocking antibody added. To see 
the contribution of IL-10 to T cell suppression, the data from the IL-10 concentration in each 
sample was analysed. Two IL-10 concentration ranges (high IL-10 and low IL-10) of ascitic 
supernatants were chosen from the Luminex data for this experiment and they all showed a 
small, though insignificant, increase in the T cell activation level. 
  
 
[A] [B] 
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Figure 4.11 PD-L1 upregulation experiment; healthy individual‟s monocytes cultured in medium only, benign ascitic supernatants, 
malignant ascitic supernatants, medium added with IL-10 and medium added with IFN-γ. Five different culture conditions were 
included in the PD-L1 upregulation experiment to monitor if there would be an increase in the mean fluorescence index (MFI) when a 
healthy individual‟s monocytes were cultured in the respective conditions. The MFI for these healthy individual‟s monocytes were 
observed at 0, 2, 6 and 8 hours. Significant PD-L1 upregulations (P  0.004) were observed between 6 and 8 hours when the healthy 
individual‟s monocytes were cultured in malignant ascitic supernatants. There was no significant PD-L1 upregulation on the monocytes 
being cultured in the media alone and also in the benign/borderline ascitic supernatants. 
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4.2.6 PD-L1 protein expression in paraffin-embedded ovarian tumour tissues 
 
The overall occurrence of PD-L1 positive cells in paraffin-embedded ovarian tumour 
tissues was scored as negative ( ) or low (+), and moderate (++) or high (+++). Based 
on this scoring, the 2 groups identified were classified with a low score if the 
occurrence of PD-L1 cells was negative or low and with a high score if their occurrence 
was moderate or high. On the other hand, the CD68 cells had a similar positive staining 
distribution as the CD11c cells. All three markers showed a higher protein expression 
in the ovarian cancer cases when compared to the non-cancer cases. The CD11c overall 
protein expression using IHC mirrored the previous protein expression using flow 
cytometry, where the CD11c were found to be co-expressing the CD14 marker (Figure 
4.4 and 4.5). The same result was hypothesised for the CD68 cells and therefore these 
three cell types consisting of monocytes, macrophages and dendritic cells were 
designated as myeloid cells. 
The protein expression of these myeloid cells could be clearly seen in between the large 
tumour cells (Figure 4.12). The PD-L1 positive cells could also be seen on nearly all 
the myeloid cells as shown in panel A, Figure 4.13. It was also found that the ovarian 
tumours were positive for PD-L1 in the observations according to the intensity of the 
PD-L1 staining, with a weak PD-L1 staining being given a low score (+) (panel B, 
Figure 4.13), a moderate PD-L1 staining being given a moderate score (++) (panel C, 
Figure 4.13) and a strong PD-L1 staining being given a high score (+++) (panel D, 
Figure 4.13). The myeloid cells and tumour cells which were positive for PD-L1 were 
included in the protein expression analysis in comparison to the previous cell surface 
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protein expression results using flow cytometry. It was shown that with the IHC 
approach, there was a correlation between the infiltration of myeloid cells and the PD-
L1 tumour expression, although the correlation that was observed was a weak one. 
 
 
Figure 4.12 Immunohistostaining for CD68 and CD11c cells. There was positive IHC (brown 
staining) of CD68 cells (panel A and panel B) and CD11c cells (panel C and panel D) at low 
power (panel A and panel C) and high power (panel B and panel D). The tumour cells remained 
unstained and were found surrounded by CD68 and CD11c cells.  
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Figure 4.13 Immunohistostaining for PD-L1. There was PD-L1 positive staining within the 
macrophages and dendritic cells (panel A) and tumour cells according to intensity, with a low 
score being + (panel B), moderate score being ++ (panel C) and high score being  +++ (panel D).  
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4.3 Chapter 4: Discussions 
 
4.3.1 PD-1 expression by immune cells 
 
PD-1 is an immunoglobulin superfamily member related to CD28 and CTLA-4. In 
contrast to CD28 and CTLA-4, which are all obligate, disulfide-linked homodimers, 
PD-1 is monomeric, both in solution and on the cell surface (479). The cell surface 
expression of PD-1 is observed on activated T cells. In addition, compared with other 
B7 co-stimulatory members, PD-1 is expressed at a relatively late phase following T 
cell activation (479). 
The CD69 marker was used in this study to detect activated T cells isolated from the 
circulating blood and ascites of ovarian cancer patients. It was found that there was a 
relationship between the T cell activation status and the total PD-1
+
 expression 
according to where the T cells were from. A low percentage of T lymphocytes from 
ovarian cancer patients‟ circulating blood showed CD69+ and PD-1+ expressions. 
Similar observations were obtained from the T lymphocytes isolated from benign / 
borderline ascites, whilst a high percentage of T lymphocytes in the ascites expressed 
PD-1
+
 and CD69
+
 (Figure 4.1).  
Previous reports suggest that CD4
+
 and CD8
+ 
T cells are differentially affected by 
particular activation and deactivation pathways. It was decided to systematically 
investigate the PD-1 expression according to T cell subsets and B cells in both ovarian 
cancer patients‟ blood and ascites. The PD-1 expression was shown on both the CD4+ 
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and CD8
+ 
T cells from the blood and ascites but not on the CD19
+ 
cells. Similarly, the 
total PD-1
+
, CD4
+
 PD-1
+ 
and CD8
+
 PD-1
+ 
expression was investigated on T 
lymphocytes obtained from the blood of patients with benign / borderline and 
malignant diagnosis as well as on T lymphocytes obtained from healthy women (Figure 
4.2). There was a higher number of total PD-1
+
, CD4
+
 PD-1
+ 
and CD8
+
 PD-1
+ 
expressing T lymphocytes that were obtained from the patients‟ ascites (Figure 4.3).  
When the total PD-1
+
, CD4
+
 PD-1
+ 
and CD8
+
 PD-1
+ 
expressing on T lymphocytes from 
ascites was compared to the T lymphocytes in the blood, it was observed that there was 
a significant increase in PD-1 expressing T cells in the ascites. The malignant ascites 
showed a modestly higher level of total PD-1
+
, CD4
+
 PD-1
+ 
and CD8
+
 PD-1
+ 
expressions compared to the benign / borderline ascites (Figure 4.3). A few studies 
have been published looking at the PD-1 expression and linking it to pathologic 
features or outcomes for patients with malignancy. For example, Thompson et al. 
showed that levels of immune cell-associated PD-1 were increased in high risk RCC 
and that the presence of tumour-infiltrating PD-1
+
 immune cells predicts an adverse 
pathology and outcome for patients with clear cell RCC tumours (50). 
This study has presented data for ovarian cancer and has shown not only that there is an 
association between a high number of PD-1 expressing T cells  and malignancy, but 
also that the malignant ascites seem to have many more activated T cells and cells 
expressing PD-1 compared to peripheral blood. This suggests T cells in ascites are 
generally highly activated and that the PD-1 expression is upregulated. PD-1 may 
engage with appropriate ligands to downregulate T cell activity. This is likely in view 
of the findings with PD-L1 expression on monocytes within ascites. 
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4.3.2 PD-L1 and PD-L2 expressions on antigen presenting cells 
 
In cancer studies particularly, several groups have already looked at the expression of 
ligands of PD-1 both at the mRNA and protein levels (394), (485). There are only two 
published studies relating to ovarian cancer. Most previous studies used IHC to 
correlate their findings with the patient outcome. For example, the work by Haminashi 
et al. used stained paraffin-embedded ovarian cancer tumour sections for PD-L1 and 
PD-L2 (400). Unlike their approach, this study used qRT-PCR, flow cytometry and 
IHC to look at PD-L1 and PD-L2 mRNA and protein expressions. For the first time, 
this study compared the PD-L1 expression on monocytes in cases of cancer versus 
benign / borderline tumours of the ovary. The PD-L1 and PD-L2 cell surface 
expressions on APCs have been studied (341), (379). Curiel et al. first showed that a 
fraction of blood monocyte-derived mature dendritic cells (mDCs) express PD-L1 
(379). PD-L2, on the other hand, has been claimed to be more confined to the 
medullary macrophages / DC and epithelial cells (341). There have been conflicting 
findings regarding PD-L1 and PD-L2 expressions on mDCs and iDCs (397). 
The cell surface PD-L1 and PD-L2 expressions on APCs obtained from ovarian cancer 
patients‟ blood and ascites by flow cytometry were screened. This step was performed 
after the APCs were added and screened using a panel of MHC and co-stimulatory 
markers to determine the MHC class activation and dendritic cells maturation status. It 
had already been determined beforehand that the mDCs with CD14
+
, CD11c
+
, CD86
+
 
and HLA-DR
+
. CD80 expressions were not present in the APCs and this may have been 
due to the fact that CD80 is limited in its expression as it is only involved in sustaining 
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or regulating the activation process compared to CD86, which is constitutively 
expressed and rapidly upregulated on dendritic cells as well as participates in initiating 
immune responses. It was found that the PD-L1 cell surface expression was selectively 
present on samples from malignant ovarian cases, while the PD-L2 cell surface 
expression was not present on any samples.  
Both samples of blood and ascites from ovarian cancer patients with malignant 
diagnosis presented with a strikingly high percentage, often over 75%, of PD-L1 
expressing cells. Meanwhile, samples of blood and ascites from patients with benign / 
borderline ovarian tumour diagnosis presented with a low percentage of less than 10% 
of PD-L1 expressing cells. The observations here using the PD-L1 marker on APCs in 
this chapter showed a strong relationship between the PD-L1 expression on a 
percentage of monocytes and malignancy irrespective of whether the samples were 
obtained from blood or ascites.  In the cohort for this study, there were no crossovers in 
values between the benign / borderline and the malignant cases, making PD-L1 a 
potentially helpful marker for cancer diagnosis. Data showing the PD-L1 expression on 
APCs in patients with ovarian cancer will continue to be collected in order to correlate 
the expression with the survival and long term progression of the tumour in terms of 
stage and grade. The information from ongoing and future work will then be valuable 
for the potential use of the PD-L1 expression on APCs as a prognostic marker in 
ovarian cancer (349), (486). As it stands, it seems to be a very powerful marker for the 
diagnosis of ovarian masses and for differentiating the malignant ones from the benign 
or borderline ones. This has a huge clinical significance as the diagnosis of ovarian 
masses poses a great challenge in the clinic.  
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Clearly to make this useful in a clinical setting a simpler assay would be more 
appropriate such as an ELISA assay rather than the FACS. The research group has now 
gone on to develop an in-house ELISA assay for the detection of free PD-L1 in the 
plasma of patients and this is in the process of being validated for potential diagnostic 
use. Alternatively, a qRT-PCR based assay could be used but this would need to be 
developed and validated to see whether the observed differences can be seen using this 
platform. 
 
 
4.3.3 PD-L1 and PD-L2 on tumour cells 
 
 
 
A variety of epithelial-derived tumours express PD-L1, suggesting that these 
malignancies may exploit the PD-1 PD-L pathway to attenuate anti-tumour immunity 
(378). Ovarian cancer is typically of an epithelial origin and the majority of ovarian 
carcinomas express PD-L1 (379). At protein level detected by immunohistochemical 
staining, Dong et al. and Brown et al. both revealed that the PD-L1 expression on the 
surface of human ovarian tumours were 20/23 and 1/3 PD-L1 positive, respectively 
(364), (378). These findings in ovarian cancer, including the recent finding by 
Ohighashi et al., are just a few of the many other carcinomas that have been described 
as having a PD-L1 expression using a similar method (364). This study has shown the 
expression of PD-L1 by tumour cells and APCs within tumour tissue. This is in 
addition to the PD-L1 expression on monocytes obtained from blood and ascites. 
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Although the expression of PD-L1 is found in the majority of cancer patients, the 
expression of PD-L1 is not often present in all cells. Several freshly isolated tumours or 
established tumour cell lines do not constitutively express PD-L1, but can be induced to 
express this molecule in the presence of IFN-γ (314). IFN-γ was shown to influence 
PD-L1 expression predominantly on non-lymphoid tissues. Previous studies are in line 
with results showing that the PD-L1 promoter region contains several IFN-γ responsive 
elements (368). Initially, an attempt was made to study the PD-L1 cell surface 
expression on primary tumours isolated from fresh biopsies and epithelial cell adhesion 
molecule (EPCAM) positive cells from ascites. However, situations such as low 
frequencies of getting fresh biopsies and low percentage of EPCAM positive cells 
purified from ascites were the major limitations to the performance of both phenotyping 
and functional experiments. Instead, it was decided to use a panel of ovarian cancer cell 
lines.   
The study selected ovarian cancer cell lines that were generated from the same cell 
origin (epithelial derived) but present with different histological types so as to look at 
PD-L1 cell surface expression on ovarian cancer cells in different histological types. In 
vitro experiments have indicated that many tumour cell lines also express PD-L1 and 
upregulate PD-L1 expression upon exposure to IFN-γ (368), (485). It was decided first 
to perform similar experiments with the panel of ovarian cancer cell lines (serous, clear 
cell and endometrioid) using the flow cytometry method (Figure 4.6). From the data 
obtained, it could be determined whether the PD-L1 cell surface expression was either 
constitutive or inducible in the respective ovarian cancer cell lines. It was found that the 
PD-L1 cell surface expression was constitutive in all the serous histological type of 
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ovarian cancer cell lines (OVCAR-3, SKOV-3, OVCAR-5 and CaOV-3) and modestly 
constitutively expressed in one endometrioid ovarian cancer cell line (TOV-112D). The 
PD-L1 cell surface expression in the clear cell type of ovarian cancer cell lines 
(SMOV-2, OVISE and TOV-21G) can be induced with IFN-γ treatment after an 
incubation period of 48 hours.  
Since human cell lines may not be the best representative of actual marker expressions 
in tissues, 60 frozen tumour tissue samples were used from different histological types 
obtained from the archives of ovarian cancer cases to look for the PD-L1 mRNA 
expression in solid tumours. In addition, a normal ovary was included as the control. By 
using ovarian cancer frozen tissues, a similar trend of PD-L1 mRNA expression and 
cell surface expression was successfully obtained using ovarian cancer cell lines. The 
serous ovarian cancer tissues presented with the highest PD-L1 mRNA level, followed 
by the endometrioid and borderline tissues, with the lowest or no PD-L1 mRNA 
expression being presented in the clear cell, benign and normal ovary tissues.  
Based on this, it was proposed that ovarian cancer cell lines be used as an alternative to 
primary tumour models for future functional experiments. The serous ovarian cancer 
cell lines show similar PD-L1 cell surface expressions and mRNA levels as the primary 
ovarian cancer serous cases. This approach is not applicable for investigating PD-L2 
expression in ovarian cancer. The PD-L2 mRNA expression in ovarian cancer frozen 
tissue was constitutively expressed in all ovarian cancer frozen tissues, including the 
normal ovary (Figure 4.7). Previously, it was determined that there was no PD-L2 cell 
surface expression present on APCs obtained from any sample type, be it blood or 
ascites, by flow cytometry. 
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4.3.4 Inhibitory functions for PD-L1 
 
The PD-L1 expression has been shown to be functionally significant in inhibiting an 
anti-tumour immune response (487). It was decided to test it in a more physiological 
setting using immunosuppressive cytokines such as IL-10 and TGF-β. In previous 
studies, other than investigating that IFN-γ induces PD-L1 and PD-L2 in established 
cell lines, they have also already shown that IFN-γ induces PD-L1 and PD-L2 mRNA 
expressions in PBMCs (310), (314), (342).  To examine PD-L1 and PD-L2 protein 
expressions, these studies cultured human monocytes with or without IFN-γ and 
harvested the monocytes at the indicated time points for flow cytometry analysis (342). 
However, those studies conducted extensive experiments to investigate the role of IFN-
γ in PD-L1 upregulation but little was known about the functional role of other 
cytokines that may be present in the tumour milieu. For example, previous findings in 
1999 already showed that the human PD-L1 preferentially stimulated secretion not only 
in IFN-γ but also in IL-10 (315).  
The in vitro functional experiments were divided into three parts, where first an 
experiment was conducted to culture CD14
+
 cells isolated from a healthy individual‟s 
blood in different culture conditions and to test whether IL-10 has an effect in the 
upregulation of PD-L1 similar to IFN-γ (Figure 4.8). Secondly, the CD14+ cells were 
tested by separating them from the ascites of ovarian cancer patients and co-culturing 
them with stimulated T cells from a healthy individual. A T cell proliferation assay was 
performed to see whether suppressive effects are present when patients‟ monocytes 
from malignant and benign / borderline ascites were added together with and without a 
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PD-1 blocking antibody. T cells alone were used as a control and it was found that there 
was no difference in T cell proliferation with and without the PD-1 blocking antibody. 
In contrast, when the T cells were co-cultured with ovarian cancer patients‟ monocytes, 
T cell proliferation was found to be suppressed and this was partially reversed by the 
PD-1 blocking antibody (Figure 4.9). 
Finally, the third part of the in vitro functional experiment was to investigate the role of 
immunosuppressive cytokines present in the tumour environment on the PD-L1 
upregulation on monocytes from a healthy individual. As mentioned before, this study 
was interested in further investigating the role and effect of IL-10 on immune inhibition 
in ovarian cancer. Therefore, ascitic supernatants from malignant and benign / 
borderline ovarian cancer ascites were used for the next T cell proliferation assays 
(Figure 4.9 and 4.10); and they were also cultured with a healthy individual‟s 
monocytes (Figure 4.11). Just as in the T cell proliferation assay conducted in the co-
culture experiments, a PD-1 blocking antibody was used to reverse the suppression. In 
the same way, an IL-10 blocking antibody was added to T cells cultured in malignant 
ascitic supernatants of different IL-10 concentrations to see if similar effects were 
present.  
A number of interesting findings have also been demonstrated in the in vitro functional 
experiments. It has been shown that IL-10 has an effect on PD-L1 upregulation in a 
healthy individual‟s monocytes, though this is not as much as the PD-L1 upregulation 
by IFN-γ. These results show that more study is needed with regard to the role of IL-10 
in the immune inhibition of ovarian cancer. The study has gone on to show that 
monocytes from the malignant ascites have a more suppressive effect on T cell 
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proliferation compared to monocytes from the benign / borderline ascites and healthy 
individual‟s monocytes. In addition, this suppression could be partially reversed by the 
addition of a PD-1 blocking antibody to the culture. Finally, a similar T cell 
proliferation assay was conducted using stimulated T cells from healthy individuals 
with patients‟ monocytes; patients‟ ascitic supernatants were used and the stimulated T 
cells were added into them. Ascitic supernatants from malignant cases and benign cases 
were used for the first T cell proliferation assay and this was performed in a dose 
dependent manner. Malignant ascites were selected according to IL-10 concentrations 
for the second T cell proliferation assay and this was performed with or without an IL-
10 blocking antibody. It was concluded that IL-10 contributes in part to the suppression 
observed when T cells are cultured in an ascitic supernatant. Furthermore, it was found 
that there was a significant increase of PD-L1 cell surface expression on normal 
monocytes cultured in malignant ascitic supernatant compared to benign / borderline 
ascitic supernatant. This supports the hypothesis that immunosuppressive cytokines, 
such as IL-10, may be an important factor responsible for PD-L1 upregulation in the 
tumour environment and therefore for maintaining immune inhibition in ovarian cancer. 
IL-10 had previously been shown to upregulate PD-L1 on dendritic cells in patients 
with HIV and hepatitis B infections (488), (489). 
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5.0 Chapter 5: Arginase as a potent immunomodulatory enzyme in ovarian 
cancer 
 
 
5.1   Chapter 5: Introduction 
 
L-arginine is one of the amino acids which have relative effects on the immune system 
(412). L-arginine is the common substrate for two enzymes, arginase and NOS (420). 
Many studies have investigated the importance of arginine on specific cellular and 
molecular functions in the T lymphocytes. The association of L-arginine depletion and 
T cell dysfunction was initially described in liver transplantation and trauma patients 
(416). Recently, subsets of myeloid cells known as MDSCs can regulate T cells by 
manipulating the metabolism of L-arginine (412). Arginine is mainly metabolised either 
by iNOS or by Arginase 1, enzymes that are stimulated by Th1 or Th2 cytokines, 
respectively (415). 
Arginase metabolises arginine to ornithine and urea (420). Myeloid cells expressing 
Arginase 1 are described in a growing number of disease processes which include 
cancer (420). In humans, the arginase expression is mainly observed in granulocytes, 
which can in turn exert a suppressive effect (439). However, the mechanisms that 
induce the arginase expression, specifically myeloid cells expressing Arginase 1 in 
cancer, are unclear. In the few studies done on human cancer such as renal cell, 
pancreatic, lung and breast cancer, the accumulation of MDSCs was found to contribute 
to a major alteration in the T cell receptor expression and T cell function (407), (408), 
(409), (424). Different models have been used and these have demonstrated that 
207 
 
MDSCs inhibit T cell proliferation, CD3-ς chain expression and IL-2 production (407), 
(408), (409), (424). This study was aimed at characterising myeloid cells expressing 
arginase in ovarian cancer patients, both in the patients‟ circulating blood and tumour 
microenvironment. The MDSCs in murine ovarian cancer have already been described 
and this study has provided important knowledge as to the regulatory effects of arginase 
expressing cells in ovarian cancer (490). Previous reports have also suggested there is a 
significant difference between human and murine models in mechanisms leading to 
Arginase 1 induction. Therefore, the initial studies here are important in order to find 
the existence of myeloid suppressor cells or myeloid cells expressing high Arginase 1 
in human ovarian cancer patients. The data may also open new approaches to enhance 
the therapeutic efficiency of immunotherapy.   
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5.1.1       Chapter 5: Aims and hypotheses 
 
In this chapter, it was decided to investigate which cell population in ovarian cancer 
patient is responsible for the release of the arginase enzyme which is known to inhibit T 
cell proliferation and promote tumour growth indirectly. In comparison to the MDSCs 
cell population known in other cancer types, immunoprofiling of myeloid cells was 
performed in both the CD14 positive and CD14 negative subsets which were purified 
from the patients‟ peripheral blood and ascites. In addition, the mRNA expression for 
Arginase 1 and Arginase 2 expressions were looked at and an enzyme activity assay 
was conducted on the corresponding cells. The same experiments were also tested using 
ovarian cancer cell lines and both primary and frozen tumour tissues. 
The hypotheses for this chapter are that ovarian cancer and associated immue cells 
produce high arginase that contributes to the immune suppression in this cancer and 
that high arginase producing cells in ovarian cancer patients may originate from the 
myeloid cells of either with CD14 positive and CD14 negative subsets.  
The aims for this chapter are: 
 To characterise the arginase enzyme activity and mRNA expression by ovarian 
cancer cells, cell lines and tumour tissue. 
 To determine the arginase enzyme activity and mRNA expression of myeloid cell 
subsets purified from patients‟ peripheral blood and ascites and correlated to the 
diagnosis of cancer and non cancer. 
 To confirm the inhibition of T cell proliferation by the downregulation of CD3-ς 
chain expression on ovarian cancer patients‟ lymphocytes. 
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5.2    Chapter 5: Results 
 
5.2.1 Arginase activity of cells isolated from ovarian cancer ascites 
5 cases were collected during the study period where ascites were collected from 
patients diagnosed with other cancer types in the peritoneum cavity such as bowel 
cancer, breast cancer, and endometrial cancer (n = 5). These were compared with 
ovarian cancer cases (n = 11), where ascites cells were isolated and counted before they 
were used for an arginase activity assay. The arginase activity from both the other 
cancer type cases and the ovarian cancer isolated ascites cells showed on average a low 
activity of 8 Mµ and 9 Mµ per millions of cells, respectively. Therefore, there was no 
significant difference in arginase activity levels in the ovarian cancer ascites cells 
compared to the ascites cells of other cancers (Figure 5.1). 
 
Figure 5.1 Arginase activity in cells isolated from ascites in ovarian cancer compared to other 
cancers. No significant difference in arginase activity was observed between the ascites cells of 
other cancers (n = 5) and the ascites cells of ovarian cancer (n = 11). 
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5.2.2 Arginase expression by ovarian tumour cells 
The arginase expression by ovarian tumour cells was studied by looking at the arginase 
activity and also the Arginase 1 and Arginase 2 mRNA expressions. Various human 
ovarian cancer cell lines of different histological types (n = 10) were used and an 
arginase activity assay was performed on them. The ovarian cancer cell lines of the 
serous histological type used were IGROV-1, OVCAR-3, OVCAR-5 and SKOV-3, of 
the clear cell histological type were ES-2, TOV-21G, OVISE, SMOV-2 and KOC-7C 
and of the one endometrioid ovarian cancer cell line was TOV-112D. The negative and 
positive control of HEP-G2 and HUH-7 respectively were included as an indicator of 
the low or high arginase activity present. The ovarian cancer cell lines were mostly 
found to have a low arginase activity of less than 15 Mµ per million cells of arginase 
activity, except for one cell line, IGROV-1, which showed a moderately high arginase 
activity with 23 Mµ per millions cells of arginase activity (panel A, Figure 5.2).  
Next, a qRT-PCR was performed to look at the mRNA expression in Arginase 1 and 
Arginase 2 on the same ovarian cancer cell lines that were tested for arginase activity. It 
was demonstrated that at mRNA levels, Arginase 1 and Arginase 2 were constitutively 
expressed in ovarian cancer cell lines, with Arginase 1 being expressed slightly higher, 
but not significantly so, compared to Arginase 2. In Figure 5.2, panel B shows the 
representative data of Arginase 1 and Arginase 2 mRNA expressions from each ovarian 
cancer of serous, clear cell and endometrioid histological types, including HEP-G2 and 
HUH-7 as controls. It was observed that the mRNA expression patterns of most ovarian 
cancer cell lines were similar, with a lower mean Arginase 1 mRNA expressions being 
present when compared to the positive control. 
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Figure 5.2 Arginase activity in various ovarian cancer cell lines (panel A), and Arginase 1 and 
2 mRNA expressions of selected human ovarian cancer cell lines compared to human liver 
carcinoma and human hepatocytes as controls (panel B). 
 
[B] 
[A] 
IGROV-1 SMOV-2 TOV-112D HEP-G2 HUH-7
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Arginase 1
Arginase 2
Cell lines
A
rg
in
as
e 
1
 a
n
d
/o
r 
A
rg
in
as
e 
2
 /
H
P
R
T
 m
R
N
A
IGROV-1 OVCAR-3 OVCAR-5 SKOV-3 ES-2 TOV-21G OVISE SMOV-2 KOC-7C TOV-112D HEP G2 HUH 7
0
10
20
30
40
50
Ovarian cancer cell lines
A
rg
in
as
e 
ac
ti
v
it
y
 M
u
/m
il
li
o
n
 c
el
ls
212 
 
The use of ovarian cancer cell lines alone as a model to look at arginase expressions 
would not be an ideal approach as it assumes that similar arginase expressions would 
also be present in the primary tumour cells of ovarian cancer patients. Therefore, 
arginase activity was carried out on tumour cells isolated from fresh tumour tissues and 
ascites using the EPCAM separation method. When comparing the mean arginase 
activity observed in ovarian cancer cell lines with ovarian cancer primary tumours, the 
latter showed low arginase activity similar to the arginase activity observed in ovarian 
cancer cell lines when compared to the positive control (Figure 5.3). Therefore, this 
observation confirmed the earlier hypothesis that ovarian cancer tumour cells have very 
limited and low arginase expressions and biological activity. To measure Arginase 1 
and Arginase 2 mRNA expressions on ovarian cancer primary tumours, frozen ovarian 
tumour tissues (n = 60) were collected and processed so that a qRT-PCR could be 
conducted to look at Arginase 1 and Arginase 2 mRNA expressions on them. Normal 
ovary tissues were included as the control (n = 6). Similar to Arginase 1 and Arginase 2 
mRNA expressions of ovarian cancer cell lines, both genes were constitutively 
expressed with no significant difference in levels of expression except in the Arginase 1 
mRNA expression for normal ovaries (Figure 5.4). It was found that normal ovarian 
tissue has a significantly lower level of Arginase 1 expression (P = 0.0001) compared to 
ovarian cancer tumour tissues (Figure 5.4). The Arginase 2 mRNA expressions were 
similarly expressed between the ovarian tumour tissues and normal ovary tissues 
(Figure 5.4). 
The characterisation of myeloid cells isolated from ovarian cancer patients‟ ascites and 
blood, including cells from healthy women‟s blood, was carried out. The mononuclear 
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Figure 5.3 Arginase activity in ovarian cancer cell lines (n = 10) and primary ovarian tumour 
cells (n = 8) were compared to arginase activity from human hepatocytes cell lines (n = 2). 
Figure 5.4 Arginase 1 and Arginase 2 mRNA expressions in ovarian cancer (n = 60) and 
normal ovary tissues (n = 6). Normal ovary tissues present with significantly lower level of 
Arginase 1 expression (P = 0.0001) compared to ovarian tumour tissues. No difference in 
Arginase 2 mRNA expression was observed between ovarian tumour tissue and normal ovary 
tissue. 
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cells that were separated from the patients‟ ascites and blood as well as blood from 
healthy women using the Ficoll-Histopaque centrifugation method were investigated by 
the flow cytometry method. Using the literature as a guide, the cells were stained with 
antibodies against the CD14, CD11b, CD11c, CD33, CD16, CD62L and CD3-ς chain 
of monocytes and the lymphocyte markers on the patients‟ ascites and PBMCs. The 
percentage of cell surface expression for the myeloid cells markers and the mean 
fluorescence intensity for the CD3-ς chain expression were looked at. The cells in the 
monocyte gate had similarly high levels of CD14, CD33, CD11b and CD11c in all the 
sample types, including the healthy women‟s PBMCs (Figure 5.5). The PBMCs and 
ascites of the ovarian cancer patients had low levels of CD62L compared with the high 
levels of CD62L present in the PBMCs of the healthy women (Figure 5.5). In contrast, 
CD16 was present in high levels in the PBMCs of healthy women and in low levels in 
the PBMCs and ascites of the ovarian cancer patients (Figure 5.5).  
The phenotyping also revealed that CD14 and the double positive expression gating 
with CD33, CD11b, CD11c and CD16 therefore also expressed the myeloid cell 
markers previously used by other research groups which hypothesised that cells with 
the mentioned phenotype were human myeloid cells expressing Arginase 1. The 
downregulation of the CD3-ς chain was seen in ovarian cancer patients‟ blood 
compared with healthy women‟s blood and the same was also demonstrated by 
obtaining the downregulation of the CD3-ς chain in ovarian cancer patients‟ ascites 
(Figure 5.6). The CD14
+
 cells were then purified and tested for the arginase expression 
and for the biological activity as described in 5.2.3 and 5.3.4. 
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Figure 5.5 Phenotyping of patients‟ ascites cells, patients‟ PBMCs and healthy women‟s PBMCs using markers related to Arginase 1 
expressing cells. Myeloid cells isolated from patients‟ ascites (n = 20) and PBMCs (n = 20), and healthy women‟s PBMCs (n = 10) have 
similar levels of CD14, CD11b, CD11c, and CD33. 
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Figure 5.6 CD3-ς chain expression in patients‟ ascites, patients‟ PBMCs and healthy women‟s 
PBMCs in the lymphocyte flow cytometry gate. The downregulation of mean fluorescence 
intensity of lymphocytes isolated from patients‟ ascites and PBMCs were observed when 
compared to the mean fluorescence intensity of lymphocytes isolated from healthy women‟s 
blood. 
 
 
 
 
 
 
P = 0.3114 
 
P = 0.0554 
 
Patients' ascites Patients' PBMCs Healthy women's PBMCs
0
250
500
750
1000
1250
n = 8 n = 4 n = 5
Cell type
C
D
3
 z
et
a 
m
ea
n
 f
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 (
M
F
I)
217 
 
5.2.3 Arginase activity of myeloid cell subsets purified from patients’ blood and 
ascites 
 
There are many theories from several human cancer research groups determining which 
cell subsets the human myeloid cell expressing high arginase belongs to. This study 
was aimed at determining whether myeloid cells producing high arginase exist in 
ovarian cancer patients. 
An arginase activity assay was performed on purified CD14
+
 cells and CD14
 
cells by 
using the same protocol used before on all ascites cells and PBMCs. Controls were 
incorporated for each sample type which comprised cells from healthy women‟s 
PBMCs (n = 3) and cells from benign and / or borderline ovarian cancer ascites. The 
CD14
+
 cells purified from the patients‟ PBMCs (n = 7) had a lower mean arginase 
activity compared with autologous CD14  cells (n = 4). When the CD14
+
 cells purified 
from the patients‟ PBMCs was compared to the healthy women‟s cells, the mean 
arginase activity was seen to be even lower. The patients‟ PBMCs CD14+ cells showed 
a higher arginase activity for both healthy women‟s CD14+ cells (n = 5) and similar but 
a more striking result was seen for CD14  cells (n = 5) (P = 0.001) (Figure 5.7).   
The arginase activity was lower in CD14  cells (n = 6) purified from malignant 
patients‟ ascites compared with their autologous CD14+ cells (n = 11) (Figure 5.7). This 
observation was in contrast to the first observation from the patients‟ PBMCs (Figure 
5.7). 
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Figure 5.7 Arginase activity of different myeloid cell subsets; CD14
+
 cells and CD14
 cells purified from malignant patients‟ 
ascites, benign / borderline patients‟ ascites, patients‟ blood and healthy women‟s blood. CD14+ cells purified from benign / 
borderline patients‟ ascites and patients‟ PBMCs had lower arginase activity compared with autologous CD14  cells. A 
contrasting arginase activity expression pattern was observed from malignant patient‟s ascites. Low arginase activities were 
observed for CD14
+
 cells and CD14  cells purified from normal PBMCs.  CD14
 
cell subsets from patients‟ blood presented 
with a significant difference in arginase activity when compared to their autologous CD14
+
 cells arginase activity (P = 0.004) 
and the difference was even more significant when compared to healthy women‟s CD14  cells arginase activity (P = 0.001).
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5.2.4 Arginase 1 and Arginase 2 mRNA expression of CD14+ and CD14  cells 
purified from patients’ ascites, patients’ PBMCs and healthy women’s 
PBMCs 
 
This study investigated whether Arginase 1 and 2 are differentially regulated in the 
CD14
+
 cells and CD14
 cells purified from patients‟ ascites, patients‟ PBMCs and 
healthy women‟s PBMCs. The CD14+ cells from the patients‟ ascites (n = 11) 
presented with significantly higher Arginase 1 mRNA expression (P = 0.03) when 
compared to their autologous CD14  cells Arginase 1 mRNA expression (n = 6) (Figure 
5.8). This data supported the previously obtained arginase activity data of the CD14 cell 
subsets purified from the patients‟ ascites. For the CD14  cells from the PBMCs (n = 
11) in the patients‟ circulating blood, the CD14 cell subset presented with significantly 
higher Arginase 1 mRNA expression (P = 0.03) when compared to its autologous 
CD14
+
 cells Arginase 1 mRNA expression (n = 6) (Figure 5.8). This data also 
supported the previously obtained arginase activity data of the CD14 cell subsets 
purified from the patients‟ PBMCs.  
On the other hand, the CD14
+
 cells from healthy women‟s PBMCs showed a similar 
expression of Arginase 1 expression when compared to the CD14
+
 cells from the 
patients‟ PBMCs. However, the patients‟ CD14  cells expressed significantly higher 
levels compared to the healthy women‟s CD14  cells (Figure 5.8). Arginase 2 is present 
constitutively in both CD14 cell subsets with no differential expression existing 
between the CD14
+
 cells and the CD14  cells purified from the patients‟ PBMCs and 
ascites.
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Figure 5.8 Arginase 1 and Arginase 2 mRNA expressions in CD14 cell subsets in ovarian cancer patients‟ and healthy women‟s 
PBMCs and ascites. 
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5.3 Chapter 5: Discussions 
 
5.3.1 Arginase activity of cells isolated from ovarian cancer ascites 
 
It was decided to investigate the role of tumour cells expressing arginase in ovarian 
cancer due to the fact that until now there is no conclusive evidence on the importance 
of tumour cells expressing arginase in patients (420). Some previous reports suggested 
that the increased arginase activity in cancer patients came from tumour cells 
metabolising arginine to ornithine that is needed to sustain rapid cell proliferation 
(421). 
This study attempted to compare arginase activity between non-ovarian ascites with 
ovarian cancer ascites. Patients of other cancer types such as bowel cancer, breast 
cancer, and endometrial cancer that presented with ascites were found to have no 
significant difference of arginase activity when compared to arginase activity obtained 
from ovarian cancer patients‟ ascites. However, an elevated level of arginase activity 
was found in ovarian cancer patients when compared to non-ovarian cancer patients. 
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5.3.2 Arginase expression by ovarian tumour cells 
 
Arginase has two isoforms, Arginase 1 (hepatic arginase), which is a cytosolic enzyme 
present in the liver; and Arginase 2 (extrahepatic arginase), which is located within the 
mitochondrial matrix (421). Arginase 1 is primarily involved in the detoxification of 
ammonia and urea synthesis, whereas Arginase 2 is involved in biosynthetic functions, 
such as the synthesis of ornithine, proline and glutamate (414). Polyamines are 
subsequently synthesised from ornithine, the second product of arginase reaction. 
Previous studies in breast cancer reported that there is an increase of polyamines in 
breast cancer tumour tissues in comparison to the surrounding normal tissues (418). 
Following these findings, more investigations to find the role of arginase in modulating 
polyamine biosynthesis and the growth of tumour cells were conducted. In contrast to 
these studies, instead of looking at increased levels of polyamines, ovarian tumour cells 
or tumour tissues were tested for arginase expression directly. Therefore, both arginase 
activity assay and qRT-PCR were incorporated to look at arginase expression levels 
using a panel of ovarian cancer cell lines and ovarian tumour tissues later.   
Surprisingly, no high levels of arginase expressions were observed in the panel of 
ovarian cancer cell lines. Compared to the positive control which showed 45 Mµ per 
million cells of arginase activity, the highest expressing ovarian cancer cell line, 
IGROV-1, had a moderate level of 23 Mµ per million cells of arginase activity while 
other ovarian cancer cell lines showed a low level of around 15 Mµ per million cells of 
arginase activity. The arginase expression was then compared using the arginase 
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activity assay that was used before on human ovarian cancer cell lines, only this time it 
was used on human ovarian primary tumour cells. There was no significant level of 
arginase activity in the ovarian primary tumour when compared with the positive 
control. 
Confirmation at the mRNA level using qRT-PCR to look at Arginase 1 and Arginase 2 
expressions in human ovarian tumour tissues was also conducted with a different 
analytical approach compared to a previously conducted qRT-PCR on a panel of human 
ovarian cancer cell lines. Instead of comparing the increased mRNA level of Arginase 1 
and 2 between different histological types, the average of Arginase 1 and 2 was now 
compared between human ovarian tumour tissues with normal ovary tissues. A 
significant difference was observed, with the average Arginase 1 mRNA expression of 
the normal ovary being lower than that of the human ovarian tumour tissue. Arginase 2, 
for both the normal ovary and the human ovarian tumour tissue, maintained a 
constitutive expression that was similarly found previously in the panel of human 
ovarian cancer cell lines. This suggested that there was some level of upregulation of 
arginase expression in ovarian cancer but the level of activity in ovarian tumour cells 
did not appear to be as high as some positive control cell lines. It is unclear whether this 
level of expression / activity in ovarian cancer has any biological significance. 
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5.3.3 Phenotyping high arginase producing cells using myeloid cell markers 
and CD3 zeta expression on ovarian cancer patients’ lymphocytes 
 
There have been very limited studies on human high arginase producing cells and 
efforts to characterise these cells. In murine models on the other hand, a cell subset 
known as the MDSCs of CD11b
+
 and granzyme B
+
 phenotype were found to be 
responsible for expressing high arginase by many groups or studies (411), (423), (424). 
In human cancer studies, reports have shown that arginase comes from MDSCs 
circulating in peripheral blood and infiltrating the tumours (416). The cell separation 
studies have shown that the increased arginase activity in a human model was limited to 
a specific subset of CD11b
+
, CD14 , CD15
+
, CD34
+
, CD33
+
 and CD13
+ 
cells with a 
PMN morphology and markers (416). As mentioned in the result, freshly isolated 
mononuclear cells were stained with a panel of myeloid cell markers of CD14, CD11b, 
CD11c, CD33 and CD16; and also with a lymphocyte marker or CD3-ς chain. The 
phenotyping of the mononuclear cells using these selected markers was necessary in 
order to identify whether similar cell subsets of high arginase producing cells found in 
blood and tumour-associated myeloid cells were present in ovarian cancer as well. 
Firstly, the large and granulated cells, which can easily be seen in the FACS scatter dot 
plot or by gating the CD14
+
 cells, were analysed. The positive single cell surface 
staining of each myeloid cell markers was obtained and compared between the sample 
types in this experiment. A phenotypic analysis was conducted on patients‟ ascites 
cells, patients‟ PBMCs and healthy women‟s PBMCs. The phenotypic analysis resulted 
in similarly high levels of most myeloid cell markers except for CD16, which was 
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shown to be differentially expressed in healthy women‟s PBMCs with a low level of 
CD16 cell surface expression present. Although at this point there was no significant 
correlation with the high arginase producing cells yet, this study at least identified that 
CD14
+
 cells in ovarian cancer patients‟ ascites and PBMCs presented with positive cell 
surface staining of the majority of myeloid cell markers which were hypothesised to be 
present in high arginase producing cells by others. However, they did not necessarily 
behave like MDSCs (see below).  
This information is valuable for setting cell separation studies in order to determine 
which cell subset the high arginase producing cells in ovarian cancer belong to. Not 
only that, this study managed to determine the cell separation experiment design from 
the phenotyping approach. It also confirmed another important aspect, which was the 
observation of the downregulation of the CD3-ς chain in patients‟ ascites and PBMCs 
compared to healthy women‟s PBMCs but it was felt that this may or may not be 
related to arginase activity and it certainly does suggest some biological significance if 
it is due to arginase activity in the tumour microenvironment. 
 
5.3.4 Arginase activity and arginase mRNA expression of myeloid cell subsets 
purified from patients’ blood and ascites  
 
It is known that tumour-associated myeloid cells express high levels of arginase protein 
and have a high arginase activity (406). In 2005, Zea et al. performed an arginase 
activity assay on subsets of CD11b
+
, CD14  and CD16
+
 cells with PMN morphology 
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and showed that there was an increase in arginase activity in RCC patients‟ PBMCs 
compared to healthy women‟s PBMCs (420).   
The cell separation of CD14
+
 cells from freshly isolated patients‟ ascites, patients‟ 
PBMCs and healthy women‟s PBMCs was performed using the bead separation 
technique. The CD14
+
 and CD14  cells were counted and used in appropriate numbers 
for an arginase activity assay to determine the biological activity between cell types. 
For this particular arginase activity assay, this study managed to make a comparison 
between the different cell types comprising malignant patients‟ ascites, benign / 
borderline patients‟ ascites, patients‟ PBMCs and healthy women‟s PBMCs. 
Differential expressions of arginase activity were observed in the CD14
+
 and CD14  
cells of the patients‟ ascites, patients‟ PBMCs and healthy women‟s PBMCs. The 
CD14
+
 cells in the malignant patients‟ ascites were shown to be present with a higher 
arginase activity when compared to the CD14
+
 cells in benign / borderline patients‟ 
ascites, patients‟ PBMCs and healthy women‟s PBMCs. In contrast, the CD14  cells 
presented with the highest arginase activity in the patients‟ PBMCs whereas the CD14  
cells in the malignant patients‟ ascites, benign / borderline patients‟ ascites and healthy 
women‟s PBMCs presented with a lower arginase activity. A very distinct change of 
arginase activity profile was observed depending on the origin of the cell type, whether 
it was from the circulating blood or the tumour environment, and also according to the 
malignancy. It was predicted at first that a higher arginase activity would be observed 
in the CD14
 cells of the patients‟ circulating blood when compared with the CD14  
cells in healthy women‟s PBMCs. However, surprisingly, in the tumour environment 
the arginase activity profile was the opposite. Therefore, it was hypothesised that there 
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was a mechanism involving the myeloid cells subset of CD14  that controls the release 
of arginase into the tumour microenvironment and therefore affects the increase of 
arginase activity in the tumour microenvironment. 
Following the findings at the activity level that arginase was differentially expressed in 
CD14 cell subsets obtained from patients‟ ascites, patients‟ PBMCs and healthy 
women‟s PBMCs, a qRT-PCR was performed to detect the Arginase 1 gene to support 
this further. Previously, Munder et al. suggested that Arginase 1 is also expressed in the 
granulocytes of healthy individuals (439). Therefore, it was decided to prove this in the 
CD14
+
 and CD14  cells. For the MDSCs cells observed in RCC, the Arginase 1 mRNA 
expression was higher in MDSCs compared with the autologous granulocytes and 
granulocytes from healthy individuals (434). It may be concluded that the CD14  cells 
in ovarian cancer patients‟ PBMCs behave in a similar manner to the MDSCs cells.  
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6.0 Overall discussion  
 
Diagnostic tests for ovarian cancer patients to differentiate between benign / borderline 
and malignant tumours are very much limited and are not always accurate. Often 
women with ovarian cancer fail to have an early detection of EOC. Therefore, 
experiments were first initiated to help determine a more reliable diagnostic and 
prognostic marker. It was decided to do this by investigating the protein and mRNA 
expression using a panel of cell surface markers on T cells and monocytes from 
different groups of patients with ovarian cancer using PBMCs, ascites and tumour 
tissues. 
By using flow cytometry, it was shown that some markers, such as Tregs, CD69, PD-1 
expression on T cells and PD-L1 expression on monocytes, were significantly 
upregulated in patients with malignant ovarian tumours compared with benign / 
borderline tumours in both PBMCs and ascites. PD-L1 was found to be the only marker 
with a very significant association with the patients‟ diagnosis. Approximately 70% of 
the total antigen presenting cells containing monocytes and granulocytes from 
malignant ovarian cancer patients expressed PD-L1, whereas no PD-L2 expression was 
present. Patients with benign and borderline ovarian masses had a very low number of 
PD-L1 monocyte cells in their PBMCs or ascites. This interesting finding was not only 
confirmed by flow cytometry but it was also validated by using qRT-PCR for its 
mRNA expression when there was the chance to do so on those cases which managed 
to isolate high numbers of monocytes for RNA isolation. It was concluded that PD-L1 
cell surface expression and PD-L1 mRNA expression on monocytes is likely to be 
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associated with diagnosis in a complex manner. In ovarian cancer, so far there are no 
studies that show that the PD-L1 expression on tumour cells is associated with the 
tumour type. Therefore, experiments were conducted to determine the expression of the 
PD-L1 marker according to the histological type such as serous, endometrioid, clear 
cell, benign and borderline; including the normal ovary as the control. A qRT-PCR was 
performed on the ovarian tumour tissue and on established ovarian cancer cell lines of 
various tumour histological backgrounds. It was found that serous and endometrioid 
ovarian cancer cases were associated with a high PD-L1 mRNA expression, while clear 
cell cases were associated with a moderate PD-L1 mRNA expression. 
Clinically, clear cell ovarian tumours have the poorest prognosis followed by serous 
and then endometrioid ovarian cancers. For example, it is known that the expression of 
IDO is likely to be associated with the clear cell type. Therefore, the same was 
hypothesised and the tumour tissue samples were tested not only with IDO, but also 
with PD-L1, PD-L2 and other immunomodulatory enzymes such as Arginase 1 and 
Arginase 2.  A qRT-PCR was used to look at the mRNA expression of these markers in 
the tumour tissue samples from the ovarian cancer patients. It was found that a high 
PD-L1 mRNA expression was strongly associated with the serous histological type, 
whereas a high IDO mRNA expression was associated with the clear cell histological 
type (Figure 4.7 and Appendix 4). Both the benign and borderline types have low a PD-
L1 and IDO mRNA expression; and in addition only a low PD-L1 mRNA expression 
correlated with the clear cell tumour type. Arginase 1 and Arginase 2 mRNA 
expressions in the tumour tissue samples have no correlation with the ovarian tumour 
histological types. Therefore, the preliminary results from the study showed that only 
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PD-L1 and IDO significantly correlate with the ovarian cancer histology type. Hence, a 
suitable target may be determined for treating ovarian cancer according to the tumour 
type. This study has looked at the potential of using the PD-L1 marker as a diagnostic 
marker for ovarian cancer on monocytes in the circulating blood. Almost all of the 
cases of ovarian cancer in the cohort were in an advanced stage of cancer. It will 
however be interesting to compare the PD-L1 expression on the monocytes in women 
with benign or borderline tumours compared to stage 1 cancers, which are not easily 
distinguishable from say, borderline or some benign tumours. It is believed that the 
group is currently carrying out this work. The goal is to develop a diagnostic tool, 
which is easily used in clinical settings, for early EOC based on findings obtained from 
studies. A simplified approach such as an in-house ELISA assay for the detection of 
free PD-L1 in patients‟ plasma could be the next step towards achieving this goal. 
From the flow cytometry results, this study then aimed to look for a prognostic marker 
for survivors of ovarian cancer. 23 immunological markers were tested in this study. 
The immunological studies that have been reported in the context of EOC have mostly 
focused on a single prognostic factor at the tumour site (17), (491) (492). The CD3
+
 
TILs and other T cell markers in TILs have been correlated with an improved clinical 
outcome and increased survival rates in many cancers including ovarian cancer (18), 
(179), (493). Studies by Woo et al., Zhang et al. and Curiel et al. were the first few 
studies that reported the relationship between specific T cell subsets and prognosis in 
EOC (18), (476), (494). By using an IHC, these studies have shown that the number of 
tumour infiltrating Tregs was correlated to a poor clinical prognosis in EOC (18), (494). 
Unlike many other ovarian cancer studies, including these, which adapted the IHC on 
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ovarian tumours as their main experimental method, this study, on the other hand, 
performed both an IHC on tumours and a cell surface marker analysis on patients‟ 
PBMCs and TALs. It has been shown that ovarian cancer patients with poor prognosis 
have an elevated number of Tregs using the IHC and flow cytometry method. It is 
suspected that the IHC results using tumours may be influenced by the density of TILs 
and that the precise anatomical location of CD8
+
 and FOXP3
+
 TILs is important. 
Therefore, further analysis should be done in the future for positive staining at the 
stromal site versus positive staining at the tumour-infiltrating site. In the current study, 
the flow cytometry analysis of the PBMCs in ovarian cancer showed that there was a 
correlation between PD-1 on T cell subsets and monocyte markers of CD14
+
 and HLA-
DR
+
 with the overall survival. In the patients‟ TALs on the other hand, the number of 
Tregs was the only marker to have a correlation with the patients‟ overall survival. No 
correlation with disease-free survival with any marker was obtained using both the 
patients‟ PBMCs and ascites flow cytometry results.  
PD-L1 and PD-L2 are both expressed in several human malignancies and can correlate 
with the prognosis. Haminashi et al showed that PD-L1 has an inverse correlation with 
the PD-L1 expression and the intraepithelial CD8 count in ovarian tumours (400). They 
found a correlation between its expression and poor prognosis using 5-year survival 
rates by IHC analysis on ovarian tumours. Besides using paraffin-embedded tissue 
blocks, which provide an advantage for longer survival data when compared to using 
fresh frozen tissue, they also used an „in-house‟ antibody against their paraffin-
embedded tissue for staining. This study attempted to reproduce similar results using a 
commercially produced PD-L1 antibody and it identified a similar trend of higher 
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intensity for PD-L1 expression in high stage and grade ovarian cancer cases. However, 
the statistical significance of the prognosis was not achieved. It could be that the 
incidence of death in the cohort of patients was low due to the short length of the 
follow-up in this study. It is known that only 60 to 70% of patients will experience 
recurrence within 2 to 5 years after the first treatment for ovarian cancer (9). The 
median length of follow-up in the cohort was only 16 months. In time the plan is that 
the group will continue collecting more cases and will aim to present the survival 
analysis for both progression-free and overall survival with a longer median follow-up 
time (ideally five years). 
In addition to the attempt to find a suitable marker for ovarian cancer prognosis, the 
patients recruited in this study were also tested for the number of CD11c
+
 and CD68
+
 
cells present in them by using an immunohistochemical analysis on the patients‟ 
tumour tissues. This study set out to investigate whether an increased number of 
dendritic cells and macrophages in ovarian cancer patients contribute to any clinical 
outcome. No significant difference was found in the CD11c
+
 and CD68
+
 expressions 
between ovarian cancer cases of different histology types or diagnosis of cancer versus 
benign. This immunohistochemical analysis result confirms the flow cytometry analysis 
of the immunoprofiling of ovarian cancer patients‟ PBMCs and TALs using a series of 
APCs cell surface markers such as CD14
+
, CD11c
+
, CD86
+
 and HLA-DR
+
. By using 
the immunoprofiling approach, it was concluded that the APCs obtained from patients‟ 
ascites showed a slightly higher, although insignificant, percentage of matured 
monocytes and dendritic cells compared to the APCs of patients‟ PBMCs. Another 
statistical analysis was conducted also on these APCs cell surface markers using the 
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Cox statistical analysis for the survival analysis. No correlation was found between 
these APCs cell surface markers in patients‟ PBMCs and ascites and disease-free 
survival except for the CD14
+
 and HLA-DR
+
 marker in the patients‟ PBMCs for overall 
survival. Other than conducting a survival analysis, this study looked at whether the 
PD-L1 marker has any significant correlation with other clinical parameters such as the 
debulking status and residual disease. Many studies in ovarian cancer and other cancers 
have revealed that residual disease or tumour size after primary surgery is a prognostic 
factor for patients‟ survival (29) (495). A statistical analysis was performed using the 
flow cytometry results for the APC associated with PD-L1 markers that is CD14
+
 PD-
L1
+
 and CD11c
+
 PD-L1
+ 
in both PBMCs and ascites. Out of 23 immunological markers 
tested, only three markers were significantly correlated with residual tumour size. 
These three markers were the PD-L1 related cell surface markers, which also showed a 
significant difference in cell surface expressions when compared with the malignant 
and non-malignant cases. 
While the PD-L1 expression is mainly on the APCs, the PD-1 expression is found on T 
cells, and interactions between PD-L1 and PD-1 are thought to maintain a peripheral 
tolerance (393). The PD-1 expression is mainly seen in activated T cells. It has been 
shown that TALs isolated from ascites were enriched with activated T cells, evidenced 
by the expression of CD69 when compared with T cells from matched PBMCs samples 
from each patient. This finding indirectly explained why the total number of PD-1 
expressing cells in T cell and B cell subsets was found to be higher in TALs when 
compared to PBMCs. Within the respective TALs and PBMCs, the PD-1 expression in 
T cell and B cell subsets was higher in malignant cases compared to benign and 
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borderline cases. Since it was predicted that the effect of the overexpression of PD-1 
will initiate T cell inhibition, therefore in vitro studies were performed for T cell 
proliferation to demonstrate this. It is also known that the blockade of PD-1 in 
experimental models enhances T cell immunity against ovarian cancer by restoring T 
cell proliferation (490). Therefore, a PD-1 blockade was performed in the experimental 
models and T cell proliferation managed to be restored only partially, which confirmed 
the previous findings by Curiel et al. (379). It was suggested that it is likely that 
immunosuppression in ovarian cancer is only partly mediated by PD-1 signalling. Other 
than immunosuppression due to PD-1 signalling, it was hypothesised that monocytes 
from malignant ovarian cancer patients can suppress T cell proliferation. The 
experiments showed that T cell proliferation was significantly suppressed when 
monocytes from malignant ovarian cancer patients were co-cultured with T cells from 
healthy individuals. It is believed that monocytes from patients with malignant tumours 
have a unique ability to suppress T cells, although the exact mechanism is unclear. One 
approach towards finding this mechanism is to ensure that no assumptions are made 
that the contribution to cancer immunosuppression was due to cell-to-cell contact only. 
Therefore, soluble components such as cytokines and also immunomodulatory enzymes 
were investigated in the tumour microenvironment.  
A large number of soluble components in the tumour microenvironment can impair T 
cell immunity in EOC. These soluble components can be found in ovarian cancer 
patients‟ ascites, which show a highly variable composition between EOC patients (23). 
Recent studies in EOC have confirmed that patients‟ ascites would consist of soluble 
components such as IL-10, Fas-Ligand, TGF-β, VEGF, CD80/PD-L1, B7-H4 and 
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soluble IL-2 receptors (496). These studies have produced evidence from in vitro and in 
vivo experiments that proves that each of these soluble components mediated 
immunosuppression in the tumour microenvironment (497), (498). This study 
incorporated approaches to detect and identify which of these soluble components 
would correlate with EOC patient diagnosis using the patients‟ ascitic supernatants. A 
multiplex ELISA was performed using Luminex technology which detects a panel of 
cytokines simultaneously. These cytokines were believed to contribute towards cancer 
progression and may be associated with ovarian cancer patients‟ prognosis. IL-10, 
TGF-β and VEGF were the 3 out of 13 cytokines analysed that showed a significant 
difference in concentration between malignant and non-malignant ascitic supernatants. 
It is likely that specific cells such as Tregs, tumour associated macrophages (TAMs) 
and a population of DCs called mDCs, released these cytokines into the ovarian cancer 
tumour microenvironment and ascites. Cell-cell contact enables the induction of these 
specific cells to express or secrete these cytokines, which in turn inhibit T cell 
proliferation and anti-tumour activity (499).  
EOC patients‟ ascitic supernatants, which are known to have elevated levels of IL-10, 
TGF-β and VEGF, were tested for T cell inhibition effects using activated T cells and 
blocking antibodies. EOC patients‟ ascitic supernatants of various IL-10 concentrations 
and co-cultures were first tested with activated and non-activated T cells to observe the 
T cell proliferation effect. It was found that T cell proliferation decreased when T cells 
were cultured in ascitic supernatants obtained from patients‟ with high IL-10 
concentration. This showed that an elevated concentration level of IL-10 in the ascites 
impacts T cell activation and is likely to promote tumour escape. Since only T cell 
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proliferation managed to be restored partially by adding an IL-10 blocking antibody, 
therefore it is likely that multiple factors are involved in T cell anergy in this setting. It 
was predicted that a combination of many blocking antibodies against 
immunosuppressive cytokines may potentially more fully restore T cell proliferation. 
Therefore, the next plan is to see whether the addition of TGF-β alone or both IL-10 
and TGF-β to healthy monocytes can upregulate the PD-L1 expression when compared 
to monocytes cultured in a medium alone. This work plan will be included in future 
experiments. 
Despite the findings of this study in investigating IL-10 and its effects, it has yet to be 
proven which type of APC sub-type in the CD14 positive cells from patients with 
ovarian tumour is responsible for the upregulation of PD-L1 and has a correlation with 
increased IL-10. Previous studies with other cancers have shown a correlation with 
increased IL-10 and PD-L1 expression on dendritic cells (488), (489). It has been 
demonstrated that IL-10 can control the PD-L1 expression on monocytes and that the 
IL-10 present in ovarian cancer patients‟ ascites is responsible, at least partially, for the 
PD-L1 upregulation on monocytes. 
Besides secreting cytokines, specific cell phenotypes such as myeloid cells may also 
express immunomodulatory enzymes. Recently, a subpopulation of myeloid cells, 
called MDSCs, was found to play a significant role in cancer growth both in mice and 
humans. Unlike murine MDSCs, human MDSCs are not well characterised and it is still 
unclear what their role and function is in the tumour escape mechanism. Instead of 
focusing on the characterisation of human MDSCs, it was decided to characterise the 
human arginase producing cells as these cells have been reported in human cancers 
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(420), (500). It was found that the human arginase producing cells were increased in 
ovarian cancer patients when compared to healthy controls. More work is needed, 
especially to study the potential for the reversal of T cell inhibition and suppression in 
EOC, not only by human arginase producing cells but also by all the markers 
mentioned in the studies which have a potential to be further exploited for diagnosis as 
well as for a target for therapy. It is planned to assess the functional relevance of these 
markers by using ovarian tumours of either ovarian cancer cell lines or ovarian tumour 
tissue.  
It would have been desirable to carry out more in vitro studies, such as culturing 
ovarian cancer cell lines with T cells, antibody blocking experiments or co-culture 
experiments using a transwell model. Also further functional in vivo assays could be set 
up to validate the findings. The use of animal models to investigate the immune 
responses towards ovarian cancer will allow the study of the immunological processes 
that may be important in the killing of tumour cells or in immunosuppression. This 
proof of principle experiment using an in vivo system of a mouse model is important for 
the development of effective immunotherapeutic strategies. The future aim of this study 
is to incorporate these experimental approaches as it is very important to find 
alternative strategies for the early detection of ovarian cancer and hence to allow for 
better patients‟ survival and outcome. 
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Appendix 1                
Avidin/labeled biotin complex (ABC) immunohistochemical staining method  
1. Slides were dewaxed in 3 (x5 min) changes of xylene, rehydrated through 
graded alcohols ie 2 (x5 min) changes in 100% ethanol and once (for 5 minutes) 
in 70% ethanol, and brought to tap water.  
 
2. Slides were then transferred to a plastic staining rack and treated with antigen 
retrieval solution (sodium citrate buffer at pH 6.0) using the microwave method 
for 10 minutes at 850W (empirical optimum). 
 
3. After cooling and washing in running tap water, endogenous peroxidase was 
blocked with 0.3 % H2O2 in methanol for 20 minutes. 
 
4. Slides were then rinsed in running water and washed twice in phosphate 
buffered saline (PBS) for 5 minutes. Appropriate normal serum diluted 1:30 in 
volume was applied for 30 minutes. 
 
5. After flicking off the previous solution 100 µl of the primary antibody in PBS 
diluents was applied and overnight at 4 ºC on the tissue sections. Sections were 
washed twice in PBS for 5 minutes each and incubated for 30 minutes with 
biotinylated secondary antibody (monoclonal biotinylated goat anti-mouse Ig or 
polyclonal biotinylated goat anti-rabbit Ig) appropriately diluted in PBS diluent. 
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6. A negative antibody control, PBS diluent for monoclonal or normal rabbit 
serum 1 : 8000 dilution for polyclonal antibodies, was included for every 
experiment in place of the primary antibody. 
 
7. Sections were rinsed thrice for 5 minutes in PBS and incubated for 30 minutes 
with either horseradish peroxidase (Px) - or alkaline phosphatase (AP)-labelled 
ABC reagent (Vectorlab, UK). 
 
8. Slides were rinsed in PBS for 5 minutes, 3,3-diaminobenzidinetetrahydrocloride 
(DAB) hydrogen peroxide substrate (Vectorlab, UK) or Fast Red with Naphthol 
Phosphate substrate (Biogenex, UK) was prepared for Px and AP staining, 
respectively. 
 
9. The chromogenic reagent was applied to the sections and allowed to develop for 
2 to 10 minutes while being checked under microscope. Slides were washed 
with PBS and then brought to tap water. 
 
10. Horseradish peroxidase (Px) sections were counterstained with haematoxylin 
for 10 seconds, dehydrated in graded alcohols, cleared with xylene and mounted 
in DPX medium. 
11. AP sections were counterstained with Meyer‟s haematoxylin, washed in running 
water and then mounted with an aqueous mountant (Shandon Imunon
TM
, 
ThermoElectron, UK). 
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Appendix 2           
Supersensitive Polymer detection (Biogenex) for PD-L1 protocol:  
1. Collect all slides into staining racks according to pre-treatment technique. 
2. Immerse slides in 3 changes of xylene, 3 changes of 74 OP, and 1 70% alcohol for 
2 minutes each change. 
3. Place slides in tap water. 
4. Immerse slides in hydrogen peroxide block (H2O2)- 0.6% hydrogen peroxide in 
tap water: 2ml of 30% H2O2 per 100ml of water for 15 minutes. (For cytology 
preps use 1ml of 30% H2O2 in 50ml 70% methanol in PBS for 30 minutes). 
5. Rinse slides in tap water. 
6. Antigen retrieval as required for this antibody we placed the slides in a tub of 
citrate buffer (ph 6) then placed this in the microwave for 20 minutes. Once 
finished place under slow running tap water to allow slides to cool. 
7. Rinse slides in tap water. 
8. Immerse a rack slides in 0.01M PBS prior to loading the sequenza. 
9. Remove a slide from the rack and place it against a sequenza clip immersed in the 
PBS. The bottom of the slide must be placed on the bottom projections of the clip, 
and the section side of the slide gradually apposed to the smooth surface of the 
clip, between the lateral projections. An unbroken film of PBS is held between the 
clip and the slide. 
10. Hold the clip and slide together with the spring of the clip and insert into a 
„sequenza‟ rack (this manoeuvre is learnt through experience). 
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11. Check that all slides are correctly inserted between the projections of the clip by 
partially filling the troughs with PBS and watch to make sure the rate of flow is 
neither too fast nor too slow. 
12. Cover sequenza carriers to avoid evaporation. 
13. Apply 100 l power block (diluted 1/10) for 10 minutes. 
14. Apply 100 l of primary antibody PDL1 (diluted 1/50); incubate at room 
temperature for 1 hour.  
15. Rinse with 0.01M PBS with Tween by filling the trough and leaving it to drain 
through for 5 minutes. 
16. Apply 100 l Super Enhancer (Ready to use), incubate at room temp for 20 
minutes. 
17. Rinse with PBS/Tween for 5 minutes. 
18. Apply 100 l poly-HRP (ready to use), incubate at room temp for 30 minutes. 
19. Rinse with PBS/Tween for 5 minutes. 
20. Remove slides from the sequenza, wipe excess PBS from slides and PAP line 
around the slides to avoiding spreading of DAB. 
21. Place slides into petri dishes. 
22. Cover sections in DAB. 1 drop (from a plastic pipette) of DAB mixed with 1 ml 
of substrate buffer, leave for 5 minutes.  
 Or, if a red end product is requested, use the AEC kit from 
Biogenex. To 2 ml of distilled water, add 0.5 ml hydrogen 
peroxide substrate and 1 drop of AEC solution, shake well and 
apply to sections for 10 minutes. 
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23. Rinse in tap water, and check controls for specific staining. 
24. To intensify the DAB brown end product, immerse the slides into a copper 
sulphate solution for 2 minutes, and rinse in tap water. 
25. Any unused DAB/AEC should be discarded down the sink with copious amounts 
of cold, running tap water. 
26. Counterstain the DAB slides by immersing in Coles Haematoxylin for 2 minutes, 
rinse in tap water, dip briefly in acid alcohol, rinse again in water, then blue in 
Scotts tap water. 
 Or, for AEC slides, dip briefly in Harris Haematoxylin, wash in tap 
water and check for nuclei staining. Repeat until the desired nuclei 
staining has been achieved. 
27. Dehydrate and clear slides through 1 change 70% alcohol, 3 changes of 74OP 
alcohol and 3 changes of xylene for 2 minutes each.  
28. Mount sections by hand with Pertex mounting medium, or place on the Leica 
cover slipper. 
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Appendix 3           
The optical density of each sample was to determine arginase activity by using the 
following equations in 3 steps. 
 
1.  Urea amount (µg)= 25.439×O.D +7.2671  
2.     Molecular weight of urea is 60. 
 
   
2. Arginase activity Mu/million cells= arginase activity in all cells/total number of 
cells. 
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Appendix 4:          
Appendix 4. IDO mRNA expression in ovarian tissues. Six types of tissues included in this 
experiment consist of five different histological types of ovarian tumour tissue and also normal 
ovary as control. The Y axis shows IDO mRNA expression levels normalised to HPRT mRNA 
level.        No IDO mRNA expressions present in normal ovary and benign tumour tissues. 
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